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Chapter 1
Introduction
Hybrids of two different cell types, so-called heterologous hybrids, are of particular interest
for a number of applications such as hybridoma cell lines for the production of monoclonal
antibodies (Ko¨hler and Milstein, 1975), somatic cell hybrids for the generation of gene
databases (adapted from gene localisation experiments on chromosomes) and oocyte-skin cell
fusions for the creation of human embryonic stem cells (Cowan et al., 2005). In recent
years, besides several implementations of hybrid technologies for research purposes, also another
potential use has emerged. Hybrids of antigen presenting cells (especially dendritic cells) and
tumour cells may be used in cancer immunotherapy, since the initiation of anti-tumour immune
responses from such hybrids has been suggested (Galea-Lauri et al., 2002). However, the
processes for generating heterologous hybrids by chemically induced fusion or by electrofusion
are inefficient, thus severely limiting the clinical application of this technology.
1.1 Objectives and Concept
The research presented in this thesis was completed as part of a project funded by the European
Commission as a component of the 5th framework programme (Project QLK3-2002-01980,
http://www.fz-juelich.de/ibt/cancer-immunotherapy). Its research consortium is investigating
the ”Development of an immunotherapy for breast cancer based on dendritic cells by developing
and comparing different types of tumor-specific immunogens (cancer immunotherapy)”. This
includes the design and constitution of new, and the improvement of existing strategies for en-
hanced antigen presentation by dendritic cells. In this context, the work is intended to discover
dendritic cell-tumour cell hybrids and their application for breast cancer immunotherapy. The
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Figure 1.1: The concept of this thesis
goals of this thesis have been specified as follows:
• Process development of an optimised fusion for the generation of large numbers of viable
hybrids
• Investigation of all relevant fusion parameters, addressing technical and biological prob-
lems of generating heterologous hybrids, e.g. development of a new fusion device
• Application of the process to dendritic cell-tumour cell fusions, thus delivering whole
tumour cell information to dendritic cells
• Evaluation of the in vitro immune stimulatory capacity of the generated hybrids
Figure 1.1 illustrates the structure of this thesis. The theoretical background is divided into
two parts, the biological and the microtechnological background in chapter 2, section 2.1 on
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page 5 and section 2.2 on page 23, respectively. The former gives the reader an understanding
of the nature of cancer, the immune system and the background to cancer immunotherapy,
cancer vaccines and fusion vaccines in particular. The latter introduces technologies available
for the development of new fusion devices. Subsequently, in chapter 3 the results are presented,
structured into four sections, dealing with the development of two new fusion chambers based
either on immobilisation (see section 3.1 on page 38) or microfluidics (see section 3.2 on page
94), the fusion process itself (see section 3.3 on page 185) and the immunological evaluation of
the fusion products in section 3.4 on page 204.
4 CHAPTER 1. INTRODUCTION
Chapter 2
Theory
2.1 Biological Background
2.1.1 Cancer
Cancer represents a group of diseases in which the patient suffers from uncontrolled growth of
abnormal cells. Normally, the division of cells take place in an orderly and controlled manner.
If, for some reason, this process gets out of control, the cells will continue to divide and can
accumulate in one place in the form of a tumour. Tumours can be either benign or malignant.
The prefix ”benign” means that the tumour cells cannot invade the normal tissue and do not
spread to other parts of the body and so are not cancerous. If they continue to grow at the
original site, however, they may cause a problem by pressing on the surrounding organs and
damage them. A malignant tumour consists of cancer cells, which, if left untreated, may invade
and destroy the surrounding tissue. Sometimes cells break away from the primary cancer and
spread through the bloodstream or lymphatic system beyond the original sites to other organs
in the body. When these cells reach a new site they may go on dividing and form a new tumour,
often referred to as a secondary tumour or metastasis.
Numerous mutations in the genes of normal somatic cells can cause malignant proliferation
in a multistage process. During carcinogenesis, mutations sequentially and collectively promote
deviation from normal growth constraints and contribute to evasions of apoptosis (programmed
cell death), genomic instability, tissue invasion, angiogenesis (growth of new blood vessels) and
metastasis - all of which have implications for tumour formation.
As a cause of death in developed countries, cancer is second to cardiovascular disease,
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with an overall cause of 13 % of all deaths in the world in 2005. While cardiovascular disease
has declined, cancer deaths have remained relatively constant since 1950. Each year cancer
is diagnosed in 9 million people worldwide. It causes 7.6 million deaths, which means that
approximately 21,000 people die of cancer each day (from World Health Organisation
(WHO) statistics).
2.1.2 Breast Carcinoma
Breast carcinoma (cancer in breast epithelium) is by far the most common cancer in women
accounting for more than 25 % of all cancer cases. Earlier detection and better treatment helped
driving down breast cancer death rates in the last few years. Most breast cancer patients now
live for at least ten years after their diagnosis (from WHO statistics).
The female breast consists mainly of milk producing epithelial glands, called lobules, of
epithelial ducts and stroma. The ducts are tubes that carry the milk from the lobules to the
nipples, while the stroma surrounds the ducts and lobules with fatty tissue. Carcinomas arise
in epithelial cells. For breast cancer, about 80 % of cancers originate in the mammary ducts
(ductal cancer), while about 20 % arise in the lobules (lobular cancers).
Two major genes, BRCA1 and BRCA2 have been associated with the susceptibility to breast
cancer. Mutations in these genes affect the activity of the molecular repair kit for DNA in normal
cells and result in a lifetime risk of breast cancer of between 60 and 85 percent. However, only
about 5 % of all breast cancers are due to this inherited gene mutations. In the far more common
nonfamilial cancer, the gene mutations are induced environmentally (Wooster and Weber,
2003).
Early detection of breast cancer is crucial. Treatment is far more likely to be successful at
early stages of the disease before the tumour has had a chance to metastasise.
Treatment of Breast Cancer
Each women’s treatment will be slightly different, depending on many factors such as the
patient’s age and the type, side and spread of the cancer. Most patients will have surgery to
remove the tumour from the breast. This may be followed by radiotherapy and/or chemotherapy
to kill cancer cells that might be left in the breast or surrounding areas after surgery or have
spread from the breast. They can also be used before surgery, in women with large tumours,
to shrink the tumour so that breast conserving surgery becomes possible. Despite its successes,
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chemotherapy and radiotherapy will affect all of the patient’s dividing cells, whether cancerous
or not, causing weakening the patient’s immune defence as well as other severe side effects both
in the short term and later in life (Lo´pez et al., 2005; Poole et al., 2006).
Many women will also have hormone therapy using drugs such as Tamoxifen or Arimidex,
since some breast cancers require the hormone oestrogen for their continued development and,
if deprived of the hormone, will stop growing. Tamoxifen prevents the growth-promoting action
of oestrogen on breast cells by blocking the oestrogen receptor, while Arimidex, an aromatase
inhibitor, shuts down the production of oestrogen. One problem of hormone treatment is that
it is only effective in a proportion of patients with tumours expressing the oestrogen receptor
and, even in these, a resistant form of the disease can appear in time.
Trastuzumab (Herceptin), a humanised monoclonal antibody to the protein HER2/neu is
another possible treatment (Piccart-Gebhart et al., 2005). It can only be used in 20-25
% of breast cancer patients, whose cancer cells are HER2/neu positive and express high levels
of HER2/neu on their surface. One major risk linked to Trastuzumab is congestive heart failure
(3-4 % of patients).
Altogether, a problem with many current breast cancer treatments is the occurrence of
severe side effects, resistance to the used drugs and the lack of long-term protection against
recurrences.
2.1.3 New Approaches – Targeted Cancer Treatment
Recent approaches in the treatment of cancer use the body’s immune system, in particular
immune cells for fighting the disease. Cell-based immunotherapies are thought to stimulate and
activate the patient’s natural immune response to eliminate cancer cells, inhibit metastasis and
prevent tumour recurrence. In contrast, with traditional nonselective cancer treatments, im-
munotherapy targets specific molecular lesions within tumour cells and thus has the advantage
of avoiding toxic side effects. Immunotherapy might soon be called the fourth leg of cancer
treatment, squaring the triad of surgery, radiation and chemotherapy.
2.1.4 The Immune System
The immune system is very complex and consists of a number of components. It protects the
body against pathogens such as bacteria, viruses and parasites and also attacks other foreign
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entities. Therefore, the immune system has to distinguish self from nonself or foreign to mount
a destructive immune response against foreign, but not against self.
In general, the immune system can be divided into innate and adaptive immunity. The
innate immunity represents the first line of defence, which is triggered immediately or within
several hours of encountering invaders. Conserved molecular patterns (i.e. pathogen-associated
molecular patterns (PAMPs)), which are shared by a large group of microorganisms, are recog-
nised by pattern-recognition receptors (PRRs) (e.g. Toll-like receptors (TLRs), C-type lectins)
and launch the innate immune response. The innate immunity can be seen as a relatively spe-
cific first line response to evolutionary conserved molecular structures and has the purpose to
confine the pathogen infection (Luster, 2002).
In contrast, the adaptive immunity is directed against unknown, differentiated or mutated
proteins and unconserved structures of viruses, bacteria and other parasites. This adaptive
immune response is mediated by lymphocytes such as T- and B-cells. They are named after
their place of maturation, which is the thymus (T-cells) or the bone marrow (B-cells). The
initiation of an adaptive immune response requires the recognition and binding of lymphocytes
to very specific molecular sequences called antigens, which are small parts of proteins. Every
nucleated cell of the body processes endogenous proteins to small fragments (antigens) and
displays them bound to specific presenting proteins called Major Histocompatibility Complex
class I (MHC I) on their surface. When for example a virus infects a cell, it takes over the cells
protein manufacturing equipment to make viral proteins, which are assembled to new viruses.
One of the defence mechanisms of the body is that the infected cell presents fragments of these
viral proteins bound to MHC class I on its surface, where it can be recognised by cells of the
immune system. The same applies for other intracellular pathogens. Their proteins are reduced
to peptides by proteasomes, special protein complexes present in the cellular cytosol that have
proteolytic function. Once the parasite proteins have been digested to small peptides, they are
transported into the lumen of the endoplasmatic reticulum (ER), where they bind to the MHC
class I molecule, which is being fold in the ER. The MHC class I peptide complex is then
transported to the surface via the classical secretory pathway (Janeway et al., 2005).
Extracellular antigens derived from extracellular parasites like bacteria are processed
through a different pathway, which combines the internalisation of extracellular antigen with
the exocytosis of MHC class II molecules. Antigens are captured and internalised by antigen-
presenting cells (APC). Soluble extracellular molecules are engulfed through endocytsosis, bac-
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terial particles and dead cells through phagocytosis, and localised to intracellular vesicles de-
rived from the plasma membrane and are subsequently digested by proteolytic enzymes (Belz
et al., 2004). The MHC class II molecule is like MHC I assembled in the endoplasmatic
reticulum, but their loading with the endogenous antigens present in the ER is prevented by
invariant chain/CLIP (class II-associated invariant chain peptide), which occupies the binding
groove of MHC II. Histocompatibility Complexes class II (MHC II) are then diverted from
the classical secretory pathway into the endosomal/lysosomal system, where they fuse with
vesicles containing internalised antigens. Subsequently, the release of CLIP is catalysed and
exogenous antigens can bind the MHC II in a competitive displacement reaction. Thus, the
role of the MHC II molecules is preserved for presentation of exogenous antigens (Janeway
et al., 2005).
MHC class I:antigen complexes are recognised by cytotoxic CD8+ T-cells (CTLs), while
the MHC class II:antigen complex activates CD4+ T helper cells. This two T-cell types can
be distinguished by the presence of one of two leukocyte differentiation antigens or cluster of
differentiation (CD), CD8 or CD4.
The primary adaptive immune response takes place in the draining lymph nodes and not in
the tissue itself. Antigen is picked up by dendritic cells in the tissue and carried into regional
lymph nodes.
Dendritic Cells
Dendritic cells (DCs) are often referred to as the sentinels of the immune system or the most
potent antigen presenting cells (APCs) for the initiation and modulation of antigen-specific
immune responses. In addition to their ability to efficiently acquire and process antigens, they
express high level of both class I and class II MHC molecules as well as co-stimulatory molecules
essential in antigen-presentation (Shortman and Liu, 2002).
DCs derive from bone marrow stem cells and exist in two activation stages, as immature
and mature dendritic cell. The function of a DC is highly influenced by its level of maturation.
Immature dendritic cells are found in nearly all tissues, especially in the skin and the mucosal
surfaces. They are recruited to sites of inflammation caused by pathogens in peripheral tissues
by TLR-mediated events. There, they are activated by innate stimuli and loaded with foreign
antigen, which they internalise via pinocytosis or receptor-mediated endocytosis. After antigen
uptake and processing, the immature dendritic cell differentiates into a mature DC, induced
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by a danger signal (PAMP) such as bacterial cell wall components. During maturation the
dendritic cell converts from an immature, antigen-capturing cell to a mature antigen presenting
cell, expressing co-stimulatory molecules and becoming a potent stimulator of T-cells. Thus,
DCs translate and integrate innate signals into adaptive immunity (Reis e Sousa, 2004).
Furthermore, the innate immune stimuli (TLR activation) set in motion the expression
of chemokines from resident tissue macrophages and dendritic cells, which modulates the ex-
pression of chemokine receptors on dendritic cells. These changes in chemokine and chemokine
receptor expression trigger the migration of the antigen-loaded DCs from the tissue to secondary
lymphoid organs (e.g. regional lymph nodes)(see figure 2.1).
Figure 2.1: Dendritic cell life cycle: In tissue resident dendritic cells take up antigens and
migrate towards lymphoid organs. During this time they get matured and are then able to
activate T-cells in the lymph nodes to launch an effective immune response.
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Figure 2.2: T-cell stimulation requires three dendritic cell-derived signals: MHC/TCR interac-
tion, a co-stimulatory signal via CD28 and a signal via the cytokine receptor.
In the regional lymph nodes, the mature antigen-loaded dendritic cell activates na¨ıve T-cells,
triggering several effector pathways, including activation of B-cells and antibody production,
activation of CD8+ cytotoxic T lymphocytes and stimulation of cytokine production by CD4+
T helper cells to initiate an effective, adaptive immune response.
The signals that lead to T-cell activation (see figure 2.2) are generated by the physical
contact between dendritic cells and T-cells by forming an immunological synapse, which is
stabilised by adhesion molecules (Huppa and Davis, 2003). The first signal is received through
the T-cell receptor (TCR) after it recognises antigenic peptides displayed by MHC molecules
on the surface of DCs. The consequence is an upregulation of the expression of co-stimulatory
molecules. The second signal is provided by plasma membrane bound co-stimulatory molecules
such as CD80 and CD86, which are present on the antigen-presenting cell and are recognised
by a co-receptor on the cell surface of T-cells, called CD28 (Acuto and Michel, 2003). The
receipt of the second signal results in the production and secretion of cytokines and expression
of cytokine receptors on T-cells. The third signal is then provided by the secretion of cytokines,
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whose nature defines the type of the activated T-cell.
The activation process is completed by proliferation and evolving of T-cells to effector cells
(Lanzavecchia and Sallusto, 2001). Helper T-cells are activated to proliferate and to
secrete a variety of interleukins, supporting antibody production by activated B-cells (plasma
cell) and cytotoxic T-cell responses. Target cells that carry the same class I MHC molecule
and the same antigen that originally induced CTL activation are killed by activated CTLs by
induction of apoptosis. Not only endogenous antigens can be presented via MHC I by dendritic
cells, but also exogenous antigens by so-called cross-presentation. This unique cross-priming
capacity of dendritic cells was shown to be indispensable for induction of CTL responses against
viruses that do not infect dendritic cells themselves and to maintain self-tolerance against non-
DC components (Lize´e et al., 2003).
After activation, T-cells leave the lymph node and find their way back to the site of inflam-
mation, guided by cytokines (Banchereau and Steinman, 1998).
2.1.5 Cancer Immunotherapy
Immunotherapy involving recruitment of the patient’s immune system has been shown to be
an alternative or addition to conventional treatments targeting tumour cells with far greater
precision resulting in fewer side effects. In general, cancer vaccines are not used to induce pro-
phylactic immunity, but to act on an existing disease, e.g. the tumour. However, immunisations
of patients bearing established tumours have often been ineffective since the tumour may have
already elicited an immune suppressive response. Thus, prior to immunotherapy, it had been
necessary to reduce the tumour mass. The first clinical trials on cancer immunotherapy have
indicated this form of treatment as feasible and safe. Furthermore, in some cases, objective
clinical responses were observed, even in patients heavily pretreated with standard chemo- or
radiotherapy approaches (Bremers and Parmiani, 2000).
The target for cancer immunotherapy are tumour antigens. They can be either tumour-
specific, meaning they are exclusively expressed on tumour cells, as in the case of viral antigens
and mutated gene products, or tumour-associated. Tumour-associated antigens (TAA) are also
expressed to a certain degree on normal tissue, but overexpressed in the tumour cells. The
immune system can recognise those tumour antigens and even eliminate early stage transformed
cells. One evidence of such an immune surveillance is the fact that patients with drug-induced
immunosuppression after organ transplantation or due to severe immunodeficiency syndromes
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develop a higher frequency of several tumours. All those tumours are virally induced, but this
does not mean, that other cancer types are not under the control of immunity. The latter is
proved by lymphocyte infiltration into tumours (Pardoll, 2003).
However, most progressed human tumours are capable of evading the host immune system.
They can downregulate the expression of co-stimulatory signals that are essential for T-cell
activation. Presentation of antigens in the absence of co-stimulatory signals or signals that
accompany tissue destruction and inflammation may lead to immunologic tolerance instead of
cytotoxicity because of ignorance, anergy or physical depletion. Other immune escape mechan-
isms of tumours are known such as generation of a tumour microenvironment by local release of
inhibitor factors, e.g. inhibiting maturation and migration of dendritic cells. Thus, the primary
aim of cancer vaccines is to overcome immune suppression, circumvent the immune escape
mechanisms of the tumour and break tolerance to the tumour (Gunzer et al., 2001).
In the 1890s, Coley treated cancer patients with bacterial extracts of streptococcal cultures
that boosted non-specifically the general function of the immune system. Nowadays, more
specific ways are used and the immune system is activated by optimising the presentation of
antigens by vaccination. Since the most effective antigen presentation to a na¨ıve immune systems
occurs through antigen presenting cells, dendritic cells are the cells of choice (Armstrong et
al., 2001).
2.1.6 Dendritic Cell-based Vaccines
Dendritic cells express elevated levels of the important co-stimulatory molecules, which tumour
cells lack. They can attract and recruit T-cells by chemokines and efficiently stimulate them.
DCs loaded with tumour-associated antigens (TAAs) can induce immunity to tumours as shown
by successful tumour vaccinations in several animal models. Studies in humans have also shown
the capacity of TAA loaded DCs to prime effective antitumour immune responses. In addition,
it was shown that tumour-specific CD8+ cytotoxic T lymphocytes (CTL) and their tumourlytic
action constitute an important arm of the antitumour response (Bocchia et al., 2000).
In cancer, however, dendritic cells, although capable of efficient tumour antigen processing,
may be unable to stimulate T-cells successfully, because of factors secreted by the tumour,
which inhibit the maturation and migration of DCs, or the lack of a danger signal. These
problems can be circumvented by loading the DCs with tumour-associated antigens and their
additional activation in vitro. The loaded DCs are then reinfused into the patient to generate
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an integrated CD4+ and CD8+ T-cell response.
Thus, DCs are used as efficient vector. As the number of immature precursors of dendritic
cells in the circulating blood is very low (< 0.5 percent of all peripheral blood mononuclear cell
(PBMCs)), large numbers of dendritic cells for clinical use can be generated, e.g. from peripheral
blood monocytes. Blood monocytes differentiate in vitro in the presence of exogenous cytokines
into immature DCs (iDCs). These iDCs possess functional characteristics typical of this dif-
ferentiation status, such as phagocytosis, macropinocytosis, receptor-mediated endocytosis and
antigen-processing (Bohnenkamp and Noll, 2003).
Dendritic cells can then be loaded with the tumour antigens, whereas the antigenic source
has to be carefully selected. Just a single tumour-associated antigen can be chosen, or the full
profile of antigens expressed by a cancer cell. Nevertheless, one has to keep in mind that the
tumour is heterogeneous and its cells can mutate. If a immune response is elicited against only
one or a few antigens, some tumour cells can escape immune detection. In addition, for the
extension to some cancer types, for which no defined tumour-associated antigens are known,
the whole-tumour cell approaches are needed. They have the further potential advantage of
generating a broader T-cell response on the basis of the antigens selected by the dendritic cell
processing machinery.
Several methods have been devised, for successful loading of MHC molecules on dendritic
cells. These methods range from pulsing DCs with peptides (Thurner et al., 1999), proteins
(Hsu et al., 1996), cell lysate (Kurokawa et al., 2000) and apoptotic cells (Jenne et
al., 2000), through fusion with whole tumour cells, transfection with RNA (Do¨rfel et al.,
2005) or with viral vectors (Song et al., 1997). These numerous methods for tumour antigen
delivery to dendritic cells, still need further extensive investigation, addressing technical and
biological problems of the loading process. The efficacies of these immunotherapeutic strategies
for the loading of dendritic cells have rarely been directly compared (Parajuli et al., 2004).
2.1.7 Fusion Vaccines
One promising way of delivering tumour-associated antigens to dendritic cells is the fusion of
a DC with a live tumour cell resulting in a hybrid. In 1997, Gong et al. proposed that such
fusions of dendritic cells with a murine carcinoma cell line used as a vaccine induced T-cell
protective immunity against tumour challenge and immune rejection of established tumours
in mice. Therefore, immature dendritic cells are generated from patient’s blood monocytes in
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vitro and fused with autologous tumour cells, which can be obtained from surgery or pleural
effusions (see figure 2.3 on page 16). The use of allogeneic tumour cells or even cell lines as well as
allogeneic DCs from an unrelated donor is also possible, but reduces the patient specificity of the
vaccine (see table 2.1). Thereby, four different combinations are possible: fusion of autologous
DCs with autologous tumour cells, autologous DCs with allogeneic tumour cells or allogeneic
DCs with autologous tumour cells or selection of both fusion partners from allogeneic origin.
Table 2.1: Impact of autologous versus allogeneic fusion composition on TAA presentation
DC origin autolog autolog allogen allogen
Tumour origin autolog allogen autolog allogen
DC MHC matching matching non-matching non-matching
Tumour MHC matching non-matching matching non-matching
TAAs all TAAs from
heterologous tu-
mour
some TAAs (if
corresponding)
all TAAs from
heterologous tu-
mour
some TAAs (if
corresponding)
DC function antigen present-
ation, supply of
co-stimulatory
molecules
antigen present-
ation, supply of
co-stimulatory
molecules
supply of co-
stimulatory
molecules,
mismatched
response
supply of co-
stimulatory
molecules,
mismatched
response
Tumour function TAA presenta-
tion and delivery
TAA delivery TAA presenta-
tion and delivery
mismatched re-
sponse
If allogeneic cells are used, the MHC complexes of either the dendritic cell or the tumour
cell or both do not match with the MHC complexes of the patient, due to histocompatibility
differences. The name histocompatibility complex was given because originally these proteins
were found due to skin transplant rejection of different donors. Usually, different donors have a
different set of MHC complexes and are recognised by a transplant recipient as foreign. MHC
mismatch results in graft rejection in organ transplantations and in graft-versus-host disease in
a bone-marrow transplant. Therefore, the matching of MHC complexes by skin, tissue or organ
transplantation is sine qua non. Using allogeneic DCs for fusion vaccines results in immune
responses to the mismatched MHC complexes rather than in specific immune responses to
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Figure 2.3: Dendritic cell/cancer cell hybrid vaccination strategy
Figure 2.4: Schematic depiction of a hybrid resulting from DC/tumour cell fusion: It is hypo-
thesised that the DC/tumour cell hybrid functions as antigen-presenting cell expressing TAAs
on MHC class I and II alongside with co-stimulatory molecules.
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tumour-associated antigens and should be avoided.
Cell-cell fusions share one cell membrane and all proteins. Tumour-associated as well as
proteins from DC origin are comprised within the hybrid cell. It is assumed that the hybrid
still functions as an antigen-presenting cell and the tumour antigens are allowed to be processed
and presented as endogenous proteins by the MHC I pathway as well as cross-presented on MHC
class II (see figure 2.4). For this reason, hybrids from DC/tumour cell fusions could induce both
MHC class I and class II responses (Rosenblatt et al., 2005). Furthermore, on the dendritic
cell, TAAs are presented in the context with co-stimulatory molecules. Nevertheless, the DC
loading should be followed by maturation to obtain a fully functional antigen presenting cell,
which expresses high levels of co-stimulatory molecules and is able to migrate to the lymph
nodes, ensuring correct antigen presentation (Barratt-Boyes and Fidgor, 2004).
Several potential advantages distinguish this approach from other DC vaccine strategies.
The applicability is not dependent on the identification of tumour-associated antigens (TAAs),
but is based on the whole antigenic repertoire of the tumour cells, which can contain a variety
of TAAs, including those that are unidentified and those specific to a particular patient. The
TAAs are generated endogenously by the fusion cell resulting in a more efficient and stable
antigen presentation compared to exogenous loading. In contrast to other whole-tumour cell
approaches with endogenous antigen synthesis such as loading of DCs with tumour RNA or
DNA, the fusion vaccine has the advantage of comprising all tumour proteins, not only those
which were translated or transcribed by the tumour cell at the time of RNA/DNA extraction.
However, the main limitation is the available amount of tumour material for vaccine production.
Fusion hybrids can be generated by chemically induced fusion with polyethylene glycol
(PEG) or by electrofusion, whereby tumour cells and DCs are subjected to an electrical pulse.
Independent from the used method, not more than 10-15 % of heterologous hybrid formation
were documented (leaving out the overly optimistic interpretations of data by some authors). A
low fusion yield avoids the transfer of this technique to cancer types where only small samples
of tumour material are available (e.g. breast cancer) or to early stage disease without a sig-
nificant tumour burden. For a therapeutic setup, multiple vaccinations would be needed for
an effective induction of an antitumour immune response. Thurner et al. (1999) suggested
four vaccinations with 107 hybrids each, resulting in a need of 2.6 · 108 tumour cells, if a fusion
efficacy of 15 % could be achieved. The dose is based on the percentage of heterologous hybrids.
Homologous DC/DC fusions and tumour/tumour cell fusion should not be considered. Never-
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theless, homologous hybrids and unfused cells are normally not sorted out, leaving a need for
radiation treatment of the vaccine prior to administration, because of the risk of tumour cell
proliferation.
2.1.8 Electrofusion
Cell-cell fusion can be induced artificially by subjecting the cells to electric pulses. This process,
known as electrofusion, is preferred to chemically induced fusion by polyethylene glycol (PEG).
PEG can have toxic side effects and the method is only partly controllable and difficult to
standardise (Karsten et al., 1988).
Electrical field-mediated cell fusion has found application in the formation of hybridomas
for monoclonal antibody production and in animal and plant breeding. It is based on electro-
permeabilisation of the cell membrane achieved by exposure of the cells to a short (micro-to
milliseconds) but intense (hundreds of volts per centimetre) electrical field. The external field
induces an increase in transmembrane potential, which in first approximation is proportional
to the applied field strength and the cell radius. It is assumed that a membrane destabilisation
occurs that is associated with aqueous pore formation, if the transmembrane potential is high
enough or rather exceeds a certain threshold (Teissie´ and Ramos, 1998). In 1958, Staempfli
reported for the first time that electrical stimulation of cell membranes can lead to a reversible
electrical breakdown of the excitable membrane. Large cells for example are more sensitive to
lower electric field strengths than small cells and would not survive a high electrical field pulse.
About 50 years later the basis for pore formation still remains poorly understood. The in-
duced pores have a lifespan in a microsecond time range (Gabriel and Teiss´ıe, 1999), which
complicates their observation and description. Several models have been proposed, using cell
models with simple shapes, which can only describe pore formation as an approximation. Re-
cently, researchers tried to address pore formation on a molecular basis by computer simulations
(Tieleman, 2004).
Permeabilised cell membranes allow insertion of proteins that are of biological and medical
interest. They are introduced through the pores into the cell, by-passing the normally inper-
meable plasma membrane. When present on two or more cells, the permeabilised membranes
allow cell fusion, with spontaneous merging of the two lipid cell membranes into a single con-
tinuous membrane bilayer. This associated fusogenicity has been described by Zimmermann in
1982. The efficacy of electropermeabilisation and fusion strongly depends on many parameters.
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It can be distinguished between parameters of the electric field such as pulse duration, number
of pulses and pulse strength, and biological parameters of the cells such as cell size, shape,
transmembrane potential, osmotic pressure and temperature (Teissie´ et al., 1999). Strict
control of electric field parameters allows electropermeabilisation to be reversible.
Electrofusion is a multistep procedure (Ramos and Teissie´, 2000). First of all, the cells
have to be brought into close contact, before the fusion can take place. Therefore, the forces
exerted by non-uniform a.c. electrical fields on cells in liquid media can be harnessed. Cells
become polarised in the presence of such an electrical field with high frequency and low in-
tensity (100V per cm). The resulting dipole is due to an ion charge separation inside the cell
(see figure 2.5). The dielectrically polarised cells then experience lateral forces in the non-
uniform field and move to regions of highest field intensity (see figure 2.6), a process called
positive dielectrophoresis (DEP). The magnitude and direction of the dielectrophoretic force
are dependent on the electric field, the size of the particles and the electrical properties of the
particles relative to those of the surrounding medium (Ghallab and Badawy, 2004). In a
uniform field dipoles are also induced in the cells, but the cells do not move, because the forces
affecting the cells are the same in both directions. The induced movement in a non-uniform
field causes the cells to align at the electrodes, forming strings of cells resembling pearl chains
(Zimmermann et al., 2000). Thus, a close membrane contact is established by cell alignment
through dielectrophoresis prior to fusion.
Secondly, the cells are subjected to one or more short high-voltage d.c. pulses, which cause
permeation of the cell membrane and initiate cell fusion. The electrical breakdown of the cell
membrane leads to induction of transient membrane pores along the field lines (Sugar et
al., 1987). These aqueous pores form in protein-free lipid domains of the membrane, which
occurred by lateral movement of membrane proteins in the a.c. field (see figure 2.7). During
healing of the membrane, the cell membranes of two cells can form bridges of lipid molecules,
leading to the establishment of cytoplasmic continuity and the fusion of the cells. Thereby, all
transition states are governed by forces that minimise exposure of non-polar surfaces to water
(see figure 2.8).
In the third step, the post-alignment, a weak non-uniform a.c. field (as in step one) is
applied for a brief period to hold the cells in place while the fused membranes mature, the
fusion products round off and the cytoplasms mix, forming a cell with characteristics of both
fusion partners. The fusion maturation includes large rearrangements of the cytoskeleton and
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Figure 2.5: Schematic representation of an inhomogeneous electrical field between electrodes
E+ and E− that induces a dipole in a cell.
Figure 2.6: Cells in an inhomogeneous electrical field line up in pearl chains at the electrodes
by dielectrophoresis
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Figure 2.7: Schematic representation of two cell membranes (red and green)
Figure 2.8: Schematic representation of the electrical breakdown and coalescence of the mem-
branes of two adjacent cells
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continues during the next minutes, thus the hybrids should not be disturbed in this time to
stabilise the process.
A critical part of the whole cell fusion process is the medium in which the cells are sus-
pended. The dielectrophoresis process for cell alignment requires a low conductivity medium
to prevent excess heat build-up. Other factors must also be considered, as the requirement of
millimolar levels of divalent cations, such as Mg2 + and Ca2 + (Ha, 2001), which interact with
negatively charged lipids and are important for membrane healing after poration. In addition,
the use of a hypoosmolar buffer for mammalian cell fusion has been shown to facilitate electro-
permeabilisation of cell membranes due to osmotically induced membrane tension by swelling
of the cell (Barrau et al., 2004). The critical value of transmembrane potential needed to
trigger pore formation is smaller under this osmotic stress, where membrane and cytoskeleton
are temporarily loosened (Schmitt and Zimmermann, 1989). Lots of other conditions and
additives have been used to facilitate cell fusion (Abidor and Sowers, 1992; Jiang et al.,
1999). However, only hypoosmolar fusion buffers seem to influence fusion yield positively and
are nowadays applied widely.
Apart from fusion conditions and additives, the area in which electrofusion could be im-
proved most, is the design of the cell fusion chamber. The design should allow observation of the
fusion events for a quick decision for readjustment of the fusion parameters where appropriate.
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2.2 Microtechnological Background
The last decade has seen a surge in the development of so called Micro Electro Mechanical
Systems (MEMS), Micro Total Analysis Systems (μTAS) or Lab-on-a-Chip (LOC) devices.
This is due to the recent advances made in microfabrication technologies. The drive towards
miniaturisation of existing systems spread across diverse technological disciplines, but not many
devices can be found in use today.
2.2.1 Microsystems Technology
In principle, microsystems technology (MST) is an invention of nature. Each creature consists of
a multitude of specialised microsystems – the cells. Since the beginning of the 90ths, researchers
try to harness many of the underlying principles of nature for the development of technological
systems.
Microsystems are small effective systems, which satisfy many tasks better and less expensive
than their bigger paragons, fabricated with conventional techniques. The microsystems tech-
nology has developed from microelectronics. It started with the effort to combine more and
more functions on one device. The characteristic of MST compared to microelectronics is its
systemic nature. All microsystems have in common the connection of different functions, ma-
terials, components and technologies in an integrative system. Diverse basic technologies such
as mechanics, optics, fluidics and also new fields of technology are unified under the patronage
of MST.
A variety of methods exist for the fabrication of microsystems such as photolithography,
wet etching, reactive ion etching, soft lithography, injection molding, micromachining, replica
molding, hot embossing and laser ablation. Today, MST can be seen as a key technology sat-
isfying the growing demand for smaller, more economical and more integrated systems also in
new fields like biotechnology or nanotechnology.
The techniques used in this thesis, are explained in ”Technique Boxes” in the results section
where applicable.
2.2.2 Microfluidics
Microfluidics is one of the major application areas of microsystems technology dealing with small
quantities of fluids. It comprises design, manufacturing, handling and analysis of microsystems,
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which work with fluids in channel cross-sections of 1μm up to 1mm in width. In practice, the
average channel width used, is between 50μm and 500μm with a channel length of several
millimetre up to several centimetre, depending on the application.
Although a lot of research is ongoing in the field of microfluidics, this discipline is still in its
infancy. In the last decade, many microfluidic components were developed. They were either
miniaturisations of existing or conventional systems, due to the usage of new effects or the
search for new applications. Bioassays and biological procedures have been miniaturised into a
chip format including applications such as DNA sequencing and separation, polymerase chain
reaction (PCR), electrophoresis and enzymatic and immuno assays (Sia and Whitesides,
2003). Microfluidic devices and systems are also useful for cell-based applications, especially
as the size of cells fits very well with that of microfluidic devices (Andersson and van den
Berg, 2003).
Due to the small fluid volume and in most cases also the small size of the system, the design,
development and analysis of these systems show considerable differences to conventional fluidic
systems. The fluid behaviour follows the scaling law and thus changes with miniaturisation.
In the micro range, surface dependent effects such as interfacial tension, electrostatic and elec-
trokinetic forces prevail, whereas in the macro world the volume-dependent effects are dom-
inating such as vis inertiae and gravity. In general, the proportion of surface to volume rises
with miniaturisation. This is the reason for the increase of surface forces, especially the viscous
friction force of fluids (Nguyen, 2004).
2.2.3 Fluid Mechanics in the Micro Scale
Scaling laws permit a rough estimation of the systems behaviour in the micro scale. The beha-
viour of a fluid volume is dependent on weight, surface tension and adhesive force. While the
weight FG is proportional to the volume V of the fluid, the surface tension and the adhesive
force FH are proportional to the surface A.
The proportion of FH to FG can be described as follows:
FH
FG
∞ A
V
∞ S
2
S3
∞ 1
S
(2.1)
with
FH : Adhesive force
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FG: Weight
A: Surface
V: Volume
S: Scaling factor.
For miniaturisation S is smaller than 1: S < 1
The equation 2.1 describes the square-cube-law, which can be illustrated in an example:
Take a cup of coffee with 125mL of coffee. The scaling factor is set to S = 1. 125mL of coffee
correspond to a volume of 5 ·5 ·5cm3. If this amount of coffee is spilt on the table, the fluid leaks
over the table. With such a big volume, the weight outweighs the adhesive force and surface
tension, the coffee flows over the table. If only a spoon full of coffee is taken (V = 0.125mL),
which is the volume of a 5 · 5 · 5mm3 cube, and spilt on the table, it is unlikely to flow. From
the equation it is obvious, that the proportion FH
FG
is 10 times higher, since S = 0.1. Adhesive
force and surface tension alter the behaviour of the fluid volume. If the coffee volume gets even
smaller e.g. only a drop, 0.5 ·0.5 ·0.5mm3 with a volume of 0.125μL, this drop sits on the table.
It does not move, even if the surface is tilted. With a scaling factor of S = 0.01 the proportion
of FH
FG
is increased by 100fold. Adhesive force and surface tension define the behaviour of the
fluid volume.
The scaling of physical variables is dependent on the physical effect, while the dimension
or unit is independent of it (see table 2.2). This presents the real difference between scaling
analysis and the dimensional analysis used in traditional fluid mechanics.
Table 2.2: Scaling derived from physical parameters (L: length, T: time, M: mass)
Parameter Dimension Scaling
Surface L2 S2
Volume L3 S3
Velocity L/T 1 orS−2
Angular velocity T−1 1
Acceleration F/M = L/T 2 S−2, S−1, S0, S1
Force M · L/T 2 S1, S2, S3, S4
Work M · L2/T 2 S2, S3, S4, S5
Dimensionless numbers are introduced in the macro world, because of the dimensional ana-
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lysis being a helpful tool for traditional fluid mechanics. Systems with the same dimensionless
numbers are hydrodynamically similar. Therefore, scale models in different sizes/scales can rise
correct conclusions about the fluid behaviour, as long as the dimensionless numbers correspond.
The influence of the scaling law on the fluid mechanics can be shown with the help of force
analysis. The balance of forces in fluid mechanics is described by the Navier-Stokes equation:
ρ
Dv
Dt︸ ︷︷ ︸ = −∇p︸ ︷︷ ︸+ ρ · g︸ ︷︷ ︸+μ · ∇
2 · v︸ ︷︷ ︸ (2.2)
vis inertiae = pressure gradient + gravity + frictional force
with
v: Velocity vector
ρ: Density
p: Pressure
g: Acceleration vector
μ: Dynamic viscosity
The proportions between vis inertiae, pressure gradient, gravity and frictional force deter-
mine the behaviour of the fluid. In the following, the scaling law is analysed for different force
proportions of a fluid.
Proportion of Vis Inertiae and Frictional Force
When assumed for the scaling that the density ρ and viscosity μ are constant (continuums
requirement), the Reynolds number is proportional to the characteristic geometry.
Re =
vis inertiae
frictional force
=
ρ · u ·Dh
μ
(2.3)
with
Re: Reynolds number
ρ: Density
u: Average fluid velocity
Dh: Hydraulic diameter (or other characteristic length)
μ: Viscosity
Re∞ S(foru = const.) (2.4)
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with
Re: Reynolds number
S: Scaling Factor
In the macro scale the Reynolds number is the criterion for fluid behaviour. If the fluid flow
is dominated by the frictional force (small Reynolds number), the flow is laminar. When vis
inertiae is much higher than the frictional force (high Re number), a turbulent flow is present.
In the macro world a transition range between laminar and turbulent flow (2000 < Re < 4000)
exists. In general, Recrit is set as critical Reynolds number. The Reynolds number of microfluidic
components is in most cases much smaller than Recrit, because of high frictional forces due to
a high surface/volume ratio of the microfluidic systems. Thus, a laminar flow is found in most
microfluidic systems.
Proportion of Vis Inertiae and Gravity
Fr =
vis inertiae
gravity
=
u√
g ·Dh (2.5)
with
Fr: Froude number
u: Average fluid velocity
g: Gravitational acceleration
Dh: Channel height
The Froude number describes the relationship between flow velocity and velocity of the
surface waves.
Proportion of Pressure Loss and Inertia
Eu =
pressure loss
vis inertiae
=
p
ρ · u2 (2.6)
with
Eu: Euler number
 p: Pressure loss
ρ: Density
u: Average fluid velocity
For a cylindrical capillary the pressure loss accounts to:
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p =
∫
D
·L
D
· ρ · u
2
2
= 32
μ · L · u
D2
(2.7)
with
∫
D: Darcy friction factor
L: Length of the capillary
D: Diameter of the capillary
ρ: Density
u: Average fluid velocity
Consequently, the following is obtained for the Euler number:
Eu = 32
μ · L
ρ ·D2 · u (2.8)
with
Eu: Euler number
μ: Viscosity
L: Length of the capillary
ρ: Density
D: Diameter of the capillary
u: Average fluid velocity
Eu∞ S−1 (2.9)
with
Eu: Euler number
S: Scaling factor
The pressure loss in a microchannel is very high, due to the frictional force, while vis inertiae
is negligible.
Please note, that for the analysis of the above dimensionless numbers, a continuum was
assumed, which does not apply for gases in the submicrometre scale. In general, the continuum
model applies for fluid flows, since fluids cannot withstand a shear force as a solid can. Under
shear stress a fluid flows and thus looses its primary form.
The viscosity of a fluid causes a frictional force against the shear force. The dynamic viscosity
μ of a fluid is defined by the following relation:
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τ = μ · du
dy
= μ · γ˙ (2.10)
with
τ : Shear stress
μ: Dynamic viscosity
u: Velocity
The variation of the velocity u over the axis y is termed shear strain γ˙.
Under a constant fluid flow the shear strain and the shear stress τ rises with miniaturisation:
τ ∞ S−1 (2.11)
In conclusion, in microchannels, the fluid flow differs fundamentally from macroscopic flows.
The fluid in a microfluidic setting exhibits laminar flow and the occurrence of turbulence is
prevented. This is primarily due to higher importance of molecular effects such as wall slip,
because of the higher surface-to-volume ratio in microfluidic channels.
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Chapter 3
Results
The concept of cancer vaccines as described into detail in the 2nd chapter is the initiation of
an effective immune response based on a strong stimulation of the immune system to overcome
tolerance. Most of the vaccine therapies intend to stimulate T-cells that can recognise and kill
tumour cells directly and/or attempt to activate professional antigen presenting cells (APC),
such as dendritic cells, to specifically activate T-cells against tumour cell antigens. One way
to introduce the antigen to the APCs is to form hybrid cells consisting of dendritic cells and
cancer cells.
This can be achieved by chemically or electrically induced cell fusion between the respective
cells. However, the electrofusion is highly preferable for clinical use. Purchasable devices offered
by different companies can achieve this by the introduction of the cells into a micro fusion
chamber and the subsequent application of an electrical field to the solution. Dipoles are induced
within the cells, which group in pearl chains at the electrodes. This is a significant step in the
procedure, since the cells need to have physical contact for the fusion. After the alignment of
the cells a short electrical pulse is applied, resulting in a perforation of the cell membranes.
During the membrane reorganisation the membranes of neighboured cells can fuse and a hybrid
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is formed. If the damage of the membranes by the applied pulse is too substantial the cells will
not survive the procedure. Otherwise, if the perforation is not wide enough, no hybrid cells will
be formed.
In many cases, normal or altered electroporation cuvettes are used for cell fusion. There
are, however, some systems available, which are specialised for the electrofusion of mammalian
cells, e.g. the Eppendorf Multiporator. It can be used with standard electroporation cuvettes,
but also comprises the possibility to use two special chambers for cell fusion in small and in
larger scale.
The micro fusion chamber, illustrated in figure 3.1 and figure 3.2,, respectively, is developed
for the use under a microscope, while the helix fusion chamber (see figure 3.3) has been designed
for the production of larger quantities of fusion products (fusion of up to 2.5 · 105 cells).
Generally, a protocol for cell fusion implies firstly a mixture of the two fusion partners in
equal shares and their subsequent introduction into the fusion chamber. Figure 3.4 on page 34
shows a cell suspension in the Eppendorf micro fusion chamber and the cell alignment provoked
by the application of a low alternating electrical field.
Figure 3.1: Micro fusion chamber for the Eppendorf Multiporator: It consists of a casing con-
taining two electrodes above a transparent reservoir. Connection to the Multiporator can be
established by a coaxial cable via a special insert. This micro fusion chamber allows the optim˙i-
sation for cell alignment and cell fusion under microscopic control.
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Figure 3.2: Close-up view of the electrodes from the Eppendorf micro fusion chamber: The two
electrodes consist of Platinum and are 200μm apart.
Figure 3.3: Helix chamber for the Eppendorf Multiporator: It consists of a conical core that
carries the parallel wrapped electrode wires and a beaker into which the cell suspension is
added. The filling volume accounts to 250μL. The electrode gap width of 200μm is filled by
the screwing of the core into the beaker, whereupon the cell solution is pressed upwards into
the gap.
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Figure 3.4: Situation in the Eppendorf micro fusion chamber filled with a cell suspension of
106mL−1 before and after application of a low a.c. field (500V/cm) for 30 seconds. The used
breast cancer cell line MCF-7 has been stained in red using the fluorescent cytoplasmatic
Celltracker CMTMR dye. [picture by H.R. Bohnenkamp]
Figure 3.5: Mixture of two different breast cancer cell lines, T47D and MCF-7, stained in
green with CMFDA and in red with CMTMR, respectively, in the micro fusion chamber. Many
clusters of cells of the same type can be observed. However, only at sites in the cellular pearl
chains, where the two cell types alternate (see marks for example) a heterologous fusion can
take place. [picture by H.R. Bohnenkamp, modified]
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For the investigation of the cell alignment in the fusion chamber, two different breast cancer
cell lines, T47D and MCF-7, were stained with a green and a red cytoplasmic fluorescent dye and
introduced into the camber. The resulting situation in the fusion chamber after the alignment
process showed a high formation of clusters of cells of the same cell type (see figure 3.5 on page
34). This phenomenon can be explained by the differential cell specific parameters of the fusion
partners, such as cell size, cell shape and membrane potential. Their interaction during cell
alignment triggers cluster formation in an a.c. field, thus dramatically reducing the potential
fusion efficacy.
This general phenomenon, as revealed in our group, is responsible for the low yield of
heterologous hybrids. The high cluster formation reduces the fusion efficacy for heterologous
hybrids, as only the cells that are alternatingly aligned (red-green, see mark in figure 3.5) have
a chance that a hybrid cell is formed after the application of an electrical pulse. Therefore,
it can be directly understood that only a minor heterologous hybrid formation yield can be
expected.
Figure 3.6: Schematic diagram of the proportion of a cancer cell (green) in comparison to a
dendritic cell (red): A successful two-cell fusion requires the appearance of two holes in the
membranes, one in each cell. These holes, which result from a membrane breakdown due to the
applied fusion pulse, have to co-localise.
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In theory, a 50 % fusion efficacy can be obtained by simply mixing the fusion partners before
the application of the pulse. However, only 10-15 % of hybrid formation were achieved with
the Eppendorf Multiporator. It is obvious, that the cluster formation limits the heterologous
hybrid cell formation and thereby the potency for an application to a variety of cancer types (for
example breast cancer), because of a limited availability of tumour material. By circumventing
the cluster formation by alternating arrangement of the fusion partners, the theoretical fusion
efficacy could be raised up to 100 %.
Furthermore, it has to be kept in mind, that the fusion itself is a rarely occurring event,
since it requires the formation of one hole in the cell membrane of each cell, which co-localise
exactly (see fig. 3.6). Even when this situation is established, the cell membranes can reorganise
and close the holes without mergence. That means that extracellular fusion parameters such as
fusion pulse voltage, pulse length, number of pulses and the osmolality of the fusion medium
inhere a sizable influence.
Nevertheless, a straightforward improvement of the fusion efficacy would be the previous
alternating arrangement of the cells in the fusion chamber before the fusion procedure. This
eliminates the chance of cell cluster formation, thus boosting the fusion efficacy.
Figure 3.7: Schematic depiction of the targeted alternating cell alignment between the electrodes
of the fusion chamber. The arrangement has to be adjusted alongside the field lines, depicted
here in yellow.
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Within the scope of this thesis, novel electrofusion systems were established on the basis of
this conceptual design. The underlying principle of cell arrangement inside the fusion chamber
is depicted in figure 3.7, where the cells are aligned along the field lines pictured in yellow. The
development and technical engineering of such an electrofusion chamber requires a concept how
particles such small as a cell can be arranged in a specific pattern. Two theoretical approaches
were developed and their feasibility has been examined in this thesis. The first is based on cell
immobilisation, with one fusion partner being bound to a surface in a pattern (see section 3.1).
The other approach focuses on microfluidic techniques for cell arrangement and is dwelled on
in section 3.2.
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3.1 Immobilisation
3.1.1 Concept
The first approach for the implementation of an alternating cell arrangement into a fusion
chamber is based on immobilisation. One of the two cell types involved in the electrofusion
process will be immobilised on lanes of monoclonal antibodies to prevent cluster formation.
The idea of immobilising cells in an alternating cell arrangement originated from the work
of Prof. A. Offenha¨user (head of the Institute of Thin Films and Interfaces 2 (ISG-2) at the
Research Center Ju¨lich) and its work on neuronal networks. To refine existing neuronal models
and gain deeper understanding of related processes, his research group produces artificial net-
works of neuronal cells on synthetic substrate surfaces (Lauer et al., 2001). The neuronal
cell growth is thereby controlled with micropatterned structures of laminin, an extracellular
matrix protein. The structural dimensions of the laminin pattern correlated with the shape of
the resulting cellular network as shown in figure 3.8.
Figure 3.8: Phase contrast micrographs of PCC7-MzN mouse embryonic neuroblastoma cells
on straight lines of patterned laminin. Comparison of cellular growth on different line sizes at
day 4 shows that on 6μm lines cells form big clusters (a), whereas on 2μm lines monocellular
lines are visible (b). Scale bar represents 100μm (pictures taken from Lauer et al., 2001).
The patterning has been performed with polydimethylsiloxane (PDMS) microstamps, in a
process called micro-contact printing (μCP). The transfer of this technique to the immobilisa-
tion of dendritic cells in lines forms the basis for the development of an arranged electrofusion
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Figure 3.9: Immobilisation approach for an arranged electrofusion chamber
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process based on immobilisation (see figure 3.9). In the process, the width of the antibody
lines will play an important parameter. The lines should not be too small to provide good
producibility, but not that wide that several cells bind over the line width and clusters are
obtained.
The first step in the immobilisation procedure comprises the printing of small lanes of
antibodies on the surface of the fusion chamber. These antibodies are used to immobilise the
cells since mature dendritic cells are non-adherent in culture. After the first cell type is added
to the chamber and the cells have bound to the antibody lines, all excessive cells are removed
in a washing step. Cell type 2 is added to the chamber and the cells sediment between the
immobilised cells building an alternating arrangement. The electrical field lines the cells up in
pearl chains and fixates them in this arrangement until the fusion pulse is applied.
This antibody-based approach allows for the disposition of the electrofusion chamber to
other fusion pairs by simply changing the printed antibody to another one who is specific for a
surface protein on the chosen cell type.
3.1.2 Covalent Immobilisation of Antibodies
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Adsorption
Physical adsorption was the first method that was tested. Unfortunately, adsorptive immobili-
sation as used for the coating of polystyrene plates with antibodies for ELISA (enzyme-linked
immunosorbent assay) did not allow a structured immobilisation. At the first contact with fluid
during a washing step, the antibodies adsorbed in structures were detached and spread over
the complete surface. Thus, a chemical covalent binding of antibodies was mandatory.
A further advantage of a chemical binding is the oriented binding of the antibody molecule
in comparison to the unoriented immobilisation of the biomolecules by physical adsorption.
Antibodies or immunoglobulins G (IgG) are a family of Y-shaped glycoproteins. The an-
tibody molecule is a tetramer with a molecular weight of about 150 kDa. It consists of two
identical heavy and two identical light peptide chains. The upper part of the heavy chains
and the light chains build the variable region (Fab-region), which is unique for each antibody.
These Fab fragments react with antigens to yield immune complexes. The lower part of the
heavy chains is known as Fc fragment.
A covalent coupling of antibodies can be realised via the terminal amino- or carboxyl groups
of the peptide chains. The mode of the antibody immobilisation will thereby determine the
orientation of the antibody on the surface. An important factor for the successful antibody
immobilisation is the accessibility of the Fab fragments for the interaction with the antigens,
and as a result the antibody activity. In addition, the spacer length has a big influence on the
immobilisation reaction. Longer spacers optimally decrease the steric interactions among large
molecules such as antibodies and increase binding capacity. Thus, the activity of the antibodies
needed to be proven after their covalent attachment by binding of a sample cell line.
In the following, three different routes of chemical binding of antibodies have been investi-
gated. For all immobilisation reactions tested the antibody solution was applied as a drop on
the activated surfaces.
Photolinker
The immobilisation of antibodies in a photochemical reaction was tested on polystyrene (Bora
et al., 2002), polypropylene and polyethylene (Naqvi et al., 2002). The surfaces were
coated by 1-fluoro-2-nitro-4-azidobenzene (FNAB) and activated by exposure to ultraviolet
(UV) light. Upon UV excitation, the azido group of FNAB is transformed into a highly reactive
nitrene, which inserts the C-H bonds of the polymer by a covalent linkage. A primary amino
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group of the antibody is then bound to the activated polymer in a thermochemical displacement
reaction of the fluoro group of FNAB, which is then part of the polymer.
Thiol-Terminal Silanes and Heterobifunctional Cross-Linkers
A covalent bond formation between a hydroxyl group of a glass surface, a thiol-terminal
silane, a heterobifunctional crosslinker and the antibody was tested next (Bhatia et
al., 1989). The modification of the surface’s hydroxyl groups was accomplished with 3-
mercaptopropyltrimethoxysilane (MTS). The silane is covalently attached to the hydroxylated
glass surface under an inert atmosphere to protect the thiol-group of oxidation. This thiol-
group can react with the maleimide group of N-gamma-maleimidobutyryloxy succinimide ester
(GMBS), the heterobifunctional crosslinker. The succinimide residue of this linker is left to
bind a primary amino group of the antibody through the formation of a stable amide bond.
Aminosilanes and Homobifunctional Cross-Linkers
The third method uses again a silane film for modifying the negative hydroxy groups of a glass
or silica surface. 3-aminopropyltriethoxysilane (APTES) was chosen as silane, which bears the
functionality for attaching an antibody via glutardialdehyde as homobifunctional cross-linker
(see figure 3.10 for reaction scheme) (Wang and Jin, 2004). First of all, silanol groups are
formed on the glass surface by hydroxylation using aqueous sulfuric acid in a cleaning step.
Then, the aminosilane binds to these hydroxyl groups, whereupon an ethoxy group of APTES
is hydrolysed by a nucleophilic displacement resulting in a reactive silanol group, which forms
a siloxane linkage to the activated glass surface. The silanisation leaves a primary amino group
on the surface, which reacts with the cross-linker glutardialdehyde in an addition-elimination-
reaction. A stable imine is formed containing a carbon-nitrogen double bond. This Schiff’s base
reaction is repeated in the last step of the immobilisation reaction, where the residual carbonyl
group reacts with a primary amino group of the antibody.
Satisfying results could only be obtained with the last reaction. All other reactions were not
suitable in terms of the amount of immobilised antibodies. The aminosilane/glutardialdehyde
procedure gave a high density of immobilised antibodies and also maintained antibody function
as determined by antigen binding in a cell-binding test. Cells of the cell line KG-1 (from human
acute myeloid leukaemia) were used as model suspension cell line. They were immobilised
using an antibody against the CD34-Antigen (CD = Cluster of Differentiation), which is highly
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Figure 3.10: Reaction scheme for the coupling of antibodies to a glass surface by 3-
aminopropyltriethoxysilane and glutardialdehyde
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expressed on the surface of KG-1 cells.
Figure 3.11: Immobilisation of KG-1 cells on a APTES/glutardialdehyde-treated glass surface
via a covalent coupled anti-CD34 antibody: The antibodies were immobilised in a drop shape.
The picture was assembled from multiple micrographs.
The results were promising for a structured immobilisation of cells (see figure 3.11). KG-1
cells were bound circularly on the glass carrier, but it has to be noticed, that no cells were
bound inside the drop shape. This suggests that the antibodies were immobilised only on the
drop interface or that at least the antibody concentration was higher at this interface, resulting
in cell binding. Whether this behaviour may be obstructive for the patterning of antibody lines
needed to be checked in further experiments.
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3.1.3 Softlithography
For the control of the cell position inside the electrofusion chamber, small lines of antibodies
should be deposited on the surface of the fusion chamber. Such a line pattern can be created
by softlithographic methods.
The term softlithography summarises a group of microstructuring techniques, which are
based on the application of polymeric stamps. These softlithographic methods allow the gener-
ation of surface patterns in the micrometer and submicrometre range. In contrast to commonly
used photolithography, no radiation is used for the pattern formation and the resolution of the
pattern is not diffraction limited. Nevertheless, the production of the masters, which are needed
for casting the elastomeric stamps, still requires photolithographic methods (see Technique Box
on page 46).
Microcontact Printing
For a first attempt, microstamps, manufactured by the Institute of Thin Films and Interfaces
2 (ISG-2) at the Research Center Ju¨lich (Vogt et al., 2003) were used to print antibody
lines. The polydimethylsiloxane (PDMS) stamps were fabricated curing PDMS prepolymer in
2mL Eppendorf tubes upside down on a master with a line pattern. These stamps possessed
structures in a width range of 50μm to 100μm. Obviously, antibody lines printed with these
stamps would be far too wide to just bind one cell over the line width, but would give a first
impression of the transferability of the aminosilane/glutardialdehyde immobilisation reaction
to micropatterning.
The chosen surface chemistry for the antibody immobilisation consisted of three reaction
steps: functionalisation of the glass surface with 3-aminopropyltriethoxysilane, cross-linking
with glutardialdehyde and binding of the antibody. To obtain an antibody pattern in the end,
it would be sufficient to pattern just the last reaction step using an microstructured elastomeric
stamp, but patterning of two or all reaction steps is also conceivable. However, if all reactants
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are applied to the solid surface using the stamping technique, it has to be presumed that
the stamp is repeatedly contacted with the surface at exactly the same position. Therefore,
the stamp can be clamped to a special instrument, which guarantees the micrometer accurate
deposition.
In the present case, the surface chemistry circumvented the printing of all reaction steps,
since they differed strongly in the necessary reaction conditions. While the first reaction step
was carried out at 60◦C, the second step took place at room temperature. Thus, the substrate
needed to be manoeuvrable and a clamping to a special instrument was not suitable. This
left the possibility of patterning one reaction step. Preferentially, the last step, the antibody
binding, offered a good point for the patterned application. Simultaneously, the printing of the
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antibody reduces the amount of used antibody, since not the whole surface needs to be covered
with the antibody solution, but the stamp is wetted with the antibody containing solution and
then pressed onto the chemically modified surface.
Figure 3.12: Immobilisation of KG-1 cells via anti-CD34 antibody: The antibody was applied
using a microstamp to a glass surface completely functionalised with APTES/glutardialdehyde.
80μm wide antibody lines show binding of multiple cells over the line width. Cell clusters could
also be observed in the space between the printed antibody lines.
The first immobilisation results as shown in figure 3.12 confirmed that the patterned immob-
ilisation of cells is feasible. Nevertheless, the cells from the used model cell line KG-1 did not
only bind to the antibody imprinted onto the surface by the contact between the stamp and the
substrate, but also to the aminosilane/glutardialdehyde functionalised surface in between the
lines. The latter cell binding probably came from non-specific adsorption to the long aliphatic
chains of APTES. Blocking agents such as Tween 20 did not reduce this unspecific binding,
but a solution to the problem could be found, using the PDMS microstamps in an inverse
microcontact printing process.
Inverse Microcontact Printing
In the case of inverse microcontact printing, an elastomeric stamp is used to cover the whole
substrate area except for the part where the proteins/antibodies are placed (Kane et al.,
1999). Therefore, big stamps with a diameter of 7.5cm were produced, which had the size to
cover a glass wafer of the same diameter. The stamps were designed to combine four different
line widths 10, 15, 20 and 30μm on one stamp separated by a 1cm space. The width of the
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lines were chosen to bind one dendritic cell per line width. Every line bundle covered 200μm in
width (the distance between the two electrodes in the future electrofusion chamber). Obviously,
depending on the line width the amount of lines per bundle varied. The distance between each
line in a bundle to the next line was equivalent to the line width itself and should assign a place
for the second fusion partner, the breast cancer cells. For the 10μm lines (20μm pitch), 10 lines
built a bundle, for the 15μm lines (30μm pitch), the 20μm lines (40μm pitch) and the 30μm
lines (60μm pitch), the bundle consisted of 7, 5 and 3 lines, respectively.
These PDMS stamps were subsequently brought into contact with the glass substrate and
by sealing the PDMS structure with the glass surface, a microfluidic network was formed, which
defined the areas of inking. These channels could then guide the solutions for the immobilisation
reaction over the substrate. Thereby, the elastomeric properties of stamps made of PDMS
ensured conformal contact with the substrate. A watertight seal was formed via van der Waals
forces between the soft PDMS silicone structure and the hard glass surface.
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Mask Preparation
The layout for the stamps (as described above) were designed using an CAD (computer aided
design) programme. The length of the line structure was 4cm. An electron beam writer trans-
posed the different line pattern to a chrome mask.
Master Preparation
Stamp masters were produced under standard photolithographic conditions, using the nega-
tive photoresist SU-8 25 (after Mourzina et al., 2005). SU8 25 is a high contrast, epoxy
based photoresist. The exposed and subsequently cross-linked portions of the film are rendered
insoluble to liquid developers. The resist was spin-coated with a layer thickness of 15μm on
a 0.6 mm thick silicon wafer (this value corresponds to the height of the microfluidic chan-
nels in the PDMS replica). The film was exposed to UV light via a photomask for 33sec and
pre- and postbaked following the manufacturer’s instruction. After the development with PG-
MEA (propylene glycol monomethyl ether acetate), they were silanised with a 3 % solution of
chloro(dimethyl)octadecylsilane in toluene for 1.5h for better mould release. Followed by rinsing
with 2-propanol and water, the masters were dried with argon, analysed via scanning electron
microscopy (see figure 3.13 on page 51) and stored.
PDMS Stamp Preparation
Elastomeric stamps were made from polydimethylsiloxane (PDMS). The elastomer and curing
agent were mixed in a 10 : 1 ratio. Bubbles were removed from the mixture under vacuum
in an excicator and the prepolymer mix was poured onto the master. For these purposes, the
masters were clamped into a special holder (in-house production; see figure 3.14 on page 52)
and 11g of prepolymer mix were applied per master. The PDMS covered masters were degassed
again for 5min to remove all bubbles and were subsequently cured for 4h at 60◦C, whereas the
heating shortened the polymerisation time. After curing, the PDMS stamps were peeled off as
a negative cast of the master and surmounting stamp parts were removed.
Moulding provided the replica that contained three of the four walls necessary to form
enclosed channels. Sealing the replica to a flat surface as for inverse microcontact printing
provided the fourth wall. To allow filling of the channels, after conformal contact of the stamp
with the substrate surface was established, filling holes (one at every end of a channel or
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Figure 3.13: Scanning electron micrographs of master structures raised from negative photoresist
SU-8 25 on a silicon master: A) three 30μm wide and 15μm high structures, B) 30μm wide,
15μm high, c) a 100μm wide and 25μm high structure. The results demonstrated that smaller
structures can be obtained the thinner the spincoats are applied. Best results were obtained
with a structure height of 15μm.
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Figure 3.14: Photographs of the produced master for the PDMS stamp preparation. The master
was placed into a special holder for the moulding with PDMS. A) master and holder (in-house
production), B) assembled, C) defect master where the photoresist lines were detached, due to
improper handling such as sonication.
3.1. IMMOBILISATION 53
Figure 3.15: Photographs of PDMS stamps for inverse microcontact printing: A) PDMS stamp
with punched holes for filling the channels, B) punched filling hole in PDMS with connection
to channel, C) 15μm channel in PDMS stamp.
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channel bundle) were punched with the help of a ticket-punch into the PDMS stamp (figure
3.15). Subsequently, the stamps were cleaned in 2-propanol under ultrasonication and rinsed
with water. The PDMS stamps provided a hydrophobic surface. For a better filling of the
PDMS channels during inverse microcontact printing, the surface was rendered hydrophilic
by ultraviolet/ozone (UVO) treatment (Efimenko et al., 2002), simultaneously removing
organic residues. This UVO treatment caused significant changes in the surface and near surface
structure of the PDMS. The molecular oxygen and ozone created during the process interacted
with the UV-modified PDMS, resulting in a large number of hydrophilic groups.
Not to loose the hydrophilic character again, the stamps were treated for 1h with a 0.1M
sodiumhydroxid solution, thoroughly washed with water under ultrasonication and stored in
deionised water. Just before use, the stamps were dried under a stream of air. The above
protocol was also used under sterile conditions when appropriate.
Figure 3.16: Fluorescent images of channels in PDMS stamps to examine the quality and filling:
Channels of different widths from 30μm down to 10μm in a PDMS stamp filled with a green
fluorescent fluid (na.fluorescein).
For the immobilisation process, the PDMS stamps were attached to a glass wafer and air
bubbles, which disturbed the conformal contact were removed. The channels in the PDMS
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stamp were examined for quality and filling properties (see figure 3.16). Finally, PDMS stamps
with intact channels of channel widths of 10, 15, 20 and 30μm were produced successfully.
Immobilisation Reaction
Before the immobilisation reaction, the glass wafer (borosilicate glass) were incubated together
with the stamps (as described above) in a 0.1M sodiumhydroxid solution for an hour, rinsed
with water and dried under a stream of air. The stamps were contacted with the substrate and
the channels were formed.
Subsequently, all three steps of the immobilisation reaction took place in the microfluidic
channels. Firstly, a 10 % aqueous solution of 3-aminopropyltriethoxysilane was prepared and its
pH adjusted to 3.45 with 6M HCl. The microfluidic channels were filled, whereas a drop of the
reaction solution was placed in the filling hole of one side of the channel and sucked through
the channel by applying an vacuum with a vacuum pump at the other end. The solution
reacted with the glass surface for 1.5h at 60◦C in a convection oven. The oven was turned off
and another 2.5 hours were given to cool the substrate down and complete the reaction. The
channels were emptied with the use of a vacuum pump and washed three to four times with the
next reaction solution, a 2.5 % solution of glutardialdehyde in a 0.1M sodium phosphate (pH
7). Then, channels were filled free of blowholes with the glutardialdehyde solution and left at
room temperature for 2h. After depletion of the channels, a fluorescein isothiocyanat (FITC)-
labelled bovine serum albumin (BSA) solution was filled in and left over-night at 4◦C. In this
case, the BSA was used as a model protein for immobilisation instead of the antibody, since it is
cheaper and easier to detect with its higher fluorescent label per protein ratio. For analysis, the
PDMS stamps were simply peeled of the glass substrate and the latter was thoroughly washed
with water and dried in a stream of air.
Blocking of Channels
With the use of the fabricated PDMS stamps for inverse microcontact printing, a patterned
immobilisation of FITC-labelled BSA was obtained. Nevertheless, a few drawbacks were caused
by operating the whole immobilisation reaction inside the PDMS channels. The filling and
depleting of the channels after each reaction step was problematic. Not every channel was
emptied and filled for the next reaction step, because of blockage of the channels. Some channel
showed dried up parts at the boarder of the channels (see figure 3.17 A on page 56) or were
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Figure 3.17: Immobilised FITC-labelled bovine serum albumin (BSA) on glass: A) Three 30μm
lines of immobilised BSA are shown with only the middle line showing homogenous immobi-
lisation. The other two protein lines show debris at the border of the line; B) Seven 15μm
wide lines of immobilised BSA should be visible, but only part of the channels show protein
immobilisation; C) The picture shows a curved line of immobilised FITC-labelled BSA, which
probably resulted from bursting of the channel by the applied vacuum.
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totally blocked (figure 3.17 B). In conclusion, a successful protein immobilisation in the desired
pattern was possible, but the reaction protocol needed to be optimised for the use with PDMS
stamps.
3.1.4 Optimisation of the Immobilisation Reaction for the Printing
Process
To avoid blockage in the microfluidic channels, which are formed between the PDMS stamp
and the glass substrate in the inverse microcontact printing technique, the surface chemistry
for protein immobilisation using aminosilane and glutardialdehyde was further analysed. Every
single reaction step was investigated and optimised for best performance in inverse microcontact
printing.
Substrate
Borosilicate glass was used as a substrate for the protein immobilisation. Glass is widely used in
chemical and biological reactions. It is based on silicon dioxide (SiO2) and is built of oxygen tet-
rahedra around Si4+ ions with the tetrahedra being linked together to form a random network.
As all commercial glasses, it contains small amounts of water in form of hydroxyl ions (OH−).
The hydroxyl groups of the glass surface are used as starting point for the immobilisation
reaction. They are converted to stable oxane bonds by reaction with a silane.
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First Reaction Step: Functionalisation with Silane
3-Aminopropyltriethoxysilane was utilised as a silane-coupling agent. Generally, silanes
with three alkoxy groups are used as a starting point for substrate modification. 3-
Aminopropyltriethoxysilane combines the organic chemistry of an amino group with the in-
organic chemistry of silicates to bridge the hydrophilic interface between mineral substrates
and organic molecules. This aminosilane is water-soluble and the resulting solutions have un-
limited stability over a wide range of concentrations. Trialkoxysilanes hydrolyse step wise in
water to give the corresponding silanols, which ultimately condense with silanol groups of the
glass surface to form siloxane linkages without altering the amino group. At a pH of 3 to 4,
as adjusted for the used 10 % aminopropyltriethoxysilane solution in water, the initial hydro-
lysis is relatively rapid and may be considered complete to the triol in 1 to 30 minutes. The
stability of the solution was examined over 2 hours by means of nuclear magnetic resonance
(NMR), since the silanol groups can condense and become unavailable for bonding with the
substrate surface. Figure 3.18 shows the spectrum of the aminosilane. The solution was stable
over the contemplated time. No conversion of the aminosilane was observed and only the five
characteristic peaks of the C atoms of aminosilane can be seen in the NMR spectrum.
Figure 3.18: 13C nuclear magnetic resonance spectrum of 3-aminopropyltriethoxysilane
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The heating of the first reaction step to 60◦C for 2h insured the silanol condensation at the
surface, but simultaneously caused blocking problems, when the small PDMS channels ran dry.
To solve this blocking problem, different reaction times (1h, 2h and over night incubation) and
conditions (60, 100 and 120◦C) were tested (data not shown), in parallel with different solvents
such as ethanol, toluol and water for the aminosilane solution. The reaction was analysed by
imaging ellipsometry (see figure 3.19 on page 60) to assist the selection of the optimal reaction
parameters. Lower concentrations of aminosilane were also assayed regarding an effect on the
amount of blocked channels after the first reaction step (data not shown).
The results indicated, that the exchange of the solvent to ethanol or toluol did not decrease
desiccation and showed worse functionalisation of the glass surface as imaged with ellipso-
metry. Furthermore, the toluol was not compatible with the use of the PDMS stamp in inverse
microcontact printing. It spread under the stamp, thus disturbing the patterning.
Finally, the blocking of the PDMS channels in the first reaction step was avoided by reducing
the reaction time to 1h. Additionally, the reaction was carried out in a convection oven with
humidified atmosphere and filling holes of the stamp were sealed with adhesive tape to avoid
desiccation. Thereby, all channels were refillable after the first reaction step. The covering of
the stamp’s filling holes with adhesive tape was retained also for the other reaction steps.
Second Reaction Step: Cross-Linking with Glutardialdehyde
Subsequently, the aminosilane-functionalised glass surface is cross-linked with glutardialdehyde.
A 2.5 % aqueous glutardialdehyde solution in 0.1M sodium phosphate buffer was used and
reacted with the amine-containing matrix for 2h at room temperature. Again, extensive blockage
of the PDMS channels was observed. Covering of the filling holes with adhesive tape did not lead
to satisfying results. There was evidence that the blockage was related to the use of 0.1M sodium
phosphate buffer as a solvent for the 2.5 % glutardialdehyde solution (pH 7). A reduction of
the salt concentration was tested by using a 0.01M or 0.001M phosphate buffer, respectively,
but the subsequent protein immobilisation was not successful when using these buffers with
lower salt concentrations. An explanation for this observation was found in the character of
the addition/elimination reaction on the carbonyl group and the factors affecting the reaction
kinetics. In the presence of a strong nucleophil such as a primary amine, the nucleophil adds to
the carbonyl group forming a tetrahedric intermediate, followed by the transmission of a proton
and the condensation to the imine. In such a system, the total reaction rate is diminished by
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Figure 3.19: Live Images and 3D maps of aminopropyltriethoxysilane functionalised lines on
glass. A 10 % aminosilane solution in different solvents was reacted for 1h at 60◦C with the
substrate: A) 85 % ethanol (pH 4.5-5.5), B) toluol (pH not adjusted), C) in water (pH 3.45)
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proton donors, since the amount of nucleophil for the reaction is reduced. Thus, the reaction
of primary amines is not catalysed by acid, because the ammonium groups, which would result
from protonation, are not nucleophilic towards the carbonyl group, and the carbonyl group
cannot compete against the primary amine for protonation. Using the 0.01M and 0.001M
sodium phosphate buffer, the buffer capacity, which is already low because of the low salt
concentration, was exceeded. Residues of the aminosilane solution with a pH of 3.45 are left in
the PDMS channels after the first reaction step. By washing with the next reaction solution,
most of it is removed, but a good buffer capacity is still needed to keep a neutral pH for the
second reaction step. In the case of the use of lower salt concentration for the phosphate buffer,
an acidic condition is present in the second step, which slows down the reaction, because of the
reasons given above.
Analysis of the buffer revealed a high number of particles (3.5 · 106 particles) with an
average size of 4.74μm. Two filtration cycles using an aseptic filter (pore size: 0.22μm) reduced
the number of particles by 97.2 %. Removing those particles, which probably were insoluble
impurities from the sodium phosphate, solved the problem of channel blockage.
Third Reaction Step: Binding of Protein (e.g . Antibody)
The optimisation of the two preceding reaction steps solved the blockage problem. The PDMS
stamp was removed after the third step. In this step, the protein (e.g . an antibody) was immo-
bilised via its primary amino groups in a Schiff’s base reaction with the second carbonyl group
of the glutardialdehyde of the previous cross-linking step.
As a test system, the monoclonal antibody anti-CD34-FITC and FITC-labelled BSA were
immobilised successfully in lines of different width by inverse micro contact printing (see figure
3.20). The use of a FITC-labelled BSA solution with a concentration of 200μg/mL resulted in
a homogenous immobilisation of the protein over the width and length of the PDMS channels
(as shown in figure 3.20 A and B). The immobilised antibody (Ab) lines (Ab concentration:
6μg/mL) looked inhomogeneous and less dense. To analyse the immobilised protein lines, each
reaction step was examined by imaging ellipsometry, a sensitive optical method of quantifying
thin layers (see Technique Box on page 61).
The immobilised antibody (anti-CD34-FITC) and immobilised BSA lines (FITC-labelled)
were analysed qualitatively by ellipsometry of an 0.4 · 0.6mm2 area with a spatial resolution
of 2μm. Figure 3.21 on page 64 shows a live image and an image with inverted ellipsometrical
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Figure 3.20: Fluorescence micrographs of immobilised proteins on glass via aminopropyltri-
ethoxysilane and glutardialdehyde: A) BSA-FITC in a 50μm channel; B) BSA-FITC (bovine
serum albumin) in a 30μm channel; C) anti-CD34-FITC antibody in a 80μm channel.
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contrast of both samples. The ellipsometrical contrast was inverted to verify that the structure
shown in the live image was not due to interferences. The ellipsometrical images of the antibody
line confirmed the inhomogeneity, which already had been observed via fluorescence microscopy.
Generally, the lines of immobilised protein are clearly silhouetted against the background.
Figure 3.21: Live images (A and C) and ellipsometrical contrasts (B and D) of an immobilised
antibody line (anti-CD34-FITC) (A and B) and an immobilised FITC-labelled BSA line (C
and D)
In a subsequent quantitative measurement the film thickness and refractive index were de-
termined. First of all, the optical parameters of the substrate were measured in the surrounding
of the protein line. To obtain a higher accuracy, the number of the measured parameters were
increased by recording a spectrum of the angle of incidence. Data for the ellipsometrical angles
Delta and Psi were measured near the Brewster angle from 55◦ to 57.5◦ in 0.2◦ steps. From
these data, the optical constants of the substrate were defined, which were then applied for the
determination of film thickness of the protein lines.
With the help of an optical model the film parameters were calculated. Therefore, the
measured data for Delta and Psi were fitted to the model (see figure 3.22 on page 65 for an
example). The measured data showed a good compliance with the fitted data.
A refractive index of 1.495 and 1.513 was obtained for the antibody line and the BSA line,
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Figure 3.22: Measured and fitted Delta and Psi data for the glass substrate (surrounding) and
an FITC-labelled BSA line (named stripe 6).
Figure 3.23: 3-dimensional film thickness map of an immobilised FITC-labelled BSA line. The
z-axis gives the film thickness in nm, x- and y-axis are random units.
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respectively, which is a typical value for biomolecules. The film thicknesses were averaged over
the inhomogeneity of the protein lines, resulting in 80.9nm for the anti-CD34-FITC antibody
line and in 68.2nm for the FITC-labelled bovine serum albumin line, respectively. The BSA
line with a height of 68.2nm was also displayed as a 3-dimensional thickness map in figure 3.23
on page 65.
To check the reproducibility of the measurements, 10 measurements were conducted exem-
plary on one position of the substrate and also on ten different positions on the substrate. A
reproducibility of 0.05nm at the same position and 1nm at different positions of the substrate
arised from the measurements.
One reason for the inhomogeneity of the anti-CD34-FITC antibody line could be due to the
low concentration (6μg/mL) of the commercially available antibody, thus not enough antibody
was present to form an homogenous film. Unfortunately, this antibody was not available in
higher concentrations. Therefore, an unlabelled anti-CD34 antibody, which was available in a
concentration of 55μg/mL, was tested. The ellipsometrical live image (see figure 3.24) showed
a homogenously immobilised antibody in a line.
Figure 3.24: Ellipsometrical live image of an anti-CD34 antibody line
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3.1.5 Cell Binding
Using antibody lines for the binding of cells in an electrofusion chamber, the specificity of the
antibody determines the type of cell, which can bind to these lines. For a broader application to
various cell systems and different fusion partners, the immobilisation of a linker protein, such
as streptavidin could be used (see figure 3.25). This would allow binding of every cell type,
which is coupled to an individual biotinylated antibody, to the streptavidin line.
Figure 3.25: Diagram of direct binding of cells to antibodies and indirect binding via strep-
tavidin/biotin linkage
The streptavidin/biotin system was tested successfully with inverse μCP and streptavidin
was immobilised homogenously as proven by ellipsometry (data not shown). Using this system
extends the number of reaction steps by one. For this reason, the direct immobilisation via
covalently bound antibodies was used for all subsequent experiments.
In previous experiments described in section 3.1.3 and 3.1.4, the cell line KG-1 was bound
to an anti-CD34 antibody. To transfer this approach to primary dendritic cells, an antibody
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specific for surface proteins expressed by DCs needed to be chosen.
The selection of an antibody for DC binding was determined by its required properties: A
blockage of receptors important in immunological reactions such as co-stimulation by CD80 or
CD86 had to be avoided and the antibody should be usable with primary DCs as well as with the
cell line KG-1. Therefore, the antibody anti-CD45 was chosen. It is expressed on both the cell
line KG-1, an erythroleukemia cell line, which shares morphological and physiological properties
with myeloid DCs, and primary DCs. The CD45 antigen is a tyrosine phosphatase also known as
leukocyte common antigen (LCA). It is expressed on all human cells of haematopoietic origin,
except erythroid cells, platelets and their precursor cells.
Firstly, KG-1 was used for the binding experiments of a cell to the anti-CD45 antibody, which
is shown in figure 3.26. The cell line was attached to antibody lines in 10μm, 15μm and 20μm
width. As demonstrated in figure 3.26C, KG-1 cells bound to the 10μm lane of immobilised
anti-CD45 in a monocellular chain. The figure shows clearly that the arrangement of cells in
chains is determined by the cell diameter and therefore by the width of the antibody lanes. In
the next experiments, primary DCs were bound to the anti-CD45 antibody. The antibody was
immobilised in 10μm, 15μm and 20μm lanes and DCs were incubated. Figure 3.27 on page 71
demonstrates the results analysed by scanning electron microscopy (SEM). As the diameter of
DCs was bigger compared with KG-1 cells (20μm compared to 15μm), 15μm lanes showed that
the cells bound over the width of the antibody line (figure 3.27A). The dendritic cells stretched
along the line (figure 3.27B) and the extensions of the DCs did not exceed the antibody lane
(figure 3.27C). In figure 3.28, multiple lines of immobilised antibody were used to bind primary
DCs. The cells line up along the lines, but the preparation of the biological specimen for the
SEM analysis removed some of immobilised cells due to dehydration and gold sputtering.
The human anti-CD45 antibody was used in all subsequent experiments and produced in
two continous fermentations of up to 10L of the hybridoma cell line CF10H5 (data not shown).
After the binding of the cell line KG-1 and the primary DCs, the alternating arrangement
of the fusion partners was tested. KG-1 cells were stained with the cytosolic CellTracker dyes
CMTMR (red) and CMFDA (green), respectively. The red KG-1 cells were bound to the anti-
CD45 antibody lines with a width of 10μm. After removing the excess of cells by washing, the
green KG-1 cells were added (see figure 3.29 on page 73). The green KG-1 cells settled in the
spaces between the red bound cells and an alternating arrangement of red and green KG-1 cell
lines was obtained. In the following section, the detachment of bound cells was investigated. In
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Figure 3.26: Light microscopy pictures of the immobilisation of KG-1 to antibody lines: A) This
picture shows a 20μm wide antibody line. This line is too wide for the binding of KG-1, thus
the cells do not line up in a chain; B) shows binding of the cells to nine parallel antibody lines
(15μm); C) the picture shows the aligning of cells in a chain bound to antibody lanes with a
width of 10μm.
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Figure 3.27: Coloured SEM pictures of single dendritic cells bound to an antibody line: A) shows
that the chosen size of 15μm for the antibody line correlates with the size of the dendritic cell;
B) shows a dendritic cell stretching along an antibody line; C) shows that the extensions of the
DC do not protrude over the edge of the antibody line.
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Figure 3.28: Scanning electron micrographs of immobilised antibody stripes and dendritic cells
bound to it: A) The micrograph shows part of an immobilised antibody stripe on the right and
the glass substrate on the left; B) Dendritic cells bound side by side on an antibody line; C)
Coloured photo of dendritic cells on antibody lines (15μm).
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a fusion process, DCs are bound to antibody lines that are covalently immobilised to the glass
surface and fused to an unbound fusion partner. After the fusion process, the cell-antibody
connection has to be broken up to yield a fusion product.
Figure 3.29: Alternating arrangement of red and green KG-1 cells, stained with CMTMR (red)
or CMFDA (green), respectively, opposed to the schematic representation.
3.1.6 Cell Detachment
The binding of the cells to the antibody micropattern resulted in immobilised hybrids after
the fusion process. The disruption of the antigen-antibody-complex is needed for harvesting the
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hybrids. Mild conditions are preferred not to damage the cells. Pepsin (from porcine stomach),
papain, trypsin, high salt concentration and pH shift were tested as displacement agent for the
immobilised cells. The first three are proteases, which cleave protein at defined amino acids.
Especially papain and pepsin are known to cleave antibodies near the hinge region and separates
Fc and Fab fragments from each other. All five approaches were tested for the detachment of
antibodies from the bound cells, either by cleavage of the antibody or by detachment of the
antigen-antibody binding. The best results were obtained using a pH-shift from a neutral pH
to an acidic pH of 2 (see figure 3.30).
Figure 3.30: Detachment of an anti-CD45 antibody from KG-1 or dendritic cells by a short
drastic shift of the pH from pH 7.4 to pH 2. The unlabelled cell peak is outlined in blue
(negative controlled), the stained cell peaks are depicted in red (before treatment with pH 2
(red filled) and after treatment (red outlined)).
In the first step, the cell detachment analysis were performed using FACS (fluorescent
activated cell sorting). The cells were labelled with an anti-CD45-PE antibody and measured
in a flow cytometer using unlabelled cells as negative control. The labelled cells, which bound
the antibodies to their surface (CD45-antigen), were then treated with a 25 % v/v solution of
hydrochloric acid for 30sec and immediately neutralised with a great volume of saline phosphate
buffer (PBS) with neutral pH. The results (figure 3.30) showed, that all anti-CD45 antibodies
bound to KG-1 cells could be removed by this treatment. When transferring this technique to
dendritic cells, it was observed, that more antibodies bound per cell and that not all of them
could be removed with the pH shift. Whether this would be sufficient for the detachment of
immobilised cells from the substrate was tested in subsequent experiments and was successful.
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In addition, the occurrence of apoptosis, or programmed cell death, was monitored, using the
Annexin V-FITC apoptosis detection kit II for flow cytometry from BD Biosciences following
the manufacturer’s instruction. Apoptosis in its early stages can be detected by Annexin V,
which binds with high affinity to phosphatidylserine (PS). In normal cells PS is situated on
the inner leaflet of the plasma membrane, but during the early stages of apoptosis, PS is
translocated to the outer layer of the cell membrane. Because PS is exposed in the early stages
76 CHAPTER 3. RESULTS
of apoptosis when the cell membrane still remains intact an Annexin V assay coupled with
a dye exclusion test (propidium iodide) can discriminate between apoptotic and necrotic cells
(Vermes et al., 1995).
No apoptosis induction was observed in the detached cells, neither for KG-1 nor for dendritic
cells (data not shown). For KG-1 cells the result was verified by monitoring the growth curve of
pH 2 treated KG-1 in comparison to untreated cells over 14 days. No difference was observed.
Thus, both the cells and the antibodies survived the short subsidence of the pH. The latter has
been proven successfully by the reusage of the detached antibodies for cell binding. For DCs, the
results were verified by a wash-out-test additionally. After the differentiation from monocytes
to immature dendritic cells for six days and maturation for another two days, all differentiation
and maturation cytokines were removed and the DCs cultured for 48h in serum-free medium.
No differences in cell number or viability were observed for cells treated by pH 2 on day 6
compared with untreated cells.
3.1.7 Electrode Integration and Chamber Assembly
The next step in the development of a cell fusion chamber supporting the immobilisation
methods was the integration of electrodes and the build-up of the fusion chamber. According to
the commercially available fusion chamber by Eppendorf, it was aimed to integrate Platinum
wires with a diameter of 200μm. However, a positioning of the wires parallel to the antibody
lines was not possible and stretching the wires over the glass surface proved to be difficult, as
well.
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As an interim solution, electrodes were used, which were applied as conductor paths on a
400μm thick low temperature co-fired ceramic (LTCC) slab (see figure 3.31). The electrodes
were manufactured by a cut-out of 200μm width and 4 cm length in a AgPd conductor path
at Viaelectronic (Hermsdorf, Germany).
Figure 3.31: Schematic depiction and photograph of LTCC ceramic slab with electrodes for the
usage as fusion chamber in the immobilisation approach
Nevertheless, with the LTCC slab, the electrodes had to be positioned manually under
microscopic surveillance to run parallel to the antibody lines. With other approaches such as
the application of electrodes by vacuum deposition (e.g. gold electrodes), the same problem
persisted. The PDMS stamp had to be placed on the glass substrate with the electrodes in
that way, that the channels were formed parallel to the evaporated electrodes. In either way,
the positioning had to be accurate to a micrometer, which in principle was considered to be
difficult, and the instruments needed were not available.
Therefore, a method was developed, which avoided this positioning step. The electrodes
and lines for the antibody immobilisation were applied simultaneously by gold evaporation
onto a glass substrate. The applied structure combined the two electrodes with a width of
200μm and a length of 10 mm, their contact patches for impressing a voltage, and lines for
antibodies, which were applied in the 200μm space between the electrodes (see figure 3.32).
This approach was developed and realised at the university in Cranfield, UK in the research
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Figure 3.32: Schematic diagram of the electrofusion chamber assembly: A) A gold structure,
which comprises electrodes and lines for antibody immobilisation, is evaporated six times onto
a glass substrate, the size of a microscope slide; B) A bonding layer, made of double-sided tape,
is applied on top of the gold structure; C) The chamber is sealed with a acetate foil top layer.
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Figure 3.33: Photolithographic chrome mask with two times six gold structures: Three different
photolithographic masks were manufactured, which differ in the width of the lines for the
antibodies (not visible macroscopically).
group of Dr. Dave Cullen. The optical alignment of different structures were avoided and only
one photolithographic mask (see figure 3.33) was needed.
The photolithographic chrome mask was used with a photoresist lift-off process (see Tech-
nique Box on next page) to create the desired gold structures on a glass wafer. Three masks
were produced, which differ in the width of the lines for the antibodies from 5 − 15μm. The
line widths and spacing (from 15− 35μm) were varied to ensure to find the right combination
of line size and spacing for the fusion partners, dendritic cells and breast cancer cells.
LOR 3B was used as lift-off resist with the positive imaging resist S1813 to create a bi-layer
reentrant profile (see figure 3.34 on page 81 ). Thereby, the height of the lift-off resist needed
to be at least 1.2-1.3 fold the hight of the desired metal film. It was aimed for a gold film of
200nm height, plus a 2nm tick layer of chrome as adhesion mediator. Thus, the LOR spin-coat
should have a minimum of 262nm (see figure 3.34 B). The whole structure (LOR3B + S1813)
had a hight of about 1200nm.
The undercut rate is another important parameter. If the undercut is too big, the whole
photoresist structure can collapse (see figure 3.35). The undercut rate is mainly influenced
by the prebake temperature, followed by other parameters such as prebake time, exposure
dose of imaging resist, choice of developer and developing time. In general, it is recommended
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Figure 3.34: Cross sections of a bi-layer reentrant sidewall profile with LOR 3B and S1813
as imaging resist. A) The width of the photoresist structure determines the distance of the
structure elements e.g. lines within the whole gold structure. B) The height of the lift-off resist
needs to be 1.2 - 1.3 fold thicker than the metal film, which will be deposited, to obtain a
discontinuous metal film. C) Undercut of the lift-off resist.
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Figure 3.35: Cross section of a bi-layer reentrant sidewall profile with LOR 3B and S1813. The
exposure dose was to high, with 10sec exposure time, leaving only a small rest of the lift-off
resist. The photoresist structure nearly collapsed.
to keep the development time constant and adjust the exposure time as necessary to meet
critical dimension requirements. The best results for the given dimensions were obtained with a
exposure time of 8sec (UV light) and a development time of 40sec with the MF-319 developer.
After the right exposure and development settings were found, the metal film was deposited
on top of the photoresist structure. Due to the bi-layer reentrant sidewall profile, the applied
gold film was discontinuous. In the following step, the photoresist was removed with SVC-14
positive photoresist stripper, lifting-off most of the gold film, leaving only the desired gold
pattern on the glass surface (see figure 3.36). Twelve gold structures, each the basis for an
electrofusion chamber, fit on the size of a 14cm glass wafer, whereby a group of six could be
cut out, resulting in a glass slide with the size of a microscope slide.
A single gold structure comprises electrodes, contact patches and lines for the antibodies.
The antibody immobilisation to the gold surface will be described later on page 86. To avoid
immobilisation of the antibodies on the other gold structures such as electrodes and contact
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Figure 3.36: Gold structures on glass: A) Two times six structures of electrodes and lines for
antibodies of gold on a 140mm glass wafer; B) Micrograph of the 200μm wide electrodes with
five 10μm wide lines for antibodies in the space between the electrodes; C) Micrograph of the
same structure than in B, showing the branching to the contact patches.
84 CHAPTER 3. RESULTS
Figure 3.37: Assembly of the chamber for the immobilisation approach. The goldstructure was
applied 6 times on the size of a microscope slide and the electrode structures where covered by
the build-up of the electrofusion chamber: A) Microscope slide with six electrofusion chambers.
B) Each electrofusion chamber can be connected and operated individually. C) Multiple gold
lines for the immobilisation of the antibodies were deposited inside the electrofusion chamber.
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patches, they were subsequently covered by the build-up of a chamber on top of the gold
structure.
The parts for the chamber build-up were cut out of double-sided tape and acetate foil using
a CO2 laser (see figure 3.38). The three parts for the binding layer were cut out of double
sided tape and comprised holes for contacting the gold electrodes, a channel, which forms the
electrofusion chamber, and holes for filling the chamber. The self-adhesive parts were attached
to the glass surface and air bubbles were smoothed out. The structure was sealed with a top
layer of acetate foil, which comprised only the holes for filling the chamber and contacting the
electrodes.
Figure 3.38: Design drawing of the six pieces, which were used for the build-up of the elec-
trofusion chamber. Top row: These three pieces are cut with a CO2 laser out of double-sided
tape. Bottom row: Holes for filling the electrofusion chamber and contacting the electrodes are
comprised in the pieces, which seal the chamber.
The six pieces for the build up of the chamber fit accurately on a standard microscope
slide. An optical parallel positioning of the channel to the gold electrodes and gold lines for
the antibody immobilisation was not necessary, since the pieces were aligned by the outer
dimensions.
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3.1.8 New Surface Chemistry According to Design
For the immobilisation of antibodies on the gold lines a new surface chemistry based on
self-assembled monolayers (SAMs) were used. SAMs form spontaneously by chemisorption and
self-organisation of functionalised long-chain organic molecules on appropriate substrates. The
most widely studied systems have been SAMs formed by chemisorption of alkane-thiols on
metal surfaces such as gold and silver.
For the immobilisation of antibodies on the gold lines within the electrofusion chamber,
the gold surfaces were covered with a self-assembled monolayer of 11-mercaptoundecanoic acid
(MUA), an alkane-thiol with a terminal carboxy group (see figure 3.39 on page 87 for reaction
scheme). Therefore, the gold surfaces were immersed into an ethanolic solution of 1mM MUA
for 48h. Upon removal, the wafer were rinsed with absolute ethanol and soaked in water for
5min before drying under a stream of nitrogen. The well-ordered monolayers formed by this
alkane-thiol on the gold lines were carboxylic acid terminated. These functionalities of the SAM
were used to form an amide bond with primary amino groups of the antibodies.
To activate the SAM for the antibody immobilisation 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC), a water-soluble carbodiimide, was used, which activated the
carboxylic acid groups forming an unstable O-urea derivate (step is not shown in figure 3.39).
Subsequently, N-hydroxysuccinimide (NHS) esters were formed by exposure of the activated
monolayer to an aqueous solution of NHS for 1h at RT. These succinimidyl esters are susceptible
to nucleophilic attack by primary amines and form stable amid bonds in the presence of these
groups. The immobilisation occurs by the displacement of the NHS group by amino residues of
the antibody. Thus, the activated gold lines were exposed to an antibody solution where free
amine groups on the antibody surface nucleophilically attacked the succinimidyl-terminated
SAM, thus giving covalent attachment of the antibody.
The immobilisation of the antibodies were assessed using X-ray photoelectron spectroscopy
(XPS). XPS is widely applied to characterise the composition and chemistry of surfaces (see
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Figure 3.39: Strategy for the immobilisation of antibodies onto gold lines functionalised with
carboxylate-terminated SAMs
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Technique Box on page 88) and can be used for monitoring the process of surface modification
and control the binding of antibodies to a solid surface.
The XPS spectra for MUA monolayer activated with NHS/EDC (sample name: BC1) and
covalently bound antibodies to the MUA monolayer (BC2) are presented in figure 3.40. Four
different spectra regions for oxygen (O1s), nitrogen (N1s), carbon (C1s) and gold (Au4f) are
shown. Differences between sample BC1 and BC2 were particularly observed in the spectra
for nitrogen and carbon, since these two atoms are comprised within the amide bond, which
was formed when the antibodies were immobilised. This indicated that the reaction had taken
place.
Figure 3.40: High-resolution XPS peaks for four spectral regions on activated MUA monolayers
(BC1) and immobilised antibodies on MUA (BC2)
90 CHAPTER 3. RESULTS
In figure 3.41 the two regions, N1s and C1s, are shown at higher magnification.
Figure 3.41: High-resolution N1s (left) and C1s (right) spectra for activated MUA monolayers
(top) and immobilised antibodies on MUA (bottom). Peaks were fitted to the obtained spectrum
using Unifit for Windows, Version 32-32.
The presence of antibodies immobilised on the surface of the MUA SAM could be confirmed
by changes of peaks in N1s and C1s region attributed to the presence of an amide bond.
In the N1s spectra the peak at 402.5 eV corresponded to the nitrogen atom of the heterocycle
of NHS. This peak completely disappeared in the spectrum for the immobilised antibodies on
MUA (bottom panel), whereas the big peak at 400.5 eV corresponded to the nitrogen atoms
present in the amide bond. In addition, the small peak at 399.1 eV was related to amino groups
of the antibodies.
The high resolution C1s data obtained from the activated MUA surface showed three peaks
at 284.9, 286.2 and 288.9 eV, which were assigned to aliphatic carbons of the alkylchains (C-H),
carbons bound to sulfur and the acid group (CH2-S and CH2-COOH), and the carbon of the
ester group (O-C=O), respectively. The surface with the immobilised antibodies revealed the
same peak for C-H, but the third peak has been shifted from 288.9 to 288.7 eV, representing
the C atom of the amide group.
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Figure 3.42: Immobilisation of KG-1 cells stained with CMTMR (red) on a gold surface. The
left half of the gold surface was treated with MUA and the SAM layer was activated with
NHS/EDC. The right half was left untreated. Cells only bound to the functionalised part of
the gold surface.
Figure 3.43: The completed electrofusion chamber can be connected via a push-pull self-latching
connection system to the voltage generator from Eppendorf.
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In addition to the XPS measurements, which proved that the immobilisation reaction was
successful, KG-1 cells were bound via the immobilised antibody to the gold surface (see figure
3.42). These immobilisation reaction could furthermore be transferred to the immobilisation on
the small gold lines within the electrofusion chamber. Nevertheless, the glass surface should be
protected before the antibodies are added in the last reaction step (see reaction scheme on page
87). PEG silane was used for avoiding adsorption or binding of antibodies to the glass surface.
Therewith, the development of the electrofusion chamber was completed. The chamber can
be connected via a push-pull self-latching connection system to the voltage generator from
Eppendorf (see figure 3.43).
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3.2 Microfluidics
3.2.1 Concept
The second approach for the implementation of an alternating cell arrangement into a fusion
chamber is based on microfluidics. The handling of liquids and/or gases in small volumes or
small sizes is understood by this term.
The idea of using microfluidics for cell arrangement was aroused by the work of Prof. A.
Offenha¨user, who is in charge of the Institute of Thin Films and Interfaces 2 (ISG-2) at the
Research Center Ju¨lich. In former projects, he worked on the development of a microfluidic
device for localised drug application to cell cultures (Thie´baud et al., 2002).
The system was used for manipulating the growth of neuronal cell. It is displayed in figure
3.44 on page 95. This microfluidic device was fabricated using PDMS technologies. Two parts,
an array of micro-injectors and a base-flow channel, are assembled to form a system, which
allows the formation of eight independent and sharply defined lines of liquids. The published
results demonstrate that the application of different pharmaceutical components to cells of only
one culture can be performed.
The eight independent laminar flow lines possess a cross section of 100 ·200μm2. Notably, no
mixing occurred between the individual flow lines. Although not cells themselves were streamed,
but an extracellular matrix protein (laminin), which guided the neuronal growth afterwards. If
it is possible to stream cells in laminar flows without mixing, this would be a starting point for
the development of an fusion chamber for arranged electrofusion based on microfluidics.
So far, the streaming of cells in laminar flows has not been published. In many cases,
both microfluidics and laminar flows are used to overflow adherent cells to either study cell
adhesion or cell behaviour to flow conditions. They are also used to apply diverse pharmaceutical
components to distinct parts of a cell culture simultaneously.
Thus, the laminar flow of cells in microfluidic channels was tackled for the development of
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Figure 3.44: Microfluidic Device for patterned application of microfluids to neuronal cells de-
veloped by Thie´baud et al.: A) Photograph of the device compared with a syringe needle; B)
Micrograph of the PDMS microinjector top plate. The grooves of the eight injection channels
of the device are highlighted with arrows. The location of the picture frame in respect to the
entire device is shown in the insert (pictures taken from Thie´baud, P. et al., 2002).
a novel fusion chamber. This device should be designed in that way, that several small single-
cell flows will be streamed through a fusion chamber, which consists of a microchamber with
two electrodes (see figure 3.45 for graphic account). The streams are excited by two pumps,
which each deliver one cell type/fusion partner. An alternating cell arrangement arises from
the cogging of multiple flows. The further course of action envisions the stoppage or reduction
of the flows, the subsequent application of an electrical field to align the cells in pearl chains
and the fusion of the cells by an electrical pulse.
The development of such a flow-through electrofusion chamber requires the evidence, that
laminar flows from cell suspensions can be established. The laminar flow of molecular solutions
is well acquainted, but the behaviour of a fluid with particles, which are deformable, is neither
described nor can be easily predicted. Furthermore, the dimension of the microfluidic fusion
chamber has to be dramatically reduced in size compared to the microfluidic device presented
above. A cross section of 100 · 200μm2 would allow several cells to cluster and still pass the
channel. It is obvious that homologous fusions would be favoured. Therefore, the aim was to
scale down the cross section of an individual channel to 50 · 50μm2. The average diameter of a
dendritic cell is about 25μm (see chapter 3.3). Thus, a 50μm wide channel admits enough safe
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Figure 3.45: Microfluidic approach for an arranged electrofusion chamber
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distance for the cell, so that the channel walls would not harm the cells, but should prevent
the simultaneous transition of two cells or even bigger clusters.
3.2.2 Geometric Definition of Microfluidic Fusion Devices
In close cooperation with the Centre for Microtechnology and Surface Analysis of the Da-
nish Technology Institute the development of such a device, which allows the alternating cell
arrangement prior to the fusion process using microfluidic flows, commenced.
Different systems were designed taking two presettings into account: First of all, the fusion
devices had to allow for laminar flow inside the chambers. Secondly, a 50μm wide space should
be admitted for each single-cell flow. To realise these demands, elements such as channels or
trenches were integrated to guide the laminar flows in direction. In the end, two systems were
followed up.
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System 1
The first system contains channels, which end in a collective chamber. Figure 3.46 shows the
appearance of the microfluidic device. The system exhibits two levels. Cell solution A enters the
chamber via the cross section labelled in blue and is subsequently divided into four partial flows.
These flows ascend through standpipes entering the channels in the upper level. Cell solution
B is channelled through the red access area into a distributor, which divides the stream into
five partial flows. Covering a short distance in the channel system, the flows end up in the big
collective chamber.
Figure 3.46: Microfluidic system 1: It contains channels, which end in a collective chamber. The
red area highlights feed A (the input for cell solution A), blue marks feed B (cell solution B,
respectively) and the output is displayed by a green mark. Neither microfluidic feed lines nor
adapters for electric components are illustrated.
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System 2
The second system features trenches or rather implied channels, which end in a collective
chamber. The distribution systems for the single cell flows is identical to the one used in
microfluidic system 1, thus it is not depicted in figure 3.47. After the distribution of the cell
suspensions, the nine discrete flows run alongside the trenches through the joint chamber right
up to the outlet.
Figure 3.47: Microfluidic system 2: It contains implied trenches in the bottom plate. The red
area highlights feed A (cell solution A), blue marks feed B (cell solution B) and the output is
displayed by a green mark. Neither microfluidic feed lines nor adapters for electric components
are illustrated.
The software Pro-Engineer was used for the 3D design of the microdevices. The basical
design of two microfluidic systems was completed and these models were subsequently optimised
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using computer aided flow simulation (see next section for results). Dimensioning the in- and
output cross sections and the chamber length will depend on the outcome of the simulations.
3.2.3 Model Based Optimisation
The first evaluation of the two different designs of the microfluidic electrofusion chamber was
carried out in “virtual experiments” using computational fluid dynamics (CFD; see Technique
Box on page 101 for more information), thus avoiding time and cost intensive experimental set-
ups. A brief simulation study was performed for the analysis of the streamlines and velocities
in both microfluidic chambers using CFX software.
Dependent on the outcome of this virtual prototyping and the required flow conditions it
might be appropriate to re-design the flow chamber according to the desired constraints of the
system.
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Fluid Simulation
The main emphasis for the fluid simulation was the appropriability of the designed systems for
the generation of laminar flows alongside the chamber. Both microfluidic systems admit two
modes of operation:
1. Suction of the cell suspensions via one pump that is connected to the outlet
2. Pumping of the cell suspensions via two independent pumps.
For reasons of economy the solution with one pump was favoured and as a result tested
primarily. In the model based optimisation of the designs substantial parameters such as sheer
stress, velocity and pressure loss were considered. The analysis searched for conspicuities regard-
ing pressure, shear stress and velocity profiles. The run of the streamlines had been examined
in particular, since it is of great importance for the cell arrangement.
Figure 3.48: Microfluidic system 1: Partial flows with different flow velocities caused by invalid
dimensions of the input cross sections.
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Figure 3.48 shows the stream gradient, which arises, if one pump sucks the cell suspensions
and the input cross sections have invalid dimensions. Different pressure losses arise from the
badly selected input cross sections, which provokes that (in the pictured case) those partial
flows, which are not obliged to pass through the standpipes, are sucked superiorly. It has to be
noticed, that the number of streamlines do not necessarily correlate with the stream widths.
To be precise, in this case some of the partial flows would feature bigger cross sections than
the others. This could result in an increased homologous cell fusion, since the streams would
be wide enough, that two cells of the same cell type can flow side by side. This needed to be
circumvented.
Figure 3.49: Microfluidic system 2: Run of the streamlines with 2-pump-operation modus
Nonetheless, it is possible, that such a flow situation with un-balanced partial flows can
occur in the validation phase of a fabricated chamber, since the channels can only be fabricated
with a certain precision. Under these circumstances, the operation mode has to be changed. The
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cell suspensions can be pumped through the chamber via two independent pumps as illustrated
in figure 3.49. The volumetric currents were adjusted as desired. Thus, the bad dimensioning
of the input cross sections is irrelevant, since the effectiveness of the Hamilton pumps (chosen
for the pump station; see section 3.2.6) delivers fluids independently from pressure loss.
However, it is delicate to predict on the basis of a simulation, if an alternating cell arrange-
ment can be achieved. This has to be tested in real experiments.
A further example for the high influence of the pressure inside the chamber and especially
of pressure losses at inlet, outlet and standpipes, is displayed in figure 3.50.
Figure 3.50: Microfluidic system 2: The simulated streamlines, coloured in red for cell suspension
1 and green for cell suspension 2, start to trudle, due to pressure rise towards the end of the
chamber.
The simulated streamlines start to trudle, thus a laminar flow is not given anymore. This
phenomenon results from the pressure rise towards the end of the chamber. The increase in
3.2. MICROFLUIDICS 105
pressure is explained by the tapered form of the chamber’s rear part. In consequence of the
increased pressure, the flow velocity rises. Via the Reynolds number (Re), it appears that a rise
in flow velocity results in a higher Re number, indicating a transition in flow from a laminar
to a turbulent nature. For the chamber geometry on hand, a Re number of about 1 is required
for laminar flow. A turbulent flow will exist for Re > 10. The trudling of the streamlines can
be seen more easily, if only one inlet is used in the simulation (see figure 3.51). It is obvious
that such a flow situation will result in some mixing between the two different solutions, which
shall be introduced into the chamber. If the flow situation develops further, it can result in a
turbulent flow.
Figure 3.51: Microfluidic system 2: The simulated streamlines enter the microfluidic chamber
via inlet A. The other streamlines, resulting from the fluid entering via inlet B have been left
out to clarify the flow situation.
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The presented situations appeared in both chamber designs, since the designs do not differ
in this elementary items. Such problems were solved in simulation studies using a two-pump
operation modus and doubling the radius of the outlets from 50μm to 100μm. The detailed
dimensions are specified in the section ”Fabrication of the microstructures” on page 115. Accord-
ingly, the desired flow pattern was obtained in both chamber designs. The simulated streamlines
run parallel and do not mix.
Figure 3.52: Microfluidic system 1: The coloured streamlines represent cell solution 1 (red) and
cell solution 2 (green). They show a laminar flow pattern alongside the whole chamber.
The final results from the simulation studies have been captured on film (see figure 3.53 and
3.54). The corresponding movies can be found on the enclosed DVD.
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Figure 3.53: Microfluidic system 1: The selected pictures have been extracted from a movie,
which presents the final design of the microfluidic system 1, showing the chamber in 3D and
the flow of the streamlines. This movie is available on the enclosed DVD.
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Figure 3.54: Microfluidic system 2: The selected pictures have been extracted from a movie,
which presents the final design of the microfluidic system 2, showing the chamber in 3D and
the flow of the streamlines. This movie is available on the enclosed DVD.
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The velocity and pressure conditions turned out to play a decisive role for the restriction
to laminar flow conditions inside the microfluidic chambers. Thus, a more precise simulation
analysis was carried out, picturing the velocities with the help of vector graphics.
An overview of the flow velocity conditions inside the microfluidic system 1 is shown in figure
3.55. The highest velocities can be found in the channels, which guide the flow in direction, and
at the outlet. A close-up of these arrays is shown in figure 3.56 and 3.57 on page 110.
Figure 3.55: Overview of the flow velocity inside the microfluidic system 1: The highest velocities
are found in the channels and at the outlet, indicated in red.
The law of continuity applies to this situation. The mass (volume) of a fluid, which flows
through different cross section per time unit, is constant. Assuming that the fluid is incom-
pressible (simplification), the total pressure is always constant.
To transport the same mass in the very same time through a smaller cross section, the
flow velocity consequently increases in smaller cross sections. For incompressible fluids applies
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Figure 3.56: Close-up from figure 3.55 showing the channels of the microfludic system 1, which
guide the laminar flows in the right direction.
Figure 3.57: Close-up from figure 3.55 showing the outlet of the microfluidic system 1 as vector
graphic.
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the Venturi effect: The ratio of both flow velocities is reciprocally proportional to the ratio of
the cross-sectional areas. A bigger cross section surface means a lower velocity, and a higher
velocity results from a smaller cross sectional surface.
The areas with the smallest cross sections of the designed microfluidic systems are the inlets,
outlets and for system 1 the guiding channels. Figure 3.58 shows a simulated inflow of a fluid
in microfluidic system 2.
Figure 3.58: Simulated inflow of a fluid into the microfluidic system 2: The fluid arrives with
high velocity at inlet A and is decelerated by entering the chamber.
As in the case of the simulated fluid inflow, every cross sectional area and the flow velocity,
which prevails in this section, can be pictured individually as vector graphic. This is presented in
figure 3.59 for the first system and 3.60 for the second system on page 112 and 113, respectively.
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Figure 3.59: Vector graphics system 1: The selected pictures have been extracted from a movie,
which presents the flow velocity pictured as vector graphic. An animation of all cross sectional
areas is shown. This movie is available on the enclosed DVD.
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Figure 3.60: Vector graphics system 2: The selected pictures have been extracted from a movie,
which presents the flow velocity pictured as vector graphic. An animation of all cross sectional
areas is shown. This movie is available on the enclosed DVD.
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The laminar flow profile of a cross sectional area within the guiding channels in the micro-
fluidic system 1 can be observed in figure 3.61. The velocity varies from zero at the walls to a
maximum along the center of the flow stream, resulting in a parabolic flow profile.
Figure 3.61: Flow velocity profile in a cross sectional area situated inside the channels of mi-
crofluidic system 1, which guides the laminar flows in direction. The gradient of velocity is
parabolic, which is typical for a laminar flow. Thereby, the highest flow velocity, indicated in
red, can be found in the center of the channel.
All simulations in this section are based on a two-pump operation modus (except for figure
3.48). Furthermore, the underlying mass flow rates of the fluids entering the chambers have
been set to 4 · 10−9kg/s for inlet A and 5 · 10−9kg/s for inlet B due to the higher pressure loss.
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3.2.4 Fabrication of the Microstructures
The designed chambers were fabricated using a Krypton-Fluor (KrF) excimer laser (Micro-
Master, Optec), operated in the Centre for Microtechnology and Surface Analysis in Denmark.
The term EXCIMER derives from EXCited dIMERs and refers to the chemical gain medium
of the laser, which is a gas mixture, typically containing a noble gas such as krypton (Kr) and
a halogen such as fluor (F). Noble gases are highly inert and do not usually form chemical
bonds. However, in an excited state, induced by an electrical discharge, they form temporary
bonds with themselves (dimers) or with halogens (complexes). The resulting molecules such as
KrF possess only a short lifetime of a few nanoseconds (ns). Pulses with those ns time span
are emitted by the laser in the UV at a wavelength of 248nm. The interaction between the
UV photons and polymers allows structures to be made with negligible thermal damage to
the surroundings. Polymers can be finely micromachined at this wavelength by photo-ablative
decomposition. The large molecules typical of polymers are broken into smaller fragments by
electronic excitation. The resulting smaller molecules take up a bigger space, thus the irradiated
volume expands rapidly and ejects the surface layers of the polymer. Additionally, most of the
excess energy is carried away in the form of kinetic energy by the ejected material. Therefore,
the process is relatively cool, which is important for thermally delicate materials.
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With this so-called laser micromachining, it is possible to create microstructures with mi-
nimum dimensions in the order of 2μm.
Selection of Material
Following some pilot studies, the choice was made for polymethyl methacrylate (PMMA), since
a long in-house experience has been gained using this polymer with laser micromachining.
PMMA is a vinyl polymer, made by free radical vinyl polymerisation from the monomer
methyl methacrylate. It is an amorphous transparent thermoplastic with excellent optical pro-
perties, such as high light transmittance. Best known under its common trade name Plexiglas,
this hard and rigid acrylic is widely used. Prolonged exposure to moisture, or even total im-
mersion in water, does not significantly effect the mechanical or optical properties of acrylic.
With its high UV-absorbing properties, it is well suited for laser machining. Nevertheless, it
possesses some restrictions, such as a sensitivity against certain solvents, e.g. ethanol, stress
crack sensibility and a low continuous utilisation temperature at about 115◦C. The latter and
the mild solubility in ethanol circumvents sterilisation with 70% ethanol or autoclaving, but
leaves room for other sterilisation techniques such as irradiation.
Biocompatibility Test
The chosen material PMMA was subjected to a biocompatibility test. Therefore, polymer
samples with an excimer laser machined area of 20mm · 20mm were brought into contact
with cells. The laser-machined area has not been cleaned in any manner and represented a
”worst case” scenario with much ablation material remaining on the surface. Normally, the
excess ablation material would be washed off with a mild detergent solution.
A growth curve of the model cell line KG-1 was surveyed over 3 days both with direct contact
to PMMA and with PMMA conditioned medium (medium, which was incubated with a PMMA
sample for 24h at 37◦C and the polymer was removed thereafter). The cell line was cultured
with IMDM + 10% FCS at 37◦C in a T flask. No influences on their proliferation ability or
toxic effects were recognised in comparison with an untreated KG-1 culture (data not shown).
To further test the material for the use with dendritic cells, fresh matured monocyte-derived
DCs (d8) were incubated for 24h with a PMMA sample under culture conditions and compared
with the non-treated culture. Their phenotyp was analysed before and after the test (see figure
3.62) by FACS, focussing on four specific surface markers: MHC-II, CD80, CD83 und CD86.
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PMMA showed no effect on the expression levels of the analysed surface markers after one day
of co-culture. The only difference was found relating to CD83, a surface molecule, which can be
regarded as maturation marker for dendritic cells. The results showed upregulation of CD83 on
day 9 of about 20% in both cultures, DCs cultured with and without PMMA. The cells were
left in the medium, they were generated in, which still contained cytokines from the maturation
cocktail, thus advancing their maturing. Altogether, a higher CD83 level can be observed on
day 9, but no differences due to the contact to PMMA.
Therefore, the material has been rated as appropriate to the use in electrofusion chamber
development.
Figure 3.62: Phenotypical analysis of matured DCs either brought into contact with an PMMA
sample for 24h or left untreated. Shown are results of surface antigen expression after 1 day
incubation (d9) compared to the expression levels on day 8 (d8). The values are presented with
a mean standard deviation (SD) resulting from 3 measurements.
System 1
For the fabrication of the microstructures in PMMA with an excimer laser, the 3D design had
to be flatten to 2D and brought into a format compatible with the laser software. This was
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Figure 3.63: Positioning of the microfluidic system on a 15mm · 15mm polymer piece
Figure 3.64: Close-up of figure 3.63: The 2D design of the microfluidic system 1 was drawn with
the software AutoCAD showing the chamber with feedlines for inlet A, inlet B and the outlet
(from left to right).
3.2. MICROFLUIDICS 119
realised using AutoCAD software. The flattened design is shown in figure 3.63 and figure 3.64
on page 118.
To obtain a 3D structure in PMMA from the 2-dimensional design, the chamber was burned
from the upper side and all feedlines and distribution systems from the bottom side into a poly-
mer piece of 15mm · 15mm. The cut lines are pictured in red, with the black areas representing
the projection of the feedlines onto the up side. Both sides are connected via through-holes,
which are visualised in figure 3.65.
Figure 3.65: Picture of the front part of the microfluidic system 1 burned into PMMA with the
use of an excimer laser: The through holes are visible, which connect the feedlines from the
bottom side with the chamber on the Top.
The generation of these 3-dimensional structures required an alignment step during laser
micromachining, since the micromachined features of the upper side had to be aligned to the
features on the bottom side. This was done, relying on the visual identification of features,
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which served as alignment point. Minimum two of those reference points were needed, to align
all other features accordingly. In the present case the through holes were used as reference
points, since they are visible from both sides and six in number, more than enough to admit a
good orientation on the polymer piece.
Hence, those holes were established first and all other features were aligned with respect
to the existing through holes on the part to be processed. A resulting 3D structure is shown
in figure 3.66 and 3.67, respectively. More detailed pictures of the chamber, which reveal the
rasterised ablation of the surface layers, can be seen in figure 3.68 on page 122.
Figure 3.66: Sloped oversight of the microfluidic system 1 using a binocular microscope
To avoid crack propagation by mechanical stress of the handling, all processed microfluidic
systems were reheated after fabrication and chilled slowly. Initial frictions were due to thermally
induced stress during the laser micromachining process, anyhow energy densities of around 20
J/cm2 at repetition rates up to a few hundred Hz were applied. However, the stress was relieved
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by the mentioned method.
Figure 3.67: Plan view of the microfluidic system 1 using a binocular microscope
System 2
The second microfluidic system was cut the same way into PMMA as described for system 1.
Only one thing had to be considered. During the fabrication of the trenches in the bottom of
the microfluidic chamber, attention had to be payed to emission of material at the sides of the
trenches. These bulging needed to be kept low, so not to hamper the contact of the cells during
the alignment for the electrofusion process or to affect the laminar flow. The specification of
those trenches can be examined in figure 3.69 on page 123, which shows pictures from the
microfluidic system 2 using a light microscope.
At last, the developed chambers in their 3-dimensional set-up are an open system. Both,
the upper and bottom side needed to be sealed with a cover in order to obtain a utilisable
122 CHAPTER 3. RESULTS
Figure 3.68: Microfluidic system 1: Photographs from the inlets B (A), the middle (B) and rear
part (C) of the chamber taken using a light optical microscope.
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Figure 3.69: Microfluidic system 2: Photographs from the inlets B (A), the middle (B) and the
rear part (C) of the chamber taken using a light optical microscope.
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microfluidic chamber, which is discussed in chapter 3.2.5.
3.2.5 Assembly of the Microchambers
To obtain a functional microfluidic structure, the laser-machined PMMA slides were con-
nected to non polar fused silica capillaries, which allowed the subsequent connection of the
microfluidic chip to a pump station. In addition, sealing of the open structure with a top and
a bottom plate was required.
Figure 3.70: Schematic depiction of the microfluidic chip for the microsystem 1
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The silica capillaries with an inner diameter (ID) of 0.25mm were glued into the microfluidic
chip. Therefore, small channels were drilled into the PMMA slide, which bridged the gap from
the beginning of the microfluidic channel structure to the border of the PMMA slide (see figure
3.71). In this connection to the outside the capillaries were entered and fastened by a glue,
which cures under UV light (depicted in figure 3.71). This gluing was done under microscopic
observation, since a penetration of the glue into the inserted capillary had to be avoided.
The experience showed, that a penetration of the glue into the capillary was likely to occur,
if the glue was not hardened fast enough. In practice, it appeared reasonable to drill the holes,
insert and glue the capillaries in the PMMA slides before the microfluidic structure is cut, as
the latter procedure is the time-consuming and expensive one.
Figure 3.71: Light-Micrograph of a capillary with an ID of 0.25mm glued into a drilling, thus
connecting the microfluidic channels of the microstructure with outer apparatus, such as pumps.
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For batch production of the microfluidic chip it would be an advantage to find a way to
reversible connect and disconnect the standard operating polymeric microfluidic units, e.g. the
supply chains. The solution of this problem is discussed in section 3.2.9.
Bonding
The last step of the assembly of the microchamber was the sealing of the open microstructure.
Polymer slides of PMMA had to be bonded as top and as bottom to the microfluidic chip to
make a functional system. Thereby, the adhesion between different polymer layers was achieved
by thermal compression.
Figure 3.72: Cross section through a bonded microfluidic structure: A test series of channels
with different widths and depths were cut with an excimer laser in PMMA. Subsequently a
PMMA cover was welded on top of the microstructure under specific process conditions.
The adversely affect of this process, called bonding, is the occurrence of global and localised
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geometric deformation, if the parameters such as pressure, temperature or residence time are
chosen wrongly. Since PMMA cannot withstand a high bonding temperature, a low temperature
bonding of the microfluidic structure was carried out.
The biggest problem arose from the determination of the process parameters for this assem-
bly of the PMMA components. The process was empirical and iterative. The results of the pilot
studies on PMMA bonding can be seen in the pictures of scanning electron microscopy (see
figure 3.72 and 3.73).
Figure 3.73: Partial records of the channels of figure 3.72
The following effects can be recognised in the channels shown in the SEM pictures:
• Spallings as a result of the manufacturing process, which were of little importance for the
application.
• The channels seemed to be blocked, since items were spotted in the background of the
channels. However, this was primarily an optical issue: Channel walls were seen in the
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background of the channels, which did not actually extend into the run of the channel. In
addition, static charges of the polymeric material occurred (see white faces), which gave
the impression of blocked channels.
• The channel surfaces possessed a certain roughness, which might affect the flow of the
cells through the channels.
In total, the channel outcome and the bonding were applicable for the use in the described
system. Whether the channel roughness had any negative effect on the streamed cells needed
to be determined in the validation phase (see chapter 3.2.7 for results). None the less, it was
not possible to transfer the bonding process to the designed microfluidic systems, because of
the system containing both small channels with only 50μm in diameter and big cross sectional
areas like the open chamber. Bonding parameters, which applied for both were not found.
Usually, geometric deformation occurred, which were tolerable for channels in the range from
millimetres to a few hundred microns, but not for micron sized channels. The significant material
deformation distorted the microchannel geometry and consequently destroyed the microfluidic
structure.
Figure 3.74: Solution for the sealing of the microfluidic chambers instead of bonding
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Figure 3.75: Schematic (A) and real (B) view of the sandwich technique used for sealing the
microfluidic chambers.
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As a solution, the chambers were sealed by two polydimethylsiloxane (PDMS) slides, which
were pressed onto the microfluidic PMMA structure by two poly(ethylene terephthalate) (PET)
slides held together by screws and nuts. This sandwich assembly is shown in figure 3.74 and
described on page 129 in figure 3.75. In its subsequent development, the nuts were replaced by
windings, which were integrated in the holes of the PET slides. This set up was used under an
inverted microscope as shown in figure 3.76.
Figure 3.76: Sealed microfluidic chamber placed under an inverted microscope for the examin-
ation of the fusion process. The UV light is turned on to track fluorescent labelled cells (see
validation section 3.2.7 for specification).
Thus, elastomeric polymer slides of PDMS sealed the chamber and avoided a direct bonding
process. Their biocompatibility was proven (data not shown) and with their transparent nature
they possessed a good alternative to direct bonding.
3.2. MICROFLUIDICS 131
3.2.6 Design and Assembly of the Pump Station
Generally, a pump station is needed to operate the microfluidic chip. The handling of dif-
ferent fluids at certain flow rates requires a pump station with several pumps, valves and
connecting tubing. For the initial experiments a ready-to-use pump station was utilised, which
was available at the Danish Technology Institute (see figure 3.77). Later on, an analogue system
was assembled in Ju¨lich (see figure 3.78).
Syringe pumps instead of hose or flexible-tube pumps were chosen for the pump station,
since they deliver a constant volume per time independent from pressure loss. Furthermore,
the used syringe pumps produce lower pump waves than a hose pump and the volume to be
delivered can easily be determined by the syringe size, the resolution settings and the pump
motion (direction and number of steps, in which the plunger is moved).
Three of those syringe pumps (XL 3000 modular digital pumps, Cavro) were integrated in
the system. They are fully programmable and designed to automate pipetting, diluting, and
dispensing operations in the 5μL to 50mL range with excellent precision and accuracy. They
provide a wide range of plunger speeds, from 0.8 seconds to 20 minutes per stroke. Additionally,
the pumps are available in different configurations with a variety of syringes ranging up to 50mL.
The syringes are driven by a stepper motor, which drives a precision lead screw, thus moving
in half steps or microsteps depending on the resolution setting of the pump.
The three high resolution pumps, which are contained in the pump station, use a default of
3,000 half steps per full stroke (60mm) and through a firmware command they can provide up
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Figure 3.77: Pump station for fluid handling in combination with the microfluidic chips: The
main components (pumps and valves) are controlled by an external computer (not shown).
to 24,000 microsteps per stroke. Two of them were chosen with a 3-port distribution valve (3+
valve), one with a normal 3-port valve. The 3-port distribution valve has an additional valve
position, which allows to bypass the pump.
The pumps and their valves are operated from a single 24 volt power supply and are con-
trolled by an external computer or microprocessor. They are programmable through an RS-
232 or RS-485 interface and communicate through either an OEM or Data terminal protocol,
whereas up to 15 pumps can be addressed separately from the same source.
For the assembly of the pump station, three syringe pumps were installed in an upright
position, as advised by the manufacturer, to avoid problems in priming the system. In addition,
a multiinjection valve of the same series (XL series smart valve (SV6+), Cavro) and two 3-way-
micro inert valves (MIV, The Lee company) were integrated. The Cavro Smart Valve is a
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compact, stepper motor driven module for OEM liquid handling applications, which possesses
a 6-port valve and uses the same communication characteristics as the Cavro XL 3000 Modular
Digital Pumps, a RS-232 or RS-485 interface and a choice of 2 communication protocols. The
inert valves possess three inlets. The upper is always opened and usually connected to the
bottom one. By switching the valve, the middle inlet, which is normally closed, is opened and
connected to the upper inlet, whereas the bottom one is closed in return. All modules were
connected to a single 24 volt (d.c.) power supply.
Figure 3.78: An analogue pump station was assembled in Ju¨lich: The SV 6-port valve is to the
fore, whereas the inert valves cannot be seen.
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Figure 3.79: Flowsheet of the pump station illustrating the connection of the pumps and valves
to the microfluidic chip.
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The communication with the components was done from an RS-232 port. Therefore, one
device in the chain required an RS-232 interface board. This board was plugged into the mother
board of pump 1. It converts the signal into RS-485. From then on all devices in the chain
communicate through RS-485.
The various components had to be connected with capillaries and tubing to allow fluid
flow (see flowsheet in figure 3.79). As described previously, nonpolar fused silica capillaries (ID
0.1mm) were glued into the microfluidic chip. For the connection of these capillaries to the
pumps and valves, which possess standard 1/4*28 coned ports intended for 1/16” OD (outer
diameter) tubing, PTFE (polytetrafluorethylen, Teflon) tubing with an ID of 0.25mm and an
OD of 1/16” is used. The PTFE tube acts as a sealtight sleeve: It expands when heated,
thus the fused silica capillary insertion is facilitated, and encases the capillary tightly when
cooled afterwards. For the interconnecting tubing between pumps, valves, buffer reservoirs and
collecting tanks a PTFE tube (1/16”) with an inner diameter of either 0.25mm or 0.5mm
was used dependent on the desired flow rate. Flangeless ferrules and flangeless nuts, normally
used in chromatography such as HPLC, together with unions, replaced flange fittings and
facilitate replacement and rearrangement of the set-up. Furthermore, so-called frit-in-a-ferrules
were used, where buffers or cleaning solutions enter the microfluidic system. Thess special
ferrules incorporate a frit in their body, which filters the pumped solutions inline. 2μm filters
avoid blocking of the microfluidic channels by dirt.
Pump and valve operation programmes were written with LabVIEW to operate all com-
ponents from an external computer. LabVIEW is a graphical programming language, which
is primarily used for metrological tasks. The graphical dataflow language and block diagram
approach allows viewing and easily modification of data or control inputs. With its help and
in combination with the intern pump software, a communications driver was written for the
use with the OEM protocol. Full particulars of the programming work can be found in the
appendix.
Figure 3.80 and 3.81 show screen shots of two programmes, called ”sample only” and ”pump
rate ctrl”, which have been programmed at the Danish Technology Institute and were usually
used for the operation of the pump station. The sample only programme allows the easy ope-
ration of only one pump at a time. The syringe of the selected pump is repeatedly filled and
emptied at the chosen speed and for the number of repetitions. Contrary to this programme,
the pump rate control programme enables the user to operate all three pumps, the 6-port smart
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Figure 3.80: Screen shot of the sample only programme: This programme is an easy to use
programme for the operation of only one pump at a time. The pump, pump velocity and the
number of repeats are the only variables, which have to be chosen. The selected pump will then
fill and empty its syringe via valve position inlet for the number of times chosen.
Figure 3.81: Screen shot of the pump rate ctrl programme: This programme allows the simulta-
neous operation of all three pumps, the 6-port smart valve and both inert valves. The knowledge
of pump and valve commands and command structures are required for this programme.
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valve and both inert valves simultaneously. However, pump and valve commands and command
structures need to be used, which were not required with the sample only programme (see sec-
tion 7.2.3 in Material and Methods for tables of the most important pump and valve commands).
Thus, the latter provides the user with a wide range of possible operation procedure.
Figure 3.82: Screen shot of the Labview pump software programmed in Ju¨lich: This easy-to-use
system combines all important operation procedures.
A more user-friendly version was programmed in the IBT-2 at the Research Center Ju¨lich
(see figure 3.82), which combines all operation procedures needed for operating the pump station
such as insertion of syringes, initialisation of the pumps and valves, setting the resolution of the
pumps, filling pumps, cleaning and pump and valve operation without the knowledge of their
internal software commands.
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3.2.7 Validation
For the fluid dynamic analysis of the microfluidic structure, fluorescent tracer, fluorescent
polymer particles, which act as model cells, and KG-1 cells were used.
Tracer
A fluorescent tracer, Natrium-Fluorescein, was used to stain one of the inlet flows, resulting in
either four or five stained partial flows respectively in the open microfluidic chamber depending
of the utilised inlet.
Figure 3.83: Microfluidic system 2: Light microscope picture of the laminar flows. One of the
streams (inlet B) is stained with Na-Fluorescein.
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Figure 3.84: Microfluidic system 1: The solution, which enters the microfluidic structure through
inlet B, is stained with Na-Fluorescein. The pictures represent the laminar flow situation, as
apparent by the distinct flows, at the entrance of the open chamber (A), in the middle of the
chamber (B) and near the outlet, where the streams converge (C).
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These tracer experiments indicated the flow situation inside the microfluidic structure. Fi-
gure 3.83 shows the laminar flow situation in the microfluidic system 2, which is demonstrated
by nine distinct laminar flows, whereas four of them were stained green by the tracer.
The same typical flow pattern resulting from the laminar separation was found in the micro-
fluidic system 1, if inlet stream B was stained with Na-Fluorescein. The separation of the streams
could be recognised clearly (see figure 3.84).
Particles
This flow pattern was also validated in experiments with fluorescent particle suspensions. These
polymer particles acted as a model system for cells, with their size (15−19μm) correlating to the
size of a breast cancer cell (such as T47D, MCF-7 or MDA-MB-231). If the fluorescent particles
were streamed with a high velocity, the single cell could not be spotted, but a fluorescent
line was captured by the camera due to motion blur (see figure 3.85), with the resulting line
representing a flow line. Thus, fast moving particles gave an idea of the stream lines analogue
to a tracer experiment. Only when the cell were streamed slowly (see figure 3.86) the taken
pictures showed the discrete particles.
Cells
In the subsequent experiments the fluorescent particles were replaced by fluorescent labelled
cells of the KG-1 cell line. These cells acted as a model cell for breast cancer cells, but in
comparison with the polymer particles comprise features such as deformability, an important
parameter for the microfludic experiments. KG-1 cells were used instead of breast cancer cells,
since they are suspension cells, thus easy to culture and are also easy to stain. Their flow
attitude resembled the behaviour of the polymer particles, when streamed. However, the fluor-
escence intensity of the cells stained with Celltracker CMFDA (see Material and Methods) was
insufficient to capture moving cells with the digital colour picture camera used, even though the
highest dye concentration for this cytosol staining of cells was tested. For further experiments
with cells a monochromatic digital camera with higher sensitivity had to be purchased.
Further difficulties were faced as depicted in figure 3.87 and figure 3.88: Air bubbles and cell
clusters, which blocked the inlets, disturbed the flow situation inside the microfluidic chamber
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Figure 3.85: Particle flow system 1: The selected pictures have been extracted from a movie,
which shows how fluorescent particles are streamed through the chamber with high speed, thus
the single cell cannot be spotted. This movie is available on the enclosed DVD.
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Figure 3.86: Particle flow system 2: The selected pictures have been extracted from a movie,
which shows how fluorescent particles are streamed through the chamber at lower speed than
in figure 3.85. This movie is available on the enclosed DVD.
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Figure 3.87: Trouble-shooting 1: The selected pictures have been extracted from a movie, which
shows how the standpipes of the microfluidic system 1 are plugging. This movie is available on
the enclosed DVD.
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Figure 3.88: Trouble-shooting 2: The selected pictures have been extracted from a movie, which
shows the breakdown of the laminar flow situation with nine parallel flows in the microfluidic
system 1 due to the incidence of air bubbles. This movie is available on the enclosed DVD.
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and destroyed the arrangement of nine parallel fluid and/or cell flows.
A solution to the air bubble problem was easily found. The outgassing of all buffers and
solutions used with the microfluidic chip together with an extensive flushing of the chip before
usage avoided the entrance or formation of air bubbles. Furthermore, it had to be considered,
whether the use of outgased solutions affected the cells, but no influence was noticed.
The blockage of the 50μm wide channel inlets or the standpipes, respectively was scruti-
nised. Clusters of tens to hundreds of cells were found (see figure 3.89), which usually could not
be eliminated by rising the flow velocity or reversing the flow direction. The cells sometimes
gave the impressions that they were sticking together.
Figure 3.89: Plugging in the feed and standpipes: The pictures show plugging of fluorescent
particles in a standpipe (in focus in A) and in a feed pipe (in focus in B)
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Figure 3.90: Ablation material, which is characterised by a high self fluorescence (A), is found
near the inlets (B) and sometimes is plugging the channels (C).
3.2. MICROFLUIDICS 147
Figure 3.91: Scanning electron microscope pictures of the microfluidic system 2: The top part of
the laser-manufactured structure (A), a close-up of the outlet (B) and the distribution system
of inlet B (C) can be seen.
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Usually, the plugging of particles was observed in the inlets and in the standpipes, where a
sticky material could be observed (see figure 3.90). It was assumed, that this adhesive material
was not related to the glue used, but to the chamber material itself. During the laser machining
process ablation material was left inside the chamber, inlets and standpipes. It was shown that
this material accumulated preferably in the feed and standpipes when the chamber was flushed
with water for the first time and coalesced with the fluid to form a sticky compound.
A chemical removal of this ablation material was not possible without inflicting damage
on the whole microfluidic structure. Although, a mechanical removal was feasible, it also led
to minor detriments of the chamber (see figure 3.91 and 3.92). However, modifications of the
chamber due to normal usage were not recognised.
Figure 3.92: Microfluidic system 2: SEM picture of the top part of the laser-manufactured
structure. It should be mentioned here that the chamber has been extensively used before the
micrograph was taken and ablation material was removed mechanically from the blocked inlets.
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The accumulated and swollen ablation material found primarily in the feeds and standpipes
necessitated the change of the material used for the laser-machining process. In addition, an
expansion of the inlet wholes and standpipes would contribute also to a better particle flow
inside the chamber.
3.2.8 Redesign of the Microfluidic Chamber
So far, it could be shown that the microfluidic chips, both system 1 and system 2, are
functional and thus have the abilility to generate 9 parallel laminar partial flows with a total
width of about 850μm. To further optimise the performance of those chips, some changes to
the geometry and the chamber material had to be implemented.
Geometric Redesign
A necessary 3D redesign was the increase of the inflow dimensions. The channel diameters were
increased to 200μm to optimise particle and cell flow (see figures 3.93 and 3.95 for design model
and realisation, respectively).
Thereby, the geometry of the front part of the chamber was changed. The widened channel
and inlet diameters needed more space, thus the chamber was in this part enlarged from 850μm
to 1800μm (see figure 3.94 for engineering drawing). If the chamber width is kept at that
size over the full length of the chamber, the width of the resulting 9 parallel flows would be
inappropriate for the target use. Thus, in the run of the chamber its width had to be reduced
150 CHAPTER 3. RESULTS
Figure 3.93: Open Chamber of the microfluidc system 3 characterised by enlarged inflow chan-
nels and standpipes.
Figure 3.94: Engineering drawing of the microfluidic chamber 3. All data is given in μm.
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Figure 3.95: Microfluidic system 3: Photographs from the inlets (A), the middle (B) and rear
part (C) of the chamber.
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back to the size, which was proved appropriate for the microfluidic system 1 and 2. The reduction
of the chamber width to 850μm resulted in a size reduction of the distinct flows.
Consequently, the focussing of the partial flows to the designated channel widths was
achieved by hydrodynamic focussing. Due to the laminar nature of the flow inside this mi-
crofluidic structure, the partial flows did not mix during the hydrodynamic focussing, which
has been demonstrated using a fluorescent tracer as shown in figure 3.97 on page 153 .
Change of the Chamber Material
Even though the inlet and channel dimenions were expanded, the blockage problems were not
solved. Occasionally, particles still got trapped inside the standpipes and other inlets and the
same grease related to ablation material of PMMA (as described in chapter 3.2.7) was found,
when these blockages were further analysed. Due to this resisting obstructions as shown in figure
3.96, the decision was made to change the chamber material to Polyethylenterephthalat (PET).
PET has better ablation characteristics, with much less debris, and is structurally tougher
compared with PMMA.
Figure 3.96: Blockage of a channel inlet by fluorescent particles.
As shown before, the PMMA microfluidic structure was damaged in its functional parts,
when the blockage was removed mechanically (see figure 3.98). With the change to PET as
chamber material these problems were solved.
However, the change of the material to PET also entailed some minor disadvantages, such
as a higher self fluorescence than PMMA (see figure 3.99). This property indeed hampered the
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Figure 3.97: Microfluidic structure 3: The hydrodynamic focussing of the laminar flows is visua-
lised by the addition of Na-Fluorescein into the solution, which enters the microfluidic structure
via inlet B.
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Figure 3.98: SEM picture showing extensive damage caused to the microfluidic structure 3 by
mechanical removing of blockages
visualisation of fluorescent stained cells inside the microfluidic chamber, but did not have any
impact on the functionality of the microfluidic system. In addition, fluorescent particles were
found, which clinged to the channel walls probably due to electrostatic interactions between
both polymers (see figure 3.100). This phenomenon was never observed when the chamber was
used with cells, thus it is extraneous.
Altogether, the advantages of PET as chamber material outweight the higher autofluores-
cence. PET has a better chemical resistance to solvents and a much higher melting temperature
of 225◦C compared with PMMA. This means that the use of PET leaves more options for the
sterilisation of the microfluidic chamber as ethanol as well as autoclaving can be used. Anyway,
PMMA was chosen as material in the first place, since it was well known from long in-house
experience and was considered adequate.
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Figure 3.99: Microfluidic system 3 cut in PET, which shows a higher autofluorescence compared
with PMMA.
Figure 3.100: Fluorescent polymer particles sticking to the walls of the microfluidic structure.
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Introduction of a Purge Line
The introduction of additional microchannels, acting as a purge line (see figure 3.101), provided
the opportunity to flush the whole microfluidic system more flexible, thus preventing or elimin-
ating blockage of channels. For example, the outlet channel of the system can be flushed with
the use of the purgeline, bypassing the microfluidic chamber. This would represent an advantage
for the cleaning of the passage between the laser-machined structure and the drillings, where
the silica capillaries were glued in (see figure 3.102).
Figure 3.101: Microfluidic structure 3: A purgeline (shown in yellow) was introduced to provide
more flexibility for flushing the system.
The realisation of the microfluidic structure 3 with purgelines is shown in figure 3.103 and
figure 3.104 on page 158 or page 159, respectively.
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Figure 3.102: The pictures show the connection of the laser-machined area of the microfluidic
structure to the boreholes, where the capillaries are inserted. The glue does not approximate
to the entrance of the capillary. Otherwise, the risk exists that the capillary is sealed by the
glue. Thus, particles can accumulate in this passage, which need regular flushing.
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Figure 3.103: Microfluidic system 3 with purge line: The microfluidic structure is cut in PET
and before usage will be sealed with PDMS.
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Figure 3.104: Microfluidic system 3 with purge line: The picture shows the proportions of the
microfluidic system in comparison to a match.
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However, the purge line could not live up to expectations. The integration of the purge
line should provide an opportunity to better flush all connection sections between the laser-
machined structure and the drillings. This also comprised a connection between inlet A and
inlet B (see figure 3.101) to clean the inlets bypassing the microfluidic chamber.
This connection of the inlets was the area where problems arose in the first tracer experi-
ments with the microfluidic structure 3 with integrated purgeline. Short-circuit flows occurred,
which hindered the development of nine alternating parallel flows (see figure 3.106, picture B
and C). Cross-circuits as such, which led to mixing of the inlet flows A an B, had been con-
sidered before the integration of the purge line, but due to the usage of pressure-independent
pump systems, were not expected. In contrast, a clear boundary between fluid A and fluid B
(as shown in figure 3.106A) were estimated.
Thus, all changes to the microfluidic system were kept expect the integration of the
purgeline. The resulting design is shown in figure 3.105.
Figure 3.105: Final design of the microfluidic structure 3 with dimensions in μm.
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Figure 3.106: Purgeline between inlet A and B. The fluid entering the system via inlet A is
stained with Na-Fluorescein (green). In the normal operation mode of the microfluidic system, a
flow situation with a distinct boundary (A) should prevail. However, such a stable flow situation
could not be obtained and more (B) or less (C) strong cross-circuit flows were present.
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The microfluidic system 3 (as shown in figure 3.107) is continued to seal with the help
of PDMS, since no satisfying results were obtained from bonding experiments. This sealing
methods is also of advantage, since it allows the chamber to be opened for cleaning.
Figure 3.107: 3D-model of the microfluidic system 3
The fluid flow inside the redesigned microfluidic system still corresponds with the ones
observed in the previous microfluidic systems except for the inclusion of a hydrodynamic fo-
cussing section in the front of the open chamber. Nine parallel partial flows are found inside
the microfluidic chamber, which are visualised in figure 3.108 by the addition of Na-Fluorescein
into the fluid of inlet B. Furthermore, the pictures of figure 3.108, which are taken out of a
movie sequence, show, that the distinct flows appear immediately after the pumps are turned
on. They persist until the pumps are turned off and subsequently mix due to diffusion.
However, during the operation of the pumps no diffusion of the dyes from one partial flow
into the other took place, which could be visualised even better, if both inlet flows were stained
with a fluorescent dye (see figure 3.109 on page 164).
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Figure 3.108: Tracer experiment system 3: Na-Fluorescein adds a green fluorescence to the fluid,
which enters the microfluidic chamber via inlet B. With the start of the pump system, the partial
flows can be observed immediately, while they disappear, when the pumps are switched off and
the fluids mix by diffusion.
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Figure 3.109: Microfluidic system 3: The fluid flow of inlet B is stained with Na-Fluorescein
(A) and in addition, the second fluid is stained with CMTMR (B) resulting in an alternating
flow of red and green partial flows.
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3.2.9 Electrode Integration
The last step for obtaining a functional electrofusion chamber was to implement the elec-
trodes into the design of the microfluidic system. Following the design concept of the Eppendorf
electrofusion chamber for bulk electrofusion, it was aimed for an integration of Platinum wires,
200μm in diameter (see figure 3.110 and figure 3.111 respectively).
Figure 3.110: Sketch of the microfluidic system 3 with positioning of two Platinum wires as
electrodes alongside the microfluidic chamber
The identification of a possible strategy for the introduction of those electrodes into the
166 CHAPTER 3. RESULTS
Figure 3.111: Engineering drawing of the microfluidic system 3 including electrodes. All dimen-
sions are given in μm.
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already designed fluidic chamber turned out to be difficult. An irreversible implementation of
the electrodes was conceivable, using the UV glue, which was already used for the integration
of the capillaries. However, the chamber could not be sealed using this approach and leakages
occurred in the area of electrode integration. Even robot assisted microdispensing (also called
micro adhesive bonding) of the glue could not solve this problem and a reversible electrode
implementation by O-ring fabrication for electrode assembly had not been proven feasible in
surface leakage studies (data not shown).
The search for an integration strategy was expanded, considering other manufacturing pro-
cesses for the microfluidic chamber, such as injection moulding, hot embossing and new rapid
micro product development (RMPD) techniques such as one step production and assembly
using UV-cured polymers. However, none of these techniques could provide a solution for the
system in hand. Throughout all approaches either a positioning of the electrodes in micrometer
range was not possible or sealing problems occurred. Furthermore, the integration of wires as
electrodes entailed the appearance of dead zones, where either particle or air was trapped. Since
both, new manufacturing processes and new sealing and bonding techniques (e.g. laser beam
welding of polymers), failed, the integration of electrodes by coating was considered. This let
to the collaboration with Micronit Microfluidics, a Dutch company.
Micronit Microfluidics is specialised in customised glass micromachining (i.e. to produce
microfluidic devices) from prototyping up to high volumes. By a combination of their core tech-
nologies, such as micropowderblasting, wet etching, direct bonding and integration of electrodes
they were capable of producing the required micro device. In general, they produce microelec-
trophoresis chips, microtiterplates, micro reactor chips and customised chips. They provide
the knowledge of electrode integration from their electrophoresis chips, where electrodes are
integrated inside the separation channel for amperometric detection.
Since Micronit specialises in glass micromachining, the chamber material of the final electro-
fusion chamber was chosen to be Borofloat glass, which is the most commonly used glass type
for microdevices. The benefits of glass compared to plastic are the stable hydrophilic properties,
the optical superiority and proven inertness. Furthermore, no special type of glass was required
for this application, because of the detection of the cells and hybrids inside the chamber was
done by fluorescence in the normal visible spectrum (VIS). Other assumptions were the pos-
sible connection of the chip to capillaries and pumps and the adoption of the chamber design
of the microfluidic system 3 with its enlarged front part of the chamber, followed by an area
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for hydrodynamic focussing.
The through-holes of the chamber should have a minimum diameter of 100μm at entry side,
but the exact diameter is not critical and could slightly be more. This made the powderblasting
process applicable, which was used to generate semi-transparent holes with sloped sidewalls at
an angle of around 70◦.
The chamber and the channels were fabricated using hydrofluorid acid (HF) etching, to
obtain 100 % optically clear structures with a surface roughness of 0.1μm. The predetermined
dimensions of the channels by the HF etching technique (minimum channel width of 5μm, a
minimum channel depth of half the channel width (aspect ratio 2:1) and a maximal channel
depth of 100μm) were consistent with the required channel geometry.
3.2. MICROFLUIDICS 169
The direct adoption of the design of the microfluidic system 3 would result in a triple stack
glass layer (sandwich structure) with electrodes. The bonding of three thin glass layers is a
very complex and time intensive process and thus is very expensive. To reduce the costs and
enhance the connectivity, the design was adapted to suit the standard 45 · 15mm dimension
and standard hole pattern of Micronit’s microfluidic chips (10 holes per chip, five on each side;
see figure 3.112).
Instead of a triple layer stack a dual layer stack was used, minimising costs and resulting in a
better yield (number of chips resulting from one glass wafer). All channels and the electrofusion
chamber were designed to lay in one surface and had the same depth, while the electrodes were
integrated between the layers, but inside the chamber, with the connections for electrodes and
capillaries placed on top of the system. Nine of the ten access holes of the microfluidic chip
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were used as inlets in an alternating manner, the remaining one as outlet (see figure 3.112).
Furthermore, the adapted design was suitable for the high pressure chipholder, provided by
Micronit, which allowed to connect the microfluidic chips to the outer periphery with near zero
dead volume and was capable of withstanding high pressures at these microfluidic interconnec-
tions.
In this design an additional chip was needed for splitting the two inputs, which came from
one pump each (conterminously cell suspension 1 and 2), into four and five partial flows,
respectively. This splitter chip was needed to enable an alternating arrangement of the partial
flows in a double layer stack with a two-and-a-half dimensional (2.5D) design. In machining the
term 2.5D refers to a surface, which is a projection of a plane into the third dimensions, which
applies to this case, since the height of the microfluidic structure (channels as well as chamber)
is constant and they all lay in one surface.
Figure 3.112: Left: Concept of the splitter chip for the use with the microfluidic chip (on
the right), to reduce the number of required pumps from nine to two. Right: Concept of the
microfluidic chip based on Micronit’s standard hole pattern, where nine of the ten access holes
are used as inlets (in an alternating manner B-A-B) and one as outlet
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Thus, the new solution consisted of one splitterchip and two different electrofusion chips.
All chips were produced from one 4” square wafer, resulting in 12 chips of 45 · 15mm (five
electrofusion chips with 9 inlets and 1 outlet, five electrofusion chips with 2 inlets and 1 outlet
and two splitter chips with 2 inlets and 9 outlets, divided as 1 · 4 and 1 · 5 outlets).
In the design of the 9in-1out-chip the width of the chamber, where all channels come to-
gether, amounts to 1800μm (see figure 3.113 for engineering drawing). All input channels have
a width of 110μm, while the outlet channel is 190μm wide to avoid blockage by hybrids after
the fusion process.
Figure 3.113: Engineering drawing of the electrofusion chamber of the microfluidic system 4:
Nine individual channels enter the chamber, each channel gives rise to one partial flow. The nine
parallel flows are subsequently reduced in size by hydrodynamic focussing and enter the part
of the chamber, which is flanked by electrodes (depicted in blue).The electrodes are leading to
patches, where the connection to the power supply can take place. The black rectangle with a
dimension of 1 · 1.5cm2 indicates, which part of the chip will be accessible for visual inspection.
The inlet channels approach the chamber from various directions, since they are connected
to the access holes of the microfluidic chip, which are placed on the chip in Micronit’s standard
hole pattern. Thus, five of the 9 inlet holes are situated on the left side and the remaining four
are found on the right side of the chip. This situation would lead to different channel length
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from access hole to chamber entrance, which had to be avoided as it would cause different
pressure losses in the channels. Therefore, some channels have integrated wiggly lines to adjust
the channel to the right length. Electrodes are flanking the rear part of the chamber, where the
electrofusion process shall take place. They are 200μm wide with 500μm wide feed lines.
Although, the aim of the electrofusion chamber development was to enable an optimised
fusion process for the generation of large numbers of viable hybrids, a reduced version of the
above microfluidic electrofusion chip was designed. This 2in-1out-chip (see figure 3.114) can only
harbour two laminar parallel flows and was used for the improvement and the understanding
of the electrofusion process of mammalian cells itself. In this design, the entrance part of the
chamber possesses a width of 320μm, which increases to a width of 450μm at the site of the
electrodes. All channels are 110μm wide.
Figure 3.114: Engineering drawing of the 2in-1out microfluidic chip. In this design only two
channels enter the chamber, resulting in two parallel laminar cell flows inside the electrofusion
chamber.
The full design of all three microfluidic chips (9in-1out chip, 2in-1out-chip and splitter chip)
can be seen in the figures 3.115, 3.116 and 3.117 on page 173. Their realisation is shown in the
figures 3.118, 3.119 and 3.120 on page 174ff.
The chips with an outer dimension of 45 · 15mm are made of Borofloat glass. Both layers
(top and bottom layer) are 1100μm high and bonded together by direct bonding without the
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Figure 3.115: Schematic depiction of the microfluidic system 4 with two integrated electrodes
(9in-1out).
Figure 3.116: Schematic depiction of the reduced version of the electrofusion chip (2in-1out).
Figure 3.117: Schematic depiction of the splitter chip (1in-4out (left) and 1in-5out (right)).
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Figure 3.118: Microfluidic electrofusion chip with nine inlets, one outlet and two electrodes
(with feed line to contact patches) alongside the rear part of the chamber for the generation of
large numbers of hybrids.
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Figure 3.119: Reduced version of the microfluidic electrofusion chip for the study of the fusion
process of mammalian cells.
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Figure 3.120: Splitter chip for the use with the microfluidic electrofusion chip to reduce the
number of required pumps from nine to two.
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Figure 3.121: Inverted photographs of the electrofusion chamber in the 9in-1out chip (left) and
2in-1out chip (right).
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use of glue or other adhesives with an alignment accuracy of 10μm. All access holes and the
holes for connecting the electrodes were manufactured using the powderblasting process. The
inlet and outlet holes posses a bottom diameter of 600μm± 50μm, resulting in a top diameter
of 1400μm±100μm due to the natural slope of the walls with powderblasting of approximately
73◦. The holes for electrode connection are bigger with a top diameter of 2400μm ± 100μm.
The microfluidic channels and chamber were etched into the glass using hydrofluoric acid (HF).
All structures are 20μm±2μm deep. The wet etching process was used to obtain a 100 % clear
chamber with an average surface roughness of about 0.1μm. The integrated electrodes consist
of Platinum (Pt). A close up of both electrofusion chambers is shown in figure 3.121. Silver
past was used to connect the electrodes via the contact patches to wires. Micronit’s chipholder
(see figure 3.122 and figure 3.123) was used to connect the microfluidic electrofusion chip to
the macroworld.
At that time, Micronit was still working on a better solution for connection. In their latest
version a screw thread is integrated into a chipholder, which keeps the wire in place. No glue
in terms of silver past is needed anymore.
Figure 3.122: Schematic depiction of the cross sectional area of the chipholder including a ferrule
(sealing rubber).
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Figure 3.123: Chipholder from Micronit: A) The capillaries were threaded through the top
plate of the chipholder and received a ferrule at their ends. B) The assembled chipholder for
the splitter chip has two inlets and 9 outlets. C) Micronit’s chipholder was costumised for the
application with electrofusion chips and received a see-through window for observation of the
fusion process.
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Micronit’s microfluidic chipholder provided the sought-after plug and play solution for the
connection of the chip to the capillaries and thus to the pump system. It establishes a fast and
easy interconnection with a very low dead volume 20−100nL, which withstands a high pressure
up to 80 bar. It works with Micronit’s standard chips with a dimension of 45 · 15 · 2.2mm and
10 access holes.
This chipholder was adapted to suit the customised microfluidic chips. An optical area was
made above the reaction chamber, allowing optical inspection of the chamber and dection of
hybrids using fluorescence microscopy (see figure 3.123C on page 179). For the microfluidic
electrofusion chip, two contact holes for the electrodes were created, and in case of the splitter
chip an additional hole.
The chipholder with the inserted electrofusion chips can by used with an inverted microscope
(figure 3.124) or a normal microscope, respectively. The electrodes were connected to the high
voltage power supply of the Eppendorf Electroporator via a push-pull self latching connection
system as used for the immobilisation approach.
Figure 3.124: The electrofusion chip with chipholder can easily be placed on an inverted micro-
scope, whereas the splitterchip can be placed elsewhere.
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Figure 3.125: Overview of the set-up for electrofusion experiments.
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Figure 3.126: Fluorescent micrographs of the laminar flow situation inside a 9in-1out electrofu-
sion chip. The electrodes in the middel of the fusion chamber appear in white, due to reflection
on the gold surface.
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Figure 3.127: Cell flow system 4: The selected pictures have been extracted from a movie which
shows the cell flow within a 9in-1out electrofusion chip. This movie is available on the enclosed
DVD.
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The completed electrofusion chambers were connected via these chipholders to the macro-
world (see figure 3.125 on page 181 for the setup). The flow situation inside the fusion chambers
were tested with the use of fluorescent tracers (figure 3.126) and the cell flow was recorded (fi-
gure 3.127). Laminar flows and single cell flows were observed, which are the requirements for
a functional electrofusion chamber.
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3.3 Electrofusion
Cell electrofusion is a multi-step procedure. Firstly, the cells are brought into close contact
with each other via dielectrophoresis. This process uses a high frequent, non-uniform alternating
electric field (a.c.), which induces dipoles within the cells, causing them to align in pearl chains.
The second step is the fusion of the aligned cells by one or several short high-voltage pulses with
field intensities in the range of kV/cm, which cause permeation of the cell membrane and the
formation of pores. This may lead to the fusion of adjacent cell membranes, forming a hybrid.
Subsequently, a post fusion a.c. voltage is provided in order to stabilise the process and hold
the cells in alignment while they mature.
The permeabilisation of cell membranes by external electrical fields is also known as elec-
troporation. Nowadays, this is a standard technique to introduce foreign molecules into a cell.
Nevertheless, the exact mechanism, which causes the increase in permeability, is not well un-
derstood. This is due to the fact that electroporation is a very rapid membrane phenomenon,
which occurs at time scales and spatial dimensions outside the reach of direct observation. Due
to this lack of experimental observation of the mechanism of electroporation, several theories
have been put forward.
It is accepted theory now that high-voltage d.c. electric field pulses induce a reversible
destabilisation of the plasma membrane resulting in temporary depolarisation and pore for-
mation. This process, known as electrical breakdown of the cell membrane, occurs if the total
membrane potential exceeds a critical value of approximately 1V (at 25◦C). The electrical
breakdown is reversible and provides, for a short time, passage for all sorts of molecules to
enter the cell (Zimmermann et al., 2000). It is also the requirement for the occurrence of
fusion events, thus electrofusion is sometimes described as electroporative fusion.
The applied electrical field has to be strong and long enough to induce the reversible elec-
trical breakdown (REB), but not too strong to rupture the cell’s membrane irreversible, causing
the death of the cell. Besides the electrical parameters many other influences have to be taken
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into account, such as temperature, physiologic condition of the cells and osmolarity of the fusion
buffer. Sometimes also membrane active agents such as bivalent cations and proteases are used
to facilitate fusion (Haritou et al., 2000; Ohno Shosaku and Okada, 1984).
3.3.1 Fusion Parameters
Apart from the used electrofusion chamber with its electrodes, electrode material and elec-
trode geometry, the fusion process is depending on several different parameters. The principal
field factors, influencing the electrofusion process, are the field strength and the pulse duration.
But other parameters play an equally important role, including the cell species, physical pro-
perties of the cell membrane, fusion medium and alignment process by dielectrophoresis. The
important parameters for the fusion process, i.e. the electrofusion buffer, the alignment and
the biological parameters, such as cell type and cell size, were analysed in this thesis.
Electrofusion Buffer
A critical part of the cell fusion process is the medium, in which the cells are suspended during
cell fusion. Both, the fusion process and the previous cell alignment require a low conductivity
medium with high resistance to prevent excess heat build-up. Usually sugar solutions, e.g.
glucose, sorbital or sucrose, are used since they possess a low ionic strength.
Specific membrane active agents are typically added to enhance fusion yields. Millimolar
levels of divalent cations, mainly Ca2+ and Mg2+, are used as additives (Haritou et al.,
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2000; Ha, 2001). They influence the fusion process in a positive way by facilitating pore
sealing and cell recovery after the fusion has taken place. The buffer has to be chosen that way
that an optimal balance of high resistance and the presence of divalent cations is provided.
A commercially available hypoosmolar sorbital electrofusion buffer was used throughout
all experiments. It is a low-conductive (120μS/cm ± 10% at 23◦C), calcium and magnesium
acetate-based buffer (0.1mM and 0.5mM , respectively) with BSA and a pH value of 7.0± 0.2.
Due to the low osmolarity of this buffer (90mOsmol/kg) compared with culture medium or
physiological buffer solutions, the cells adsorb water and swell (see figure 3.128).
The swelling of the cells in the hypoosmolar buffer detaches the cell membrane from the
cytoskeleton and stretches the membrane. The osmotic pressure, which prevails in the cell, then
facilitates the development of pores in the electrofusion process (Perkins et al., 1991).
Figure 3.128: Size distribution of MCF-7 cells: The size distribution represented a Gauss curve
(yellow) with a mean cell diameter of about 15μm . After different time intervals of incubation
in hypoosmolar buffer (90mOsmol/kg) the size of the cells increased and the distribution curves
were shifted to the right.
Before a hypoosmolar fusion buffer is used, all cell types needed to be tested for tolerance
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Figure 3.129: SEM pictures of dendritic cells incubated for different time intervals in hypoos-
molar buffer: A) shows a dendritic cell in an isoosmolar solution. B) After an incubation of 30
minutes in a hypoosmolar buffer (90mOsmol/kg) the dendritic cells lost their dendrites and
obtained a smoother surface. C) After 120 minutes of incubation the DCs were heavily swollen
and assumed a rounded form.
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to hypoosmolar conditions. Therefore, the survival rate of the cells was determined by viability
staining with trypan blue after the cells were incubated for 30 min in the hypoosmolar buffer.
After incubation, the tested cell types KG-1, MDA-MB-231, MCF-7, T47D and DCs demon-
strated a good viability of more than 90 % (data not shown). The reduction of the viability
during the incubation time amounted to maximal 8 %.
The four tested cell lines exhibited an increase in cell diameter of about 20 %, while the
dendritic cells only increased in cell diameter by 5 % (see table 3.1).
Table 3.1: Increase in cell size by incubation in hypoosmolar buffer with an osmolarity of
90mOsmol/kg for 30 minutes. The increase in cell volume is calculated from the cell diameter.
Cell type cell diameter Increase in diameter Increase in volume
after 30 min incubation (in %) (in %)
KG-1 14.21μm 19.84± 0.84 72.14± 3.62
MDA-MB-231 14.95μm 21.21± 1.13 78.11± 5.00
MCF-7 15.43μm 22.33± 0.62 83.07± 2.77
T47D 15.52μm 21.04± 1.45 77.39± 6.38
DCs 21.62μm 5.63± 1.25 17.90± 4.18
To investigate the reason, the behaviour of dendritic cells in hypoosmolar buffer was analysed
carefully by means of scanning electron microscopy (SEM) (see figure 3.129 on page 188). The
pictures show that during incubation in hypoosmolar buffer, the dendrites were reformed and
the cell assumed a round form with a smooth surface.
Alignment
The close membrane contact between the fusion partners is the prerequisite for successful
electrofusion. This contact is established by cell alignment via positive dielectrophoresis.
For all alignment and fusion processes the Eppendorf Multiporator was used as voltage
generator. Different settings for the alignment process were tested, varying the voltage between
50 − 500V/cm in 5V steps and the alignment time from 5 − 95sec in increments of 5sec. The
optimal alignment conditions for the used cell lines and/or a breast cancer cell/dendritic cell
pair was found for a current of 500V/cm, applied for 30sec (see alignment of KG-1 in figure
3.130 on page 190 as example). During alignment the cells form pearl chains with the chains
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Figure 3.130: Cell alignment of KG-1 cells in a standard electrofusion chamber with two elec-
trodes with a separation distance of 200μm: A) The cells were aligned by an alternating field
(500V/cm for 30sec). B+C) Subsequently, a d.c. pulse of 1.8kV/cm is applied for 20μs and the
pearl chains are stretched by the electrodeformation force. Upon removal of the field, the pearl
chains assume their original shape.
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Figure 3.131: Cell alignment (KG-1) by dielectrophoresis in a standard electrofusion chamber
with to Platinum electrodes with a separation distance of 200μm: The selected pictures have
been extracted from a movie, which shows the alignment of the cells in pearl chains. This movie
is available on the enclosed DVD.
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Figure 3.132: Cell alignment (KG-1) by dielectrophoresis in the newly developed electrofusion
chamber based on immobilisation: The selected pictures have been extracted from a movie,
which shows that cell alignment was successful. This movie is available on the enclosed DVD.
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Figure 3.133: Cell alignment (KG-1) by dielectrophoresis in the newly developed microfluidic
electrofusion chamber: The selected pictures have been extracted from a movie, which shows
the alignment of cells in flow. This movie is available on the enclosed DVD.
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having no contact or contact to just one electrode (see figure 3.130A). When, subsequently,
the fusion pulse (d.c.) is applied, the pearl chains are stretched (figure 3.130B) until they have
contact with both electrodes (figure 3.130C). This electrodeformation force has been described
by Zimmermann and colleagues (Zimmermann et al., 2000). It arises from the electrostatic
interaction of the generated cell dipoles with the applied field and is thought to be responsible
for an enhanced electropermeabilisation of mammalian cells. With the same settings as used in
the last experiment (500V/cm for 30sec), the alignment process has been shown in a standard,
an immobilisation based and a microfluidic electrofusion chamber (see figure 3.131, 3.132 or
3.133 on page 191 to 193, respectively).
Biological Parameters
The cell type, cell size and the properties of the cell membrane severely affect the choice of the
electrical parameters for fusion and the fusion yield.
For the detection of hybrids after the fusion process, it is common technique that the fusion
partners are stained with different fluorescent dyes before the fusion, enabling the detection of
dual-fluorescent hybrids by FACS after the fusion has taken place (see figure 3.134). Widely-
used vital cell dyes for this purpose are CellTracker probes (Molecular Probes, Eugene, USA),
such as CMFDA (green) and CMTMR or CMRA (both orange).
Some of the experiments for this thesis gave reason to analyse, whether those dyes influence
the fusion efficacy and thus the fusion process itself. Six different dyes were tested, including
two dyes staining the cytosol of viable cells, two lipophilic dyes staining the membrane and two
nucleic acid dyes staining the nucleus: CellTracker CMFDA (green) and CMRA (orange) freely
diffuse into the cell. They are nonfluorescent until cytosolic esterases cleave off their acetate
groups, producing membrane-impermeant brightly fluorescent products, which accumulate in
the cytosol. Vybrant DiO (green) and DiI (orange) are long-chain dialkylcarbocyanines, which
stain the cell membranes due to their lipophilic character. SYTO11 (green) and SYTO17 (or-
ange) are cell-permeant nucleic acid stains that show a large fluorescent enhancement upon
binding nucleic acids, thus staining the nucleus.
The influence of those dyes of the membrane permeabilisation of MCF-7 cells in comparison
to a unstained negative control were determined by electroporative dye uptake (Neumann et
al., 1998) and are shown in table 3.2. The cells were pulsed twice (n=2) with a 20μs long
pulse of a voltage of 1.8kV/cm in the presence of trypan blue. Trypan blue is an established
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Figure 3.134: FACS analysis of a fusion process. Measurements before and after fusion pulse
application are shown. The fusion partners are stained with CMFDA green and CMTMR orange
to distinguish the two populations by means of FACS.
Table 3.2: Permeabilisation of MCF-7 cells as subject to different cellular stains
Dye Stained Colour spectrum percentage of Viability after
compartment permeabilised cells pulse (in %)
CMFDA cytosol green 16.6 85.3
CMRA cytosol orange 0.4 78.0
DiO membrane green 28.4 74.6
DiI membrane orange 5.9 64.9
SYTO11 nucleus green 14.5 41.8
SYTO17 nucleus orange 1.3 58.9
Neg. Ctrl - - 22.4 96.0
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protein dye that does not penetrate intact cell membranes. After the pulse application the cell
solution was incubated for a 10 min period at room temperature. Subsequently, the number
Nc of coloured cells of the population was determined. To estimate the number of transiently
permeabilised cells by pulse application, the number of stained cells had to be reduced by
the number Nirrev of cells, which were irreversibly damaged by the applied electrical pulse.
Therefore, another batch of cells were subjected to the pulses in the absence of trypan blue,
and the dye was added after the incubation period of 10 min. The percentage of reversible
permeabilised cells could then be calculated by the ratio of Nc-Nirrev to Nt, the total number
of the cell population.
The results showed that most of the used dyes reduced the poration yield. This could be
explained by the fact that every substance, which interacts or penetrates the cell membrane,
disturbs the regular bilayer structure, thus modifying membrane properties. For this reason,
for the analysis of fusion processes, the fusion partners should be stained with cell type-specific
antibodies after the fusion has taken place. Therefore, two antibodies were chosen, which se-
lectively bind either dendritic cells or a breast cancer cell line. For MFC-7 and MDA-MB-231
anti-CD71/anti-HLA-DR were chosen as antibody pair (see figure 3.135).
Figure 3.135: FACS analysis of DCs and the breast cancer cell line MCF-7. An antibody pair
was found (CD71 and HLA-DR), which can be used after fusion to distinguish between the two
fusion partners and hybrids by means of FACS.
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The anti-CD71 antibody was used to stain the breast cancer cell lines, while dendritic cells
are negative for CD71, and the anti-HLA-DR antibody was used to stain the DCs independently
from their maturation status, but does not stain the breast cancer cells. This allows for the
undisturbed fusion of the cells without the negative influence of intracellular staining.
3.3.2 Fusion
The experimental parameters for cell electrofusion comprise field strength, pulse length,
number of pulses and cell concentration. For the fusion efficacy a complex dependence on
field strength, pulse length and number of pulses is suggested. The optimisation of all those
parameters is essential. If, for example, the strength, duration or number of fusogenic pulses
is chosen wrongly, cell lysis instead of cell fusion can occur, due to an irreversible breakdown
of the cell membrane (see figure 3.136). If, in contrast, the parameters are chosen in the right
way, cell fusion of two or more cells can be observed (see figure 3.137 and figure 3.138 on page
198 and 199).
The progression of the fusion process between two adjacent KG-1 cells after the application
of a single pulse (field strength and pulse duration) was monitored under a light microscope.
The different phases of the fusion process, such as alignment, formation of fusion point and
fusion neck, establishment of cytoplasm continuity (plasmogamy) and rounding of the hybrid
during post-alignment were observed.
The ideal fusion parameters such as field strength, pulse duration and number of applied
pulses, vary according to the cell type, and especially the cell diameter, and must be determined
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Figure 3.136: Series of pictures taken within 1min, which show the lysis of KG-1 cells in the
electrofusion chamber based on immobilisation. The white arrows in A) mark the cells, which
were lysed by the application of one pulse of 2.5kV/cm for 25μs
Figure 3.137: Homologous fusion of T47D breast cancer cells
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Figure 3.138: Fusion Phases: The selected pictures have been extracted from a movie, which
shows the evolution of the fusion process between to adjacent KG-1 cells. Details from a series
of images captured at times of 1 to 60sec after pulse application. This movie is available on the
enclosed DVD.
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by experiment. An empirical formula is often used as a starting point for the optimisation of
the electrical parameters (see Manual Multiporator from Eppendorf):
EC =
VC
0.75 · d (3.1)
with
EC : Critical field strength (V/cm)
VC : Permeation voltage (for eukaryotic cells: 1V at 25
◦C)
d: Cell diameter (cm)
With the help of this formula, the critical field strength for permeating the membrane of
spherical cells can be estimated. The critical field strength is defined as the voltage at which
the cell membranes are permeated at points of the cell membrane, which are vertical to the
field lines. The parameters needed for the calculation are the cell diameter and the permeation
voltage of the cell membrane. The latter can be assumed as 1 V for a single membrane and
2 V for membranes that are arranged in series. The cell diameter has to be determined under
hypoosmolar conditions for a correct calculation of the critical field strength.
In general, small cells require much higher field pulses than cells with a bigger cell diameter
to permeate the membrane by inducing an reversible electrical breakdown of the cell membrane.
This local perforation of the cell membrane enables two or more cells to fuse, if the pre-requisite,
a direct contact between the cells, has been established. Again, the number of cells that can be
fused depends on the type and size of the cells, the field strength of the electrical pulse and on
the osmolar conditions of the fusion buffer.
After the formation of a local fusion point within the cell membranes that are in contact,
the primary fused membrane sections expand, resulting in a so-called plasmogamy. This is
followed by the rounding off the fusion products. The time required for the various fusion
stages is depending on many parameters such as cell size, the condition of the cytoskeleton, the
temperature, the ion environment (Mg2+, Ca2+) and probably the extent of the primary fused
membrane section as well. In general, it is advised to leave the cells undisturbed for a 5 to 10
minute post-fusion cultivation period.
Using the equation 3.1 for the calculation of the fusion voltage, the obtained parameter was
used as a basic value for the optimisation of the fusion parameters. The voltage was varied in
a range from 250 V to 15 kV with a pulse length from 10 to 300μs. The cells were subjected
to 1 to 10 electric field pulses.
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More then 200 different combinations of experimental fusion conditions were quantified
using FACS and dye penetration assays for analysis (see Material and Methods). No fusion
of dendritic cells and breast cancer cells was obtained. The optimised electrical parameters for
pore formation in these cell types confirm the findings (see table 3.3). The fusion parameters for
DCs and breast cancer cells are differing too much to allow a fusion to take place. If the fusion
parameters for breast cancer cells are chosen for the heterologous fusion of DCs and breast
cancer cells, the DCs are not perforated. Without pores being induced in the cell membranes
of both fusion partners, no heterologous hybrids can be obtained. On the other hand, if the
fusion parameters are chosen to electropermeate the dendritic cells, the pulse voltage is far to
high for breast cancer cells to survive.
Table 3.3: Optimised fusion parameters for different cell types
Cell type fusion voltage (in kV/cm) pulse length (in μs) number of pulses
MCF-7 1.8 20 1
MDA-MB-231 1.8 20 2
DCs 8.5 65 4
Although no DC-breast cancer hybrids were obtained, due to the discrepance in the electrical
parameters, sometimes dual fluorescent events could be observed by FACS. The occurrence of
dual fluorescent events should not be used as exclusive argument for the existence of heterolo-
gous hybrid cells, since cell aggregates can occur as double fluorescent events in FACS, as well.
This results in wrong outcomes, if the upper right quadrant in a dual fluorescent FACS dot
plot is used to quantify the percentage of hybrid formation.
In addition to the occurence of double fluorescent events due to cell aggregates, a shifting of
cell populations in FACS dot plots was found, due to electrical effects on the cells. The effect is
intensified the higher the applied voltage (see figure 3.139). The cell populations migrate into
the upper right quadrant of the FACS dot plot.
The displacement of the cell populations, which was observed independently from the type
of fusion buffer or the used cell staining method, would lead to a wrong quantification of the
formation of hybrids during electrofusion, if the upper right quadrant in a double fluorescent
dot plot is used for analysis. To avoid this miscalculation, either another analysis method such
as microscopy should be used in parallel, or the FACS analysis can be adjusted to take the
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Figure 3.139: Shifting of cell populations in connection with the treatment with a fusion pulse.
The displacement of the populations in the FACS dot plot increases with the applied voltage.
Figure 3.140: Correction of the cell population displacement by adjusting the dot plot quadrants
according to a pre-fused negative control
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shifting into calculation (see figure 3.140).
In general, for the fusion evaluation, the quadrants of the dot plot are arranged in that way
that the two starting populations are placed inside the upper left and lower right quadrant.
Two avoid the displacement of the populations into the quadrant of evaluation after the fusion
process, the quadrant adjustment should be based on a pre-fused negative control. This would
mean that not only a mixture of the fusion partners is used, but a mixture of the two cell types,
which, each for itself, was subjected to the fusion pulse.
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3.4 Immunological Evaluation
After the development of the electrofusion chambers one remaining task was to control,
whether the immunostimulatory capacity of the dendritic cells was not affected negatively
by the cell detachment procedure used in the immobilisation approach. The detachment by
applying an acid solution of a pH of 2 could for example influence protein integrity, such as the
MHC molecules on the cell surface. For this reason the allostimulatory capacity of pH 2 treated
DCs was tested in a mixed leukocyte reaction (see figures 3.141 and 3.142 on page 205).
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Figure 3.141: Activation of positive T-cells (CD3) was assessed by CD25 (α -chain of the IL-2
receptor) staining after 4 days of co-cultivation in a MLR. Shown is one representative donor
out of two. The experiments were made in triplicates and results are presented as mean ± SD.
Figure 3.142: Activation of positive T-cells (CD3) was assessed by CD71 (transferrin receptor)
staining after 4 days of co-cultivation in a MLR. Shown is one representative donor out of two.
The experiments were made in triplicates and results are presented as mean ± SD.
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The pH 2 treated dendritic cells were compared in a mix leukocyte reaction with untreated
dendritic cells. The activation of T-cells in the MLR was assessed by the analysis of CD25 and
CD71 activation marker expression on T-cells after four days of co-cultivation with DCs at
different ratios (1:10, 1:20 and 1:40, respectively). Both, CD25 and CD71 expression analysis
did not reveal any significant differences of pH2 treated DCs compared with untreated DCs.
Differences of the percentage of positive CD25 and CD71 T-cells might be due to different
expression kinetics of both surface proteins.
A further task was the analysis of the obtained hybrids for the stimulation of T-cells in
an autologous stimulation reaction (see Technique Box on page 207 for explanation of the
method). Thereby, the biological activity of the hybrids for the generation of tumour-specific T-
lymphocytes was tested. Since the generation of hybrids by electrofusion could not be validated,
the fusion outcomes were used for this assay. Dendritic cells, which were subjected to four 65
μs long fusion pulses with a pulse strength of 8.5 kV/cm in the presence of MCF-7 tumour
cells in a ratio of 1:1 were compared in their immune stimulatory efficacy in vitro with MCF-7
lysate-pulsed dendritic cells (see figure 3.143).
By the application of the four fusion pulses with the chosen fusion parameters most of the
MCF-cells were destroyed as described in section 3.3.2. To further explore this situation another
approach was included in the autologous T-cell stimulation assay: dendritic cells were loaded
with MCF-7 cell debris, which was obtained by the application of four fusion pulses with the
above defined parameters (dendritic cells loaded with pulsed MCF-7).
The results showed that an expansion of the T-cells could be obtained in every approach,
whereas the dendritic cells loaded with pulsed MCF-7 cell debris performed best and resulted in
a 14.1-fold expansion. The expansion factors of the other approaches were accounted as 6.5-fold
and 3.9-fold for the pulsed mixture of DCs and MCF-7 breast cancer cells and the DCs loaded
with MCF-7 lysate, respectively.
The expanded T-cells were further analysed by flow cytometry. The cytotoxic T-cells (CD8+)
were divided into four subsets: na¨ıve, central memory (CM), effector memory (EM) and effector
memory RA (EMRA) T-cells. These subsets were identified based on cell surface markers, in
particular the expression of CCR7, a molecule that mediates homing to lymph nodes through
endothelial venules, and CD45. The latter is expressed in various isoforms, which differ in their
relative molecular mass. The isoform with the highest molecular mass is called CD45RA, the
one with the lowest CD45RO.
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Figure 3.143: Proliferation of autologous T-cells stimulated with DCs pulsed together with
MCF-7 cells or DCs loaded with pulsed MCF-7. Dendritic cells loaded with a MCF-7 lysate
were used as control. Shown is one representative donor out of two.
Figure 3.144: Expansions of different cytotoxic T-cell (CTL, CD8+) subsets obtained from
autologous T-cell stimulation (see figure 3.143).
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Human na¨ıve T-cells are CCR7+ and CD45RA+. When stimulated, they can undergo clonal
expansion, culminating in a higher frequency of antigen-specific T-cells with more rapid effector
function. These antigen-specific T-cells belong to the memory T-cell pool, which functions as a
dynamic source of antigen-experienced T-lymphocytes that accumulate over the lifetime of an
individual. Antigen-specific or memory T-cells can be divided into two subpopulations, CCR7+
CD45RO+ central memory T-cells (TCM) and CCR7
− effector memory T-cells. The latter are
further sub-divided into CD45RO+ effector memory cells (TEM) and CD45RA
+ effector memory
cells(TEMRA) (see table 3.4).
Table 3.4: Memory T-cell subsets
Tnaive TCM TEM TEMRA
CCR7 + + - -
CD45RO - + + -
CD45RA + - - +
Effector memory T-cells form the protective memory of the immune system. They are able to
migrate to inflamed peripheral tissues and display immediate effector function. Central memory
T-cells in contrast home to secondary lymphoid organs and have no effector function, but may
proliferate and differentiate into effector cells in response to antigenic stimulation (Sallusto
et al., 2004).
The expanded cytotoxic T-cells from the autologous T-cell stimulation assay were analysed
by flow cytometry for the different T-cell subset, such as na¨ıve, central memory, effector memory
and effector memory RA T-cells (see figure 3.144 on page 208). The results from the pheno-
typical analysis of the proliferation assay showed that the most effector T-cells were obtained
when the T-cells were stimulated with dendritic cells, which were loaded with pulsed MCF-7
cells.
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Chapter 4
Patent Application
The developed electrofusion chambers for arranged electrofusion of mammalian cells as de-
scribed in sections 3.1 and 3.2 were both filed as patents. The patent applications were handed
in on 12th December 2003 at the German Patent Office and were published 18 months later.
For the electrofusion chamber based on immobilisation seven citations, mostly patent apllica-
tions from Japan (see patent specification on page 213), were taken into account for the assess-
ment of the patent capability. The immobilisation approach was compared with other fusion
methods, where the cells were adsorped onto electrodes, attached to cultivation sheets or seper-
ated by suction during the fusion process. In the end, all citations could be debilitated and the
patent was granted on the 22nd December 2005 (DE 103 59 189). No objections were raised
within the period for objection.
For the microfluidic electrofusion chamber only three Japanese patent applications were as-
serted as citations, but they mostly represent methods for single cell fusion. For the microfluidic
approach the patent application is still pending.
In the following, the patent specification for the immobilisation approach and the published
patent application for the microfluidic approach, respectively, are displayed.
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Chapter 5
Discussion
Since fusion hybrids play a central role in biotechnology, especially in monoclonal antibody
production (hybridomas), cloning and immunotherapy (hybrid vaccines), some approaches to
avoid homologous fusion events have already been developed in the last years. Jaroszeski et
al. (1994) tried to deposit both fusion partners in monolayers on filters, which serve as a
matrix for mechanically contacting the cell layers. With this ”mechanically facilitated cell-cell
electrofusion” a maximal fusion efficacy of 10 % was obtained.
The work of Stro¨mberg and colleagues (1999 and 2001), who arranged cells at single-cell
level by optical trapping or by adhesion to an ultramicroelectrode, and the chemical approach
of Bakker Schut et al. (1993), who used an avidin-biotin complex to couple the fusion
partners together, were other approaches to an arranged electrofusion process. They resulted in
better fusion efficacies than Jaroszeski’s approach, but are only designed for single-cell fusions
and not laid-out for the generation of large quantities of vital hybrids, especially not in a clinical
setting.
To satisfy the requirement for high-throughput cell fusion towards clinical application two
different electrofusion devices for the improved generation of mammalian cell hybrids were
developed in the context of this thesis. The underlying ultimate principle of these devices is the
alternating arrangement of the fusion partners inside the fusion chamber by either antibody-
based immobilisation of the cells in micropattern or parallel microfluidic single-cell flows.
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5.1 Immobilisation
The development of an electrofusion chamber for arranged mammalian cell fusion, as described
in section 3.1, was a multi-step procedure. Starting off with a basic idea of printing antibody
lines to immobilise one fusion partner, over the testing of different surface chemistries, the
down-sizing of the whole process to cell dimension and thus micrometer scale, the actual build-
up of the electrofusion chamber and the application to dendritic cells - knowledge from diverse
science backgrounds was needed throughout all stages.
The work combines knowledge from the fields of cell culture and immunology, with inorganic
chemistry, liquid handling and microfabrication technology. Many methods for example are
descended from the field of electrotechnology and chip design. Altogether, it can be defined as
a ”real” biotech project, since biotechnology has often been described as an interdisciplinary
science.
In the first step of the electrofusion chamber development a surface chemistry for the direct
immobilisation of cells was sought. After the test of several alternatives, a method based on the
functionalisation of a glass surface by 3-aminotriethoxysilane and cross-linking by glutardialde-
hyde was chosen to immobilise antibodies via their primary amino groups in a Schiffsche base
reaction. The choice was made based on a test, where monoclonal antibodies were immobilised
in a drop shape. Apart from the APTES/GDA method no other chemistry turned out positive
for the application, but this application was critical for a patterned deposition of antibodies in
small lines as designated for the electrofusion chamber.
After the selection of the immobilisation chemistry, soft lithographic methods, such as direct
and inverse microcontact printing were tested to deposit the antibodies in the desired pattern.
The technique of microcontact printing was used in the group of Prof. Dr. A. Offenha¨user at
the Institute of Thin Films and Interfaces 2 (ISG-2) at the Research Centre Ju¨lich, where it
was used to generate neuronal networks on synthetic substrate surfaces by providing a laminin
pattern to which the neuronal cells bind.
Microcontact printing is a state-of-the-art technique for patterning cells. It is a soft litho-
graphic method, which uses a soft elastomeric material, e.g. a PDMS stamp, for pattern transfer
of the material of interest (e.g. cell-adhesion protein) onto the substrate surface. In addition to
laminin polylysine, fibronectin or collagen are commonly used by researchers as cell adhesion
proteins. These proteins all permit cells to specifically bind to the pattern that is printed with
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these proteins on a surface, to which cells would not bind. In this way, the cells specifically bind
to the pattern, but the cells need to be adherent growing cells by nature. Suspensions cells do
not bind to a pattern of such adhesion molecules.
Since in the context of the electrofusion chamber development, dendritic cells should be
bound to small protein lines, different ”adhesion” proteins needed to be chosen. The obvious
choice were antibodies, due to their ability to bind cells specifically via different surface mo-
lecules. The printing and covalently binding of antibodies to patterns in a micrometer scale has
not been investigated before. The microcontact printing method was successfully adapted to
print antibody lines and dendritic cell binding to these cells was achieved.
The experiments were started using the APTES/GDA cross-linking reaction to immobilise
the monoclonal antibodies, but the chemistry needed to be switched due to problems with
the integration of the electrodes into this attempt. No facilities were at hand, which would
permit the positioning of electrodes (either as wires or by vacuum deposition) in parallel to the
antibody lines present on the surface. Even a reverse way of applying the electrodes first and
then printing the antibody lines accurate to a micrometer was not possible. For this reason,
a new concept for electrode integration into the fusion chamber was developed with the help
of Dr. David C. Cullen, reader of Biophysics & Biosensors, at the Biotechnology Centre of
the Cranfield University, UK. In this collaboration, a method was developed that avoided the
positioning step and combined electrode and antibody line deposition in one step. Additionally,
all further parts for chamber assembly were manufactured by laser techniques at the Cranfield
institute.
This change in chamber assembly entailed a change in immobilisation chemistry, since
in the final design the antibodies are immobilised on small gold lines. Thus, self-assembled
monolayers (SAMs) of 11-mercaptoundecanoic acid (MUA) were formed on the gold lines.
The carboxyl groups of MUA were activated with a mixture of N-hydroxysuccinimide (NHS)
and 1-ethyl-3-(dimethylamino-propyl)carbodiimide (EDC) and the resulting succinimide ester-
activated monolayer could then be reacted with primary amino groups on the antibodies to
give a peptide bond.
In conclusion, a microdevice for arranged electrofusion of mammalian cells with the use
of immobilisation was fabricated using a combination of laser, photolithographic and metal-
film-deposition techniques. The dimensions of the device have been chosen to correlate sizes
of the cells and allow fusion of large number of cells simultaneously. Due to the alternating
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arrangement of the cells within the fusion chamber cluster formation and homologous fusion
events are prevented. For the examination of the fusion process, the chamber permits direct
visualisation through a transparent top.
Furthermore, the chamber is easy to use and as a disposable device would fulfil clinical
requirements. By now, it has been tailored for the electrofusion of dendritic cells with tumour
cells, but could be upgraded for use with all cell types by replacing specific antibody binding
with a streptavidin/biotin binding step. Instead of covalently bound antibodies, streptavidin
would be immobilised. This allows for the binding of every cell type by biotin-labelled antibod-
ies.
In December 2003, an application for a patent was filed for this electrofusion chamber. Seven
citations were invalidated and the patent finally granted in December 2005 (see section 4 for
the patent specification), which emphasises the novelty of this invention.
5.2 Microfluidics
In parallel to the immobilisation approach, a second electrofusion device was developed that
is based on microfluidics (see section 3.2). The development process shows certain similarities
to the development of the fusion device based on cell immobilisation. Apart from the fact that
it was a matter of several steps to obtain a fully functional device and that microfabrication
technology was used, the first contact to microfluidics was made via Prof. Dr. A. Offenha¨user
and his research group at the Institute of Thin Films and Interfaces 2 (ISG-2) at the Research
Centre Ju¨lich. A microfluidic device was used in his group for localised drug application to
adherent cell cultures of neuronal cells to manipulate their growth (Thie´baud, P. et al.,
2002). The device found additional application in the immobilisation of laminin in lines on a
substrate, whereas the laminin solution was streamed in small lines over the surface using the
microfluidic device.
These two application areas of microfluidic devices in combination with cell culture were
found throughout the literature, but no publication could be identified at the time of research,
which described the streaming of cells by means of controlled pressure driven liquid flows
in microfluidic devices. Although, at that time, microtechnology allowed the fabrication of
microfluidic devices with channel sizes that were comparable to the size of biological particles
such as cells, only very few cell-based lab-on-a-chip applications have been published.
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In the field of electrofusion, or electroporation in the broader sense, two publications were
found, which report the design of electrofusion devices. Lee and colleagues (1995) de-
veloped a cell fusion device only for the fusion of two cells at a time, while Tresset and
Takeuchi (2004) could only show fusion of liposomes, synthetic lipid-bilayer vesicles, in their
device. Furthermore, both devices cannot be used for continuous electrofusion of cells, since
the feed of the fusion partners is done manually by pipetting, and the microfluidic channels are
filled by capillary forces.
The only work, which was promising in terms of continuous cell flow in a microfluidic
electrofusion device, was the one from Lin and colleagues, which developed electroporation
microchips for continuous gene transfection (Lin et al., 1995). Nevertheless, the dimension
of the channel, in which the cell flow and cell manipulation by an electric field takes place, was
not as such microfluidic, since the channel was 5 mm wide. Thus, the streaming of cells in single
cell flows through microfluidic channels needed to be explored first, before the development of
a functional electrofusion device came into reach.
With the help of Computational Fluid Dynamics (CFD) the development of a microfluidic
electrofusion device was started off. This model based optimisation was accomplished with
the help of Dr. Ulrich Kru¨hne from the Centre for Microtechnology and Surface Analysis of
the Danish Technology Institute. Based on two different designs for a microfluidic device, the
chambers were optimised in regard to the fluid flow and pressure profiles inside the microfluidic
structure, therewith circumventing several iterative development steps.
Following the geometric definition and model based optimisation, the microstructures were
fabricated in PMMA using an EXCIMER laser, which allows for a relatively cool process. To
obtain a functional microfluidic device, capillaries for in- and outflow into the microfluidic chip
and a bottom and a top plate were added. A bonding of a PMMA plate as top and bottom
plate to the PMMA structure could not be established and no publication was found at that
time, which reported a method for PMMA bonding. It was not until December 2005 that
Chinese researchers (Chow et al., 2006) published a way to bond two PMMA slides by PDMS-
interface bonding. They used a small PDMS spin-coat as adhesive layer between the PMMA
slides, which allowed them to bond the PMMA slides without the use of high temperatures or
pressures. Therefore, a sandwich structure with PDMS was used as a provisional solution for
sealing of the PMMA structure.
In that way, the microstructures could be evaluated in regard to fluid and particle flow inside
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the electrofusion chamber. A laminar fluid flow was demonstrated with the use of fluorescent
tracers. This flow pattern was also validated with polymer particles and cells showing a laminar
single-cell flow. For the use with these microfluidic electrofusion devices a pump station was
designed, which comprised three syringe pumps and several valves to deliver the fluids and cell
suspensions to the microfluidic chips. This pump station was controlled via a computer and
programmed to automatically handle the fluid flow in the microfluidic devices.
Some problems had to be faced during the development, which arose from air bubbles
and clogging of microchannels with trapped particles. These are the common problems with
microfluidic devices for applications in cellomics. They are the reason, why up to now, only few
products have made it to the market. In the development of a microfluidic electrofusion chamber,
these problems were avoided in the end by choosing a functional material and expanding all in
and outlet diameters to a wider extend. Microfluidic dimensions, which are comparable with
cell sizes were realised by hydrodynamic focussing.
The coupling of the microfluidic structure with the necessary equipment entailed the same
problems as in the immobilisation approach. It was not possible to completely seal the chamber
with the techniques used before. A redesign was needed, where with the help of the Dutch
company Micronit the chamber design was reduced to a 2.5-dimensional, simpler design and
electrodes were integrated by means of metal deposition techniques. The same laminar flow
patterns and particle flows were obtained in the final chamber, since the chamber dimensions
were adopted from the previous designs. Furthermore, with two functional microelectrodes, it
was possible to generate electrical fields, which enabled cell alignment by dielectrophoresis and
cell fusion.
Microfluidics has three main advantages over macroscale operations, which are its small
sample volume, the high surface to volume ratio and the possibility to integrate multiple on-
board functions (Nguyen, 2004). For the first two reason, microfluidics are a favoured tool for
chemical applications such as chromatography, electrophoresis, mixing and chemical reaction
analysis. The possibility to integrate various fluid manipulation components such as pumps,
valves, sorters and filters in one chip, would allow for hybrids generated in an microfluidic
electrofusion chamber, to be subsequently sorted by means of FACS, counted and suspended
in culture medium - all on board of a single chip.
These lab-on-a-chip devices are known throughout the land, and it is modern to downsize
everything, even though it does not bring any advantages. However, in the case of the micro-
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fluidic electrofusion chamber described here, the inclusion of microfabrication provides unique
process advantages to promote this biological application and make it suitable for parallelisation
and automation.
A patent application for the developed microfluidic electrofusion chamber was filed in
December 2003. The application is still pending, but only 3 citations were adduced.
5.3 Comparison: Immobilisation and Microfluidic Ap-
proach
Two different electrofusion chambers for arranged electrofusion of mammalian cells were de-
veloped, which are based on two different techniques, immobilisation or microfluidics. They
were developed for the fusion of dendritic cells with tumour cells for breast cancer immuno-
therapy and both have their advantages in regard to their application in a clinical setting or
the use in a different application area (see table 5.1).
While the electrofusion chamber based on immobilisation is in its assembled state an easy
to use system, the microfluidic device requires a certain amount of technical understanding
from its user, but nevertheless comprises the potential to evolve into a fully automated system
where a layperson only needs to press the start button.
In terms of the manufacturing costs the immobilisation approach also can be offered for
moderate costs, whereas for the microfluidic electrofusion device a higher investment is needed
due to the high technical demands such as the purchase of a pump station and the fundamentally
higher costs of microchip production. Hence, the fusion device based on immobilisation is
preferable for a single use clinical application.
Table 5.1: Comparison of Immobilisation and Microfluidic approach
Immobilisation Microfluidics
⊕ • easy to use • automatable
• moderate costs • independent from cell line
• single use (clinical application) • no binding of mAbs to cells
 • mechanical/chemical stress on cells • high technical demands
• limited chamber size • high costs (in case of single use)
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Nevertheless, the microfluidic electrofusion device has the big advantage that it can be
used independently from cell lines. No monoclonal antibodies are bound to the cells as in
the immobilisation approach and therefore the cells are not exposed to additional stress by
detachment from the antibodies after fusion.
5.4 Electrofusion
The fusion of mammalian cells by means of electrical fields is nowadays an established method.
However, it is not possible to fuse every fusion pair. The fusion is so much the simpler when the
physical properties of the fusion partners such as cell size and membrane stability are identical
or at least similar. This is given for homologous fusions, hence homologous fusion events occur
easier than heterologous fusions.
Also, the hybrid detection method is of paramount importance. As shown in this thesis, the
staining of cells with membrane, cytosolic or nuclear dyes alter the physical properties of the
cells and therewith the cell’s fusion parameters. The cell fusion parameters, however, can be
very different by nature, as in the case of dendritic cells and breast cancer cells, and thereby
preventing cell fusion. A more than 4-fold higher electrical field was needed to temporarily
electroporate dendritic cells in comparison to the breast cancer cell lines MCF-7 and MDA-
MB-231. This finding might be due to a very stable membrane structure of dendritic cells,
which is needed to maintain the special shape of dendritic cells with all its dendrites. It has
been presented in this work that fusion between dendritic and breast cancer cells is not feasible
and fusion events described in literature might only be due to false analysis and over-optimistic
interpretation of data.
The fusion of dendritic cells and cancer cells for the generation of a cancer vaccine has occu-
pied researchers over the last years. The first two papers reporting fusions of human dendritic
cells with tumour cells have been published in the year 2000 (Scott-Taylor et al. (2000),
Kugler et al. (2000)). Since then, further 10 articles about dendritic cell/tumour cell fu-
sions were published until and including November 2005. They are compared and analysed in
regard to the used fusion partners, parameters and results in the table on page 244 and 245.
The excitement about dendritic cell/tumour cell hybrids as cancer vaccine reached its height
in 2003/2004 with 8 published articles in 18 months.
All publications refer to the very first article in this field (Scott-Taylor et al.(2000))
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published in Biochimica et Biophysica Acta and/or to the work of Kugler and colleagues
(2000) published in Nature Medicine in the same year. Appallingly, the results of both papers
are not reproducible.
Prof. A.G. Dalgleish, in whose group Scott-Taylor conducted his research, acknowledged
that they ”gave up working on the fusion” approach, because they ”could not get the required
numbers consistently” and the hybrids ”do not divide” (personal communication). Thereafter,
the group changed their strategy and loaded dendritic cells with irradiated cells and lysates.
In the article of Kugler and colleagues (2000), the generation of tumour cell-dendritic cell
hybrids and the use of this hybrid in a vaccination strategy for cancer patients with renal cell
carcinoma has been reported. The university of Go¨ttingen, where Kugler conducted his research,
and the German Research Foundation (DFG) both launched an investigation after allegations
were raised that a picture of a dendritic cell/tumour cell hybrid that Kugler had declared its
own and used in his thesis and another publication, was downloaded from the internet. The
picture did not even show a fusion hybrid of a dendritic cell and a tumour cell, but a hybrid of
a homologous tumour cell fusion. In addition, the research presented in the Nature paper was
strongly criticised by Prof. Ulrich Zimmermann (University of Wu¨rzburg), a specialist in the
field of cell fusion. He wrote a letter to the Go¨ttingen faculty, in which he claims that the cell
hybrids used in the Kugler et al. experiments cannot be live because of the long pulses used for
fusion and may even be dangerous for patients, due to high amounts of aluminium ions in the
vaccine, which were solubilised from the electrodes upon fusion (Friedrich et al. (1998)).
Furthermore, other scientists from the University of Go¨ttingen or the Medical University Clinic
Tu¨bingen, where the vaccination trial took place, were not able to reproduce the tumour vaccine
generation. Finally, three and a half years after publishing, the article in Nature Medicine was
retracted. The following explanation was given: ”The authors unanimously wish to retract this
paper, because of several incorrect statements and erroneous presentation of primary data,
results and conclusions”. The authors were found guilty of negligence and were admonished.
They have admitted that they falsified the primary data, which made it a precarious case,
especially if one bear in mind that patients were involved.
Both lead authors, Scott-Taylor and Kugler, must have been aware of the fact, that data
from FACS analysis alone, do not suffice to proof the generation of fusion hybrids. Scott-Taylor
wrote: ”Membrane fragmentation and amalgamation are common effects of electric pulses to
cells and are well known to distort estimations of cell fusion”...”and makes surface staining
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Figure 5.1: Comparison of papers reporting tumour cell/DC fusion
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Figure 5.2: Continuation of Table from figure 5.1
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a flawed method of assessing the proportion of hybrid cells”. He therefore used cytoplasmic
CellTracker dyes to stain the fusion partners before fusion. Dual-fluorescent events detected
by FACS in the negative control (incubation without pulsing) were identified as aggregates of
individually stained cells by fluorescence microscopy. What Scott-Taylor did not allow for, was
the additional formation of hybrids due to the fusion process. Thus, the only possibility how
to validate cell fusion, and why Kugler was in need of a picture of a hybrid, is an analysis by
microscopy. For this reason, microscopic data are of paramount importance, even if articles are
published in high-ranking journals.
For the evaluation of a cell solution after the fusion process, the cells should be analysed by
FACS and confocal microscopy. Therefore, a specific monoclonal antibody should be available
for each fusion partner to allow distinction between the fusion partners. The cells would be
labelled after the fusion has taken place, so that the membrane properties are not altered due
to the staining before the fusion process. The double positive events are determined by FACS,
whereas it is important not to gate the whole upper right (UR) quarter of a dot plot as it can
often be found shown in the representative fusion analysis in figure 5.3. The obtained fusion
efficacies by this kind of data analysis are misleading and not related to the actual fusion
efficacy. As shown in figure 5.3, it is very obvious that most of the events shown in the UR
quarter are due to the shifting of the original populations into this quarter of the dot plot.
This shifting of populations as described in section 3.3.2 appears after pulse application and is
probably due to changes in the self-fluorescence of the cells caused by exposure to the electrical
field. As shown in this thesis, the shifting of the cell populations is intensified the higher the
applied field strength. In general, for FACS analysis of fusion processes, the hybrid populations
should be searched and detected in fluorescent dot plot regions that have the single fluorescent
magnitudes approximately equal to those of the unfused cells, as described by Jaroszeski
and colleagues (1993). The double positive cells found in this plot region should then be
sorted with the help of a FACSorter and further analysed by means of fluorescent microscopy
to determine between real hybrids and cell aggregates or cell fragments.
Confocal microscopy would be the best choice to analyse the potential hybrid cells. Each
hybrid should at least contain two nuclei and the cell membrane should be a mixture of the
membranes of the two fusion partners. The latter can be observed by staining the cell membrane
after the fusion using monoclonal antibodies specific for each fusion partner. Prelabelling of the
cells with discrete fluorochromes prior to fusion should be avoided.
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Figure 5.3: Three representative dot plots of FACS analysis of fusion processes.
Furthermore, it is essential to determine the viability of potential fusion hybrids and the
integrity of the cell membrane. As criticised by Zimmermann in regard to the Kugler paper:
”Dead (hybrids) do not migrate” ( Ba¨r (2001)) - and do not process or present tumour-
associated antigens.
Regarding the electrofusion chambers some precautions should be taken to provide an op-
timal fusion environment. Electroporation chambers (especially those with Aluminium elec-
trodes) should not be diverted from their intended use. Due to their big electrode distance, the
cell solution is considerably heated up when the chamber is used with field strength of more than
1 kV/cm, which can damage the cells. The wax, which is applied by some researchers to one
electrode of the electroporation cuvette to obtain a non-uniform electrical field, could detach
during the fusion process. Its influence on the fusion process itself and the effect when injected
into patients with the rest of the cell vaccine is unknown. Thus, a fusion chamber should be
used, which was only designed for this purpose. With the development of the fusion chambers
for arranged electrofusion of mammalian cells, which is presented in this thesis, homologous
fusions, which are normally favoured over heterologous fusions, are avoided.
The above ”rules” for the fusion process and its analysis applies for every mammalian cell
fusion, but for each fusion pair the electrofusion parameters need to be determined separately,
since they are dependent on the cell radius and the other cell-specific properties. In the case of
dendritic cells and breast cancer cells, no fusion parameters were found, which would allow for
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the fusion of these two cell types. Four 65μs electrical pulses of 8.5 kV/cm would be needed
to electroporate and subsequently fuse dendritic cells, while at this field strength all breast
cancer cells would be lysed. If in contrast the optimal parameters for breast cancer cell would
be used (1.8 kV/cm, 20μs, n=1 or 2), not a single dendritic cell would be permeabilised.
With these physical parameters of monocyte-derived dendritic cells and tumour cell lines from
breast cancer patients, the fusion process is not feasible. As seen in the discussed literature,
the published data and personal communication with other researchers in this field do not
argue the converse. Additionally, after the excitement had reached its height in 2003/2004, the
successional articles in 2005 did not report dendritic cell/tumour cell fusion, but investigated
the effect of the electrofusion process on the immunogenicity of allogeneic human cells (Hock
et al. (2005)) and the impact of electrical charge on the viability and physiology of dendritic
cells (Hilpert et al. (2005)). This underlines that few was known about the biophysical
properties of DCs when earlier publications claimed the generation of DC/tumour cell hybrids.
Furthermore, huge differences in the fusion parameters might also exist for other DC/tumour
cell fusion pairs, because of a high membrane stability of dendritic cells. Discussions of strategy
and results with the workgroup of Prof. Dr. E. Neumann of the Physical and Biophysical Chem-
istry Department at the University of Bielefeld, especially with PhD student Marco Schmeer,
arrived at the conclusion that a search for other fusion pairs should be started for the field of
cancer immunotherapy. B-cell/tumour cell fusions might be feasible due to a similar cell size of
the fusion partners.
5.5 Immunological Evaluation
Although the generation of dendritic cell/tumour cell hybrids by electrofusion have not been
proven in literature and the difference in fusion parameters as presented in this thesis are
significant and should not allow an electrofusion, several papers reported induction of anti-
tumour immunity in vivo and in vitro. For this reason, the fusion outcome of experiments
accomplished in this thesis were employed in in vitro expansion assays of effector cells.
T-cells from healthy donors were amplified in an autologous stimulation by cocultivation
with dendritic cells at a ratio of 10:1. The dendritic cells were either subjected to an electrofusion
process together with MCF-7 cells, were mixed with MCF-7 cells, which were subjected to the
fusion pulse, or loaded with MCF-7 tumour cell lysate. The latter approach was chosen as
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a reference for the hybrids, since it is widely used in dendritic cell based immunotherapy of
cancer.
The quantitative and qualitive changes in T-cell number were measured over time and
showed a very strong proliferative response with an overall expansion of 14.1-fold of autologous
CD4+ and CD8+ T-cells stimulated with DCs that were mixed with pulsed MCF-7 cells. A
lower, but still strong proliferation (6.54-fold) was observed when T-cells were stimulated with
DCs, which were subjected to 4 fusion pulses together with MCF-7 cells. The lowest expansion
(expansion factor: 3.94-fold) was found for the DCs loaded with MCF-7 tumour cell lysate.
Nevertheless, the latter expansion factor was still in the expected range, as shown by other
researchers for lysate-pulsed dendritic cells in mixed leukocyte reactions (Bohnenkamp et
al. (2004)).
However, the ”fusion” approach showed a much better result with an 6.54-fold increase in
T-cell number. Although no hybrids could be detected, the ”fusion” outcome still showed a
strong immunestimulatory effect. An explanation would be the uptake of MCF-7 cell debris
by dendritic cells, either due to endocytosis or via the pores, which are formed during the
electroporation/electrofusion process. The bits and pieces of the tumour cells were then pro-
cessed internally and presented on the MHC complexes on the cell surface of the DCs. In this
connexion, the uptake of small parts of tumour cell membrane could have been an advantage
over the lysate approach, where after several freeze/thaw cycles the unsoluble cell debris such
as membrane fractions and organelles were removed by filtration. This might result in a lower
concentration of membrane proteins. Bohnenkamp tried to load DCs with tumour cell lys-
ate containing also the unsoluble parts of the lysate, but had to find that this resulted in a
reduced number of viable dendritic cells with a phenotype that did not show high expression
of DC markers such as CD80, CD86 and CD83 (Bohnenkamp, personal communication). The
”fusion” approach seems to be a better approach to load DCs also with unsoluble tumour cell
fragments. It is also the more physiologic approach, as DCs are loaded with whole tumour cells
or the debris of whole tumour cells and not with artifically produced lysate where an unknown
part of the cells is removed by filtration.
The third approach, which used dendritic cells loaded with the cell debris of MCF-7 cells,
which results from the subjection of the tumour cells to four electrofusion pulses (with para-
meters tailored for DCs), did perform even better. The difference in comparison to the ”fusion”
pulse is, that in this approach higher numbers of viable dendritic cells can be expected, since
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the DCs themselves are not subjected to the fusion pulses. If cells are subjected to electrical
pulses, which render them temporarily permeable, a small percentage of cells is lost due to
necrosis.
Furthermore, the analysis of the CD8+ T-cell subset showed a strong expansion of memory
T-cells, which normally function as constitutive immune memory and form in concert with
antibody responses the basis for protective immunity against infection and disease. According
to the signal strength model for T-cell differentiation and memory T-cell generation (Sallusto
et al., 2004), the strength of signalling received by T-cells is a major factor that determines T-
cell differentiation. Priming of CD8+ cells by a signal of suboptimal strength may induce CD8+
T-cell proliferation, but the cells fail to upregulate antiapoptotic molecules and receptors for
homeostatic cytokines and will die by neglect. Only large numbers of mature DCs carrying high
doses of antigen would promote a massive proliferation of antigen-specific T-cells, which will
persist as effector memory cells. If the DC/T-cell ratio is low or the stimulation is brief, central
memory T-cells will be generated preferentially. A too prolonged and strong proliferation may
on the other hand lead to activation-induced cell death (AICD) of the T-cells. However, the
used method of loading DCs with cell debris, which was originated by the electrical pulsing of
tumour cells, seemed to deliver a stimulation signal with exactly the right strength to produce
a large amount of effector memory T-cells.
Chapter 6
Summary & Outlook
Cellular immunotherapy of cancer is a hot topic ever since the discovery that the immune sys-
tem is capable of recognising tumour cells. Dendritic cells (DCs) are the professional antigen
presenting cells that are best suited for cell-based immunotherapy and therefore ex vivo gen-
erated DC cancer vaccines are currently applied in clinical trials. Several methods have been
devised for the loading of DCs with tumour information. Instead of identifying, characterising
and targeting only a single tumour-associated antigen (TAA), dendritic cells can also be loaded
with whole-cell tumour information. In the majority of cases, identifying a TAA is a tedious
process and targeting only a single antigen is not likely to succeed unless that antigen is neces-
sary for the function and survival of cancer cells. For this reason, a whole tumour cell approach
has several advantages.
The fusion of dendritic cells with tumour cells is used as such a whole tumour cell loading
strategy and the application of the fusion outcomes, e.g. possible hybrids cells, have been shown
to induce anti-tumour immunity in several cancer models and clinical studies (Orentas et al.
2001, Hayashi et al. 2002, Rosenblatt et al. 2005). Nevertheless, the absence of a reliable and
reproducible fusion method, the pour fusion efficacies and the limitation of autologous tumour
material for some tumour types were thought to prevent a broad application as cancer vaccine.
This study aimed for the development of new fusion devices to overcome these limitations.
Cluster formation, which typically takes place in commercially available electrofusion chambers
during cell alignment owing to similar electrophysical parameters (such as cell size, shape and
transmembrane potential), was found to be a major limitation of heterologous mammalian cell
fusion. The formation of cell clusters and homologous fusions can be avoided by a so-called
arranged electrofusion process, where two fusion partners are subjected to an alternating ar-
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rangement inside the fusion chamber. This alternating arrangement was realised in two newly
developed electrofusion chambers by means of micropatterning and microfluidics, whereas clin-
ical requirements have been considered throughout the whole process development. Both elec-
trofusion chambers were also dimensioned to produce a sufficient amount of hybrid cells at
once, thus satisfying the requirement for high-throughput cell fusion.
The electrofusion chambers were fabricated using a combination of several microtechnolo-
gical methods such as photolithography, metal-film deposition, laser and glass etching techno-
logies. These microdevices included up to 9 alternating cell lanes preventing cluster formation
and homologous fusion events by this alternating cell arrangement. Additionally, all dimensions
had been chosen to correlate sizes of cells and to allow fusion of large numbers of cells simul-
taneously. Direct visualisation of the fusion procedure was also permitted in both lab-on-a-chip
approaches, allowing for fusion evaluation by means of fluorescent microscopy.
Inside the first electrofusion chamber, the alternating cell arrangement was implemented
by the immobilisation of cells onto 15μm wide covalently-bound antibody lines. Self-assembled
monolayers (SAMs) of 11-mercaptoundecanoic acid (MUA) were formed on evaporated gold
lines, activated by a mixture of N-hydroxysuccinimide (NHS) and 1-ethyl-3-(dimethylamino-
propyl)carbodiimide (EDC), and used to covalently bind monoclonal antibodies via their
primary amino groups forming a peptide bond. By the subsequent integration of electrodes, the
build up of the framing chamber and the connection to the electrical equipment for cell fusion,
a functional microelectrofusion device was established.
The second electrofusion device was based on microfluidics and the alternating cell arrange-
ment inside the fusion chamber was realised by laminar single-cell flows. Also in this case, an
alternating cell arrangement was demonstrated and formation of hybrid cells was achieved for
test cell lines.
The deployment of microfabrication technologies for the electrofusion chamber development
provided unique process advantages to promote this biological application and was not only
used because microdevices are in and nice to have. It furthermore made these lab-on-a-chip
applications suitable for parallelisation and automation.
After fusion could be proven in model cell lines, both chambers were applied for the forma-
tion of dendritic cell/tumour cell hybrids for breast cancer immunotherapy. Thereby, all relevant
fusion parameters such as fusion buffer, alignment process by dielectrophoresis, field intensity,
pulse duration and number of pulses were investigated for their influence on fusion efficacy.
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It turned out that a fusion event between monocyte-derived dendritic cells and breast cancer
cells from tumour cell lines is very unlikely due to huge differences in the physical properties
and therewith in the needed electroporative electrofusion pulse. Dendritic cells need a more
than four times higher fusion pulse and several subsequent pulses instead of just a single fusion
pulse, to reversibly form membrane pores. Under these conditions, all tested breast cancer cell
lines were lysed and no heterologous hybrid formation was observed.
These results query other reports about DC/tumour cell hybrid formation, while erroneous
fusion analysis encourages this assumption. Nevertheless, the fusion outcomes were applied to
an immunological evaluation by in vitro expansion of effector cells, which showed high stim-
ulatory capacity of dendritic cells loaded by means of fusion or better to say electrical field
treatment. The expansion of memory cytotoxic T-lymphocytes (CTLs), potent killer cells, were
demonstrated and significantly better results were obtained compared with the widely used
lysate-pulse approach for the loading of dendritic cells.
Hence, the developed electrofusion chambers represent functional devices for a new load-
ing strategy of dendritic cells based on electrical field manipulation. Furthermore, the devices
can also facilitate other real fusion applications such as hybridoma production, where a high-
through-put cell fusion device is a benefit for the production and identification of a good
producer of antibodies. Additionally, the famous case of Dolly, the cloned sheep, would not
have been possible without fusion. Thus, several application areas are available and new might
be discovered in future, which may benefit from the electrofusion chambers for arranged elec-
trofusion of mammalian cells, developed in this project. Thereby, the low productions costs of
the electrofusion chamber based on immobilisation would be an asset for medical disposables
for clinical use on the one hand. On the other hand, the microfluidic electrofusion chamber
holds the possibility for automation and the on-chip integration of additional units for fusion
hybrid detection, by optical or impedimetric methods, units for cell sorting by FACS.
In this way and with the new findings about dendritic cell/tumour cell fusion, a project,
which was primarily focussed on breast cancer, can have benefits for other areas, as well.
Dendritic cell-based immunotherapy, for example, is a generally applicable approach, and the
tools and methods for DC loading, which were developed in the project, are widely applicable
to other types of cancer further enhancing the relevance of this project.
Nevertheless, all forms of DC-based therapies are still experimental and not approved for use
as a standard treatment, but are already being tested against a variety of cancer types in ongoing
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clinical trials. Much still needs to be learned regarding antigen loading, maturation, route of
administration and migration of DC-based vaccines. The administration route of the vaccine
needs to be investigated such as intradermal, intravenous, intralymphatic or by direct injection
into the lymph node. Most delivery methods are dependent on the migration of antigen-bearing
DCs from peripheral tissue to the lymph nodes, thus require viable cells.
Tumour-specific immunotherapy will not be available tomorrow, but the lessons learned
from this study can now be applied to the development of therapeutic breast cancer vaccines
and vaccines against other cancer types.
Figure 6.1: Three representative dot plots of FACS analysis of fusion processes.
Collaboration is an incredibly important aspect of research and being within an institute
like the Research Centre Ju¨lich, collaboration is facilitated. In this project, the key to being
successful was multidisciplinarity. A broad skill base was needed to understand all the different
aspects of cell culture, immunology and microtechnology. The combined skills, expertise and
resources of several collaboration partners at the Research Centre Ju¨lich, the Danish Technology
Institute, the Cranfield University and from companies inland and abroad succeeded in two new
electrofusion chambers for arranged electrofusion, which were both filed as patents and partly
already granted.
Chapter 7
Material and Methods
7.1 Immobilisation
7.1.1 Mask Preparation
The layout of the photolithographic mask was designed by the means of the AutoCAD LT 2000i
software. The chrome masks were manufactured by e-beam lithography or purchased from J.D.
Photo Tools Ltd. (Oldham, UK).
Table 7.1: Materials for the mask preparation
Software AutoCAD LT 2000i Autodesk, Munich, Germany
E-beam writer EBPG 5HR Leica Microsystems, Wetzlar, Germany
7.1.2 Master Preparation
The master stamp was prepared on a Si-wafer. A spin-coat of the negative photoresist SU-
8 25 was applied with a height of 25 micrometer. The film was exposed to UV light via a
photomask for 33sec and processed according to the manufacturer’s recommendations. For a
better redeemableness of the PDMS stamps after the moulding, the master was silanised with
a solution of dichlormethyloctadecylsilane in toluene for 4h at 65◦C and was then thoroughly
washed with 2-propanol and water. In the end, the master was dried with argon and stored.
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Table 7.2: Materials for the master preparation
Si wafer MEMC Electronic Materials, St. Peters, USA
Negative photoresist SU-8 25 Micro resist technology, Berlin, Germany
Spin coater
Dichlormethyloctadecylsilane Sigma, Deisenhofen, Germany
Convection oven Heraeus, Hanau, Germany
2-propanol Merck, Darmstadt, Germany
7.1.3 PDMS Stamp Preparation
A silicon solution of Sylgard 184 was prepared, whereas the two components (prepolymer and
curing agent) were mixed at the ratio 10 : 1. Bubbles were removed under vacuum in an excicator
and the mix was poured onto the master. The polymerisation time was shorten by heating at
60◦C for 4h. When the stamps were cured, they were peeled off the master and surmounting
stamp parts were removed. A ”ticket-punch” was used to make small holes into the stamp,
one at every end of a channel or channel bundle. Subsequently, the stamps are cleaned in 2-
propanol under ultrasonication and rinsed with water, followed by a 2min ultraviolet/ozone
(UVO) treatment. Not to loose the hydrophilic character again, the stamps were treated for
1h with a 0.1M sodiumhydroxid solution, thoroughly washed with water under ultrasonication
and stored in deionised water. Just before use, the stamps were dried under a stream of air.
The above protocol was also used under sterile conditions when appropriate.
Table 7.3: Materials for the PDMS stamp preparation
PDMS prepolymer Sylgard 184 Troller Kunststoffe, Jegenstorf, Schweiz
PDMS curing agent Sylgard 184 Troller Kunststoffe, Jegenstorf, Schweiz
Convection oven Heraeus, Hanau, Germany
2-propanol Merck, Darmstadt, Germany
UVO cleaner model 42-220 Jelight, Irvine, USA
Sodiumhydroxid Merck, Darmstadt, Germany
Ultrasonic bath Ko¨ttermann Labortechnik, Uetze, Germany
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7.1.4 Microcontact Printing
A PDMS stamp was inked with a 10 % aminosilane solution in water and dried. The inked
stamp was dried in a stream of nitrogen and pressed to the substrate for 30sec.
Table 7.4: Materials for direct microcontact printing
3-aminopropyltriethoxysilane Sigma, Deisenhofen, Germany
Glass wafer Pyrex, optically polished Barloworld Scientific, Stone, UK
on both surfaces
with ground standard flat
7.5cm in diameter
thickness 0.5 + 0.005mm
7.1.5 Inverse Microcontact Printing
For inverse microcontact printing, the cleaned and dried PDMS stamps were contacted with the
glass substrate. The subsequent immobilisation reactions were carried out in the microchannels,
which were formed between the PDMS stamp and the substrate.
Table 7.5: Materials for inverse microcontact printing
Glass wafer Pyrex, optically polished Barloworld Scientific, Stone, UK
on both surfaces
with ground standard flat
7.5cm in diameter
thickness 0.5 + 0.005mm
7.1.6 Immobilisation Reaction
A 10 % aqueous solution of 3-aminopropyltriethoxysilane was prepared and its pH was adjusted
to 3,45 with 6M HCl. The solution was reacted with the glass surface for 2h at 60◦C in a
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convection oven. The oven was turned off and another 2,5 hours are given to cool the substrate
down and complete the reaction. The channels were emptied with the use of a vacuum pump and
washed three to four times with the next reaction solution, a 2,5 % solution of glutardialdehyde
in a phosphate buffer. The 0.1M sodium phosphate buffer had a pH of 7 and was produced
by mixing 30.5mL of a 0.1M Na2HPO4 solution with a pH of 8.5 with 19.5mL of a 0.1M
NaH2PO4 with a pH of 4.7. The glutardialdehyde solution was reacted with the silanised glass
surface for 2h at room temperature.
Table 7.6: Materials for immobilisation reaction
3-aminopropyltriethoxysilane Sigma, Deisenhofen, Germany
HCl Merck, Darmstadt, Germany
Convection oven Heraeus, Hanau, Germany
Glutardialdehyde 50 % aqueous solution Sigma, Deisenhofen, Germany
Vacuum pump Oerlikon Leybold Vacuum
Cologne, Germany
Bovine serum albumin FITC-labelled Sigma, Deisenhofen, Germany
Table 7.7: Antibodies used for immobilisation
Antibody Clone Isotype Conjugate Manufacturer
reacts with
CD34 581 Mouse IgG1, κ FITC Becton Dickinson
CD34 581 Mouse IgG1, κ unlabelled Becton Dickinson
CD45 HI30 Mouse IgG1, κ FITC Becton Dickinson
CD45 HI30 Mouse IgG1, κ Biotin Becton Dickinson
CD45 HI30 Mouse IgG1, κ unlabelled Becton Dickinson
Subsequently, the channels were emptied using the vacuum pump and filled with a protein
solution, of the protein, which should be immobilised in lines. For a first test, FITC-labelled
bovine serum albumin was used. Later on, different antibodies were immobilised (see table 7.7
on page 258). The last reaction step took place at 4◦C over night.
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During the optimisation of the immobilisation reaction for the use with inverse microcontact
printing, the reaction time of the first reaction steps were reduced to 1h and the filling holes of
the PDMS stamp were covered with adhesive tape during all immobilisation reactions to avoid
blockage of the channels by drying.
7.1.7 Ellipsometry
For the ellipsometrical analysis of the thin films, applied on a glass wafer, an Imaging Ellipso-
meter was used. Local measurements of layer thickness and recording of a thickness map were
performed by recording a map of Delta and Psi from which the map of the thickness is cal-
culated. In addition, live-contrast-images were obtained, were the layer thickness is correlated
with the greyscale.
Table 7.8: Materials for ellipsometry
Imaging Ellipsometer EP 3 Nanofilm, Goettingen, Germany
Objective 10x Nanofilm, Goettingen, Germany
Software for optical modelling EP 3 View Nanofilm, Goettingen, Germany
7.1.8 Lift-off Photoresist Processing and Metal Coating
A 100mm glass wafer was coated with 2.5mL LOR 3B photoresist for 45sec at 3000rpm and
prebaked on a hot plate for 5min at 170◦C. The spin-coat should have 1.2 - 1.3fold the thickness
of the desired metal film. S1813 was used as imaging resist. 2.5mL of this positive photoresist
were spun on top of the LOR (45sec, 4000rpm). A prebake step was following on a hot plate for
2min at 115◦C. The obtained bi-layer stack was exposed to UV light for 8sec and subsequently
developed using the Microposit MF-319 developer in an immersion mode for 40sec. The wafer
was rinsed with deionised water using an overflow setup and dried with air. For the deposition
of the gold film a 2μm thick chrome layer was applied first as adhesive agent. Subsequently, a
200nm high gold layer was applied under high vacuum of approximately 1− 2 · 10−6mbar. The
deposition is controlled via a film thickness monitor, which measures the nominal thickness of
deposited films. The thickness and deposition rate can then be calculated from user-supplied
data on density and acoustic impedance of the film material.
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The reentrant profile of the resist ensures discontinuous film deposition and allows the lift-
off of the bi-layer resist stack, leaving only the desired gold film. SVC-14 positive photoresist
stripper is used for the lift-off process. Two stripping tanks of SVC-14 were set up and the
solvent tank temperatures were set between 70−90◦C (80◦C % baseline). The glass wafer with
LOR bilayer and deposited gold film were placed in bath 1 for 5− 20min under sonic agitation
until the biggest part of the unwished gold film was removed. Then, the wafer was transferred
to bath 2 for additional 5− 20min. After stripping, the wafer was rinsed with deionised water
(quick dump rinse) for 6-8 cycles and dried under a stream of nitrogen.
Table 7.9: Materials for LOR processing
Spincoater P-6708D Speciality Coating Systems
Indianapolis, USA
Hot plate Stuart Scientific
Lift-off resist LOR 3B Microchem, Newton, USA
Positive Photoresist S1813 Rohm and Haas, Coventry, UK
Developer Microposit MF-319 Rohm and Haas, Coventry, UK
Positive Photoresist Stripper SVC-14 Rohm and Haas, Coventry, UK
Gold wire 99.995 % purity Aldrich Chemicals, Wisconsins, USA
Vacuum Coater BOC Edwards, London, UK
Film deposition monitor IL 150 Intellemetrics Ltd, Glasgow, UK
7.1.9 Laser Processing
A CO2 laser with a wavelength of 10.6μm was used to cut 6 different parts for the build-up of
the electrofusion chamber (based on the immobilisation approach). The parts for the bonding
layer were cut into Arcare 8939. Arcare 8939 is a white, thin and flexible plastic film coated
on both sides with an acrylic medical-grade pressure-sensitive adhesive. It is 3mm thick and
suitable for bonding. The parts for the top layer were cut into Melinex polyester film. The
structures were drawn using the drawing editor of the WinMark laser marking software. The
following parameters and materials were used for laser processing.
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Table 7.10: Parameters for laser processing
Pline Start Delay Base 400μs
Pline End Delay Base 400μs
Interseg Delay Base 0μs
Off Vector Delay Base 0μs
Off Vector Velocity 2000mm/s
Laser power 100 %
Laser Cutting Velocity 400mm/s
Table 7.11: Materials for laser processing
Fenix laser marker Synrad, Mukilteo, USA
Laser marking software WinMark Lite Synrad, Mukilteo, USA
Double-sided tape Arcare 8939 Adhesive Research Inc., Glen Rock, USA
Acetate foil Melinex ST725 Dupont, Hopewell, USA
7.1.10 Immobilisation of Antibodies on Gold
The glass wafers with the vapour-deposited gold structures were immersed into 1mM 11-
mercaptoundecanoic acid in absolute ethanol (previously vortexed 30min) for 48h. Upon re-
moval, the wafers were rinsed via dipping twice into absolute ethanol and soaked in water for
5min before drying under a stream of nitrogen. NHS esters were formed by exposure of the
MUA SAM to an aqueous solution of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)
and NHS 75mM and 15mM respectively (1h, 20◦C). The glass surfaces of the sample were
immersed in a 10mg/mL PEG-silane solution in anhydrous toluene. After removal from the
PEG-silane solution, the residual PEG was removed by washing in toluene under sonication for
5min and rinsing with ethanol and distillated water. Subsequently, the NHS ester monolayers
were reacted for with an antibody-solution (0.5mg/mL) for 24h at 4◦C.
For immobilisation of antibodies under sterile conditions, the glass wafers were sterilised in
70 % ethanol and all reaction steps were accomplished under sterile conditions.
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Table 7.12: Materials for laser processing
11-mercaptoundecanoic acid 95 % Sigma, Deisenhofen, Germany
EDC Sigma, Deisenhofen, Germany
N-hydroxysuccinimide Sigma, Deisenhofen, Germany
Polyethylenglycol-silane MW 5000 Shearwater Polymers, Huntsville, USA
CD45 unlabelled HI30, Mouse IgG1, κ Becton Dickinson
7.1.11 XPS
XPS measurements were made on an XPS spectrometer Physical Electronics 5600 with a mono-
chromatised Al Kr X-ray source (1486.6eV photons) with a pass energy of 20eV . High resolution
spectra of C1s, O1s, N1s and Au4f regions were obtained and peaks fitted using the Unifit for
Windows software (version 32-32). The analysed surface areas were 2mm · 5mm big.
7.2 Microfluidics
7.2.1 Fluid Simulation
3D models of the microfluidic devices were developed using a computer-aided design programme
(CAD) called Pro-Engineer (Parametric Technology Corporation (PTC), Needham, USA). For
the subsequent computational fluid dynamics the CFX software (Ansys Inc, Canonsburg, USA)
was used.
7.2.2 UV Laser Micromachining
For the fabrication of microstructures in either PMMA or PET the Krypton-Fluor (KrF) ex-
cimer laser MicroMaster (Optec, Frameries, Belgium) was utilised. To obtain a 3-dimensional
structure the structures were burned from the upper and the bottom side of the polymer slide
and posses through holes to connect both sides with each other. In this setup, the through holes
function as alignment points, to place the microstructures in the right direction.
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7.2.3 Assembly and Operation of Pump Station
The pump station is established from the components listed in table 7.13. It contains several
pumps to pump or suck fluids through the microfluidic chambers. For the connection of these
pumps with the microfluidic chip, tubing and valves are needed.
Table 7.13: The Components of the Pump Station
Quantity Component Manufacturer
2 Cavro XL 3000 3+ High resolution
pumps
Tecan Systems Inc, San Jose, USA
1 Cavro XL 3000 High resolution pump Tecan Systems Inc, San Jose, USA
1 Cavro XL series smart valve (1 input,
6 outputs)
Tecan Systems Inc, San Jose, USA
2 3-way-micro inert Valves The Lee company, Essex, USA
1 edge connector for RS232 control Tecan Systems Inc, San Jose, USA
20 P200 flangeless ETFE ferrules 1/16”
OD
Upchurch Scientific, Oak Harbor, USA
20 P235 short flangeless PEEK nuts Upchurch Scientific, Oak Harbor, USA
10 P272 flangeless frit-in-a-ferrule with
2μm filter
Upchurch Scientific, Oak Harbor, USA
10 P702 PEEK union for 1/16” OD tubing Upchurch Scientific, Oak Harbor, USA
1 P712 1/16” PEEK tee Upchurch Scientific, Oak Harbor, USA
2 50μL syringe Tecan Systems Inc, San Jose, USA
3 100μL syringe Tecan Systems Inc, San Jose, USA
2 500μL syringe Tecan Systems Inc, San Jose, USA
30 m non-polar fused silica, 0.25mm ID Supelco, Bellefonte, USA
3 m non-polar fused silica, 0.10mm ID Supelco, Bellefonte, USA
10 m Teflon tube PTFE, 1/16” · 0.25mm Mikrolab Aarhus, Hojbjerg, Denmark
10 m Teflon tube PTFE, 1/16” · 0.50mm Mikrolab Aarhus, Hojbjerg, Denmark
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Cavro XL 3000 Digital Pump
Single or multiple commands can be sent to the pump. For example a single command such
as A3000R moves the plunger to position 3000. Commands can also be combined to form a
programme string such as IA3000OA0R. This string moves the valve to the input position,
moves the plunger to position 3000, turns the valve to the output position and finally returns
the plunger to position 0. The pump contains a command buffer of 256 characters. If a command
has been sent without < R > (execution) command, it is placed into the buffer without being
executed. If a new command is sent before the first command is executed, the new command will
overwrite the first command. Once a command is executed, the pump will answer immediately.
New commands are not accepted until the sequence has been completed.
Table 7.14: Initialisation and valve commands for Cavro digital pump
Command Description Variable
Znn Initialises plunger drive and sets valve output to
the right (when viewed from the front of the pump)
nn = 0 (full plunger force)
nn = 1 (half plunger force)
nn = 2 (quarter force)
Ynn Initialises plunger drive and sets valve output to
the left (when viewed from the front of the pump)
nn = 0 (full plunger force)
nn = 1 (half plunger force)
nn = 2 (quarter force)
I moves valve to < I >nput position. The absolute
position is dependent on the initialisation com-
mand < Z > or < Y >.
O moves valve to < O >utput position. The ab-
solute position is dependent on the initialisation
command < Z > or < Y >.
E moves valve to < E >xtra position (only for 3-port
distribution valves).
B moves valve to < B >ypass position. This con-
nects the input and output positions bypassing the
syringe (only in combination with < Y > initial-
isation).
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Before starting the operation the pumps have to be initialised. During the initialisation the
plunger moves upward until it contacts the top of the syringe, thus defining the null position.
Additionally, the valves are controlled and set. The force at which the plunger presses against the
top of the syringe can be controlled by using special parameters (see table 7.14). Smaller syringes
should use a lower initialisation force and larger syringes should use higher initialisation force.
A constant speed (500) is applied for initialisation. Using half plunger force is recommended for
250μL and 500μL syringes and quarter plunger force for 100μL syringes and smaller. Further
important commands for the operation of the Cavro digital pump are summarised in table 7.15.
Table 7.15: Important commands for Cavro digital pump
Command Description Variable
Nnn Fine Positioning off/on. This command determines the
resolution of the plunger travel (60mm).
nn = 0 (off; 3000 in-
crements/full stroke)
nn = 1 (on, 24000 in-
crements/full stroke)
Ann moves plunger to the < A >bsolute position nn. nn = 0..max
Vnn sets the < V >eloctiy. It can also be changed on the fly. nn = 5..5800 Hz
(half-steps/second)
X repeats command: this command repeats the last ex-
ecuted command or programme string.
Gnn repeats command sequence. this command repeats a
command or programme string nn times.
nn = 0..30000
g marks the start of a repeat sequence and is used in con-
junction with the < G > command. Instead of repeating
a whole command sequence the < g > command marks
the beginning of a loop. Both the < g > and the < G >
commands can be used to nest up to 10 loops.
Mnn Delay in < M >illiseconds, delays the execution of a
command in milliseconds
n = 5..30000
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Cavro Smart Valve
Single or multiple commands can be sent to the Smart Valve. A single command such as
A2R turns in the valve in the default (clockwise) or programmed direction to port number 2.
Commands can also be combined to form a programme string such as Y2A1M50A2R. This
string tells the valve to turn counter-clockwise to port 1, wait 50 milliseconds then continue
turning counter-clockwise to port 2. All commands must be followed by an < R > (execution)
command. Once a command is executed, new commands are not accepted until the sequence
has been completed. The Smart Valve contains a command buffer of 256 characters.
Table 7.16: Overview of important commands for Cavro Smart Valve
Command Description Variable
Znn Identifies number of ports on valve and initialises
it to port 1
nn = 6
Ynn Sets valve direction nn = 1 (clockwise)
nn = 2 (counter-clockwise)
Ann Moves to selected port in direction < Y > nn = 1..6
R Run command, executes a previously sent com-
mand
X Repeat command
Gnn Repeat Command Sequence, repeats a command
or programme string nn times
nn = 0..30000
g marks the start of a Repeat Sequence, is used in
conjunction with the ¡G¿ command
Mnn Delay in < M >illiseconds, delays the execution
of a command in milliseconds
nn = 5..30000
Connection of the Components
The three syringe pumps, the SV6+ multiinjection valve and two inert valves were integrated
into the pump station. All modules were connected to a single 24 volt (d.c.) power supply and
the communication with these components was done from an RS-232 port. Therefore, pump 1
obtained a RS-232 interface board, which was plugged into its mother board. It converts the
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signal into RS-485. From then on all devices in the chain communicate through RS-485. In
addition, the various components had to be connected with capillaries and tubing to allow fluid
flow.
For the prototypes (Microfluidic chamber 1-3):
Nonpolar fused silica capillaries (ID 0.1mm) were glued into the microfluidic chip with
the help of UV light curing glue. A carbon cutter (Sigma-Aldrich) was used to cut the fused
silica tubing. For the connection of these capillaries to the pumps and valves, which possess
standard 1/4*28 coned ports intended for 1/16” OD (outer diameter) tubing, PTFE (polytet-
rafluorethylen, Teflon) tubing with an ID of 0.25mm and an OD of 1/16” was used. Thereby,
the PTFE tube acted as a sealtight sleeve: It was expanded by heating over a flame, the fused
silica capillary was inserted, and the PTFE tube encased the capillary tightly when cooled
afterwards. For the interconnecting tubing between pumps, valves, buffer reservoirs and col-
lecting tanks a PTFE tube (1/16”) with an inner diameter of either 0.25mm or 0.5mm was
used dependent on the desired flow rate. Flangeless ferrules and flangeless nuts, normally used
in chromatography such as HPLC, together with unions, replaced flange fittings and facilit-
ate replacement and rearrangement of the set-up. Furthermore, so-called frit-in-a-ferrules were
used, where buffers or cleaning solutions enter the microfluidic system. These special ferrules
incorporate a frit in their body, which filters the pumped solutions inline. 2μm filters avoid
blocking of the microfluidic channels by dirt.
For the final microfluidic electrofusion chamber (manufactured by Micronit):
The connection of the final microfluidic electrofusion chamber to the macroworld was done
with the help of Micronit’s chipholder. The microfluidic chip was placed flat on the bottom
of the chipholder. The capillaries were entered in the top plate of the chipholder from above.
Subsequently, a conic sealing rubber was put on the capillary by sliding it over the capillary’s
end The conic side of the sealing rubber needed to be equal to the tip of the capillary. The chip
holes were filled with distillated water and the top layer of the chip holder was adjusted. Thereby,
the sealing rubbers were pressing the water out of the holes. This excluded the appearance of
air bubbles in the connection. In the last step, the bolts were put on the threads and finger
tighten. The electrodes were contacted via the contact patches. Small wires were glued to the
contact patches by filling the holes at half height with conducting silver paste (see table 7.17
for supplier information).
All parts of the pump station were cleaned and maintained following the supplier’s instruc-
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tions. The used fluids were filtered before use, apart from the cell solution, and the microfluidic
system flushed extensively after each experiment. When unused, the system was filled with a 3
v/v % solution of Mucasol for disinfection.
Table 7.17: Additives for the connection of the microfluidic chip to the pump station and power
supply
Glue Dymax 628 Diatom, Hvidovre, Denmark
Conducting silver Kemo-Electronic, Langen, Germany
Mucasol Merz, Frankfurt, Germany
Evaluation by Particle Flow
SPHERO fluorescent polymer particles in the range from 10 to 19 μm (see table 7.18) were
used to visualise the flow inside the microfluidic chip.
Table 7.18: SPHERO fluorescent particles
SPHERO, Nile red 10-14 μm Spherotech Inc., Libertyville, USA
Excitation 500nm
Emission 560nm
SPHERO, Yellow 15-19 μm Spherotech Inc., Libertyville, USA
Excitation 450nm
Emission 480nm
Mucasol Merz (Frankfurt, Germany)
7.3 Fusion
Before fusion, both fusion partners were harvested by centrifugation, counted and mixed in
a ratio of 1:1. The cells were washed twice with hypoosmolar fusion buffer, resuspended in
hypoosmolar fusion buffer at different cell densities and introduced into the electrofusion cham-
bers. Electrofusions were always induced by the Eppendorf multiporator regardless of the used
chamber (Eppendorf electrofusion chamber, developed microfluidic electrofusion chamber or
electrofusion chamber based on immobilisation).
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Close contacts between cells were induced by dielectrophoresis. The cells were aligned dielec-
trophoretically by the application of a low electrical alternating field (5 - 500V/cm) for 5-95sec.
After the alignment process, short ( 10 - 300μs) field pulses with field strengths from 250 to
1500V/cm were applied to achieve fusion. Then, the alternating field was applied again for 5-
95sec to keep the cells in close contact during the fusion process. Following fusion, the cells were
left untreated for 5 minutes at room temperature and subsequently analysed or transferred to
cell culture. The content of the electrofusion chambers was rinsed out by using distilled water
from a spray bottle, followed by washing with 70 % non-denaturated ethanol.
Table 7.19: Components for the electrofusion of mammalian cells
Hypoosmolar electrofusion buffer Eppendorf, Hamburg, Germany
Multiporator Eppendorf, Hamburg, Germany
The electrofusion chambers were also used for dye penetration assays, analysing, which
fusion conditions are needed to provide a transient permeabilisation of the membrane allowing
electroporative dye uptake. Therefore, cells were pulsed in the presence of trypan blue. After
the pulse application the cell solution was incubated for a 10 min period at room temperature.
Subsequently, the number Nc of coloured cells of the population was determined. To estimate
the number of transiently permeabilised cells by pulse application, the number of stained cells
had to be reduced by the number Nirrev of cells, which were irreversibly damaged by the applied
electrical pulse. Therefore, another batch of cells were subjected to the pulses in the absence of
trypan blue, and the dye was added after the incubation period of 10 min. The percentage of
reversible permeabilised cells could then be calculated by the ratio of Nc-Nirrev to Nt, the total
number of the cell population.
7.4 Immunological Methods
7.4.1 Mixed Leukocyte Reaction
For the mixed leukocyte reaction, 1 · 106 1
mL
allogeneic T-cells with known MHC mismatch
were co-cultured with matured dendritic cells (1 · 105 1
mL
(1:10), 5 · 104 1
mL
(1:20), 2.5 · 104 1
mL
(1:40) or without dendritic cells, respectively) in AIM-V medium for 4 days in 6-well plates
at 37◦C in a humidified 5% CO2 containing atmosphere. On day 4, the T cell proliferation
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was analysed by flow cytometer using characteristic surface markers. The expression of the
surface markers CD25 (Interleukin-2 α-chain) and CD71 (transferrin receptor) on day 4 of the
mixed leukocyte reaction gives insight into specific cell subsets and T cell responses in the
presence of dendritic cells (Nguyen et al., 2003). These markers are involved in activation
and proliferation of (allogeneic) T cell responses. T-cell samples were stained for CD3, CD25
and CD71 and compared to corresponding isotype controls.
Table 7.20: Mixed leukocyte reaction
AIM-V medium Gibco, Carlsbad, USA
6-well plates 4mL NUNC, Wiesbaden, Germany
anti-CD3-ECD antibody NUNC, Wiesbaden, Germany
anti-CD25-FITC antibody NUNC, Wiesbaden, Germany
anti-CD71-PE antibody NUNC, Wiesbaden, Germany
7.4.2 Generation of lysate from MCF-7 breast carcinoma cells
Table 7.21: Materials for the preparation of tumour cell lysate
Versene 0.05% in EDTA / PBS Biochrom, Berlin, Germany
Ultrasonic bath U50 Ultrawave, Cardiff, UK
BCA assay Pierce, Perbio Science, Tattenhill, UK
To generate tumour lysate, confluent MCF-7 cells were harvested by the addition of 3mL
of 0.05% versene in 0.02% EDTA solution and incubated for 10 min at 37◦C. The cells were
washed twice with Phosphate Buffer Saline (PBS), resuspended 1 · 107 1
mL
in PBS and frozen
at −80◦C. Disruption of cells was carried out by five freeze/thaw cycles. Cells were thawed
by 10min sonication at 4◦C in an ultrasonic bath and subsequently frozen at −80◦C. The
supernatant was collected after centrifugation (1000g / 15min / 20◦C) and passed through
a 0.2μm filter. The protein concentration was determined by a BCA assay according to the
manufacturer’s instructions (Wiechelman et al., 1988).
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7.4.3 Autologous T-cell Expansion Assay
Monocyte-derived dendritic cells were harvested after 6 days of differentiation. These immature
DCs were either loaded with MCF-7 cell lysate (100μg 1
mL
) or electrically pulsed MCF-7 cells
(ratio 1:1), or submitted to four fusion pulses of a length of 65 μs and a pulse strength of 8.5
kV/cm in the presence of MCF-7 cells (ratio 1:1). After the loading procedure, the DCs were
matured for two additional days in the presence of TNF-α (1000 U
mL
) and PGE2. In the case of
lysate-pulsed dendritic cells 1 μg
mL
(0.003μM) PGE2 were added for maturation, whereas for the
other two approaches 18 μg
mL
(0.051μM) PGE2 was used.
On day 8, the mature dendritic cells were subjected to a co-cultivation assay with autologous
PBMCs. 1 · 105 1
mL
DCs were mixed with 1 · 106 1
mL
PBMCs and 2400 U
mL
IL-7 in a volume of
4mL (triplicates) AIM-V medium and cultured in 6 well plates for 14 days. During this time,
the cells were fed according to proliferation and the cell density of PBMCs was kept between
5 · 105 1
mL
and 1 · 106 1
mL
to avoid substrate limitations such as glucose and glutamine (see also
Bohnenkamp et al., 2002). The PBMCs are restimulated after one week of culture with
thawed tumour antigen-loaded dendritic cells at a ratio of 1:20 with fresh medium and 20 μg
mL
IL-2. All cells were harvested on day 14 and analysed for CD3, CD4, CD8, CCR7, CD45RO
and CD45RA expression by FACS.
Table 7.22: Materials utilized for the autologous stimulation of T cells with lysate-pulsed dend-
ritic cells
AIM-V Gibco, Carlsbad, CA, USA
TNF-α 1000 U
mL
R&D, Wiesbaden, Germany
PGE2 1 or 18
μg
mL
Sigma, Deisenhofen, Germany
rhuIL-7 2400 U
mL
R&D, Wiesbaden, Germany
rhuIL-2 20 U
mL
R&D, Wiesbaden, Germany
6 well plates 4mL NUNC, Wiesbaden, Germany
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7.5 Cell Culture and Cell Analysis
7.5.1 Cultivation of Human Tumour Cell Lines
MCF-7, MDA-MB-231 and T47D are three human breast carcinoma cell lines used in this thesis.
These breast carcinoma cell lines were cultivated in Iscove´s modified Dulbecco´s medium
(IMDM) supplemented with 10% heat-inactivated (56◦C, 30min) fetal calf serum in standard
tissue culture flasks (75cm2) at 37◦C and 5% CO2. Cells were detached by addition of versene,
subcultivated at a ratio of 1:5 and maintained at low passage number (5 to 20). In addition,
two leukaemia cell lines, KG-1 and K-562, were used as model cells for several experiments,
since they are suspension cells. They were culture as described for the breast carcinoma cell
lines.
Table 7.23: Materials for the cultivation of breast carcinoma cell lines
MCF-7 human breast adenocarcinoma cell line ATCC Number: HTB-22
MDA-MB-231 human breast adenocarcinoma cell line ATCC Number: HTB-26
T47D human breast adenocarcinoma cell line ATCC Number: HTB-133
KG-1 human acute myeloid leukaemia cell line ATCC Number: CCL-246
K-562 human chronic myeloid leukaemia cell line ATCC Number: CCL-243
Medium IMDM Biochrom, Berlin, Germany
Serum 10% fetal calf serum Biochrom, Berlin, Germany
Versene 0.05% in EDTA / PBS Biochrom, Berlin, Germany
Cultivation Tissue culture flask, 75cm2 NUNC, Wiesbaden, Germany
7.5.2 Cell Counting and Viability
Cell counting and viability determination was performed using a haemocytometer with stand-
ard trypan blue dye exclusion and a CASY 1 TT particle counting system (Schaerfe System,
Reutlingen, Germany).
The cell concentration with a haemocytometer is determined with the term:
number of cells
mL
=
number of cells in 4 quadrants
4
· 104 · dilution factor (7.1)
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The viability (trypan blue dye exclusion method) is calculated by utilising the following
formula:
viability =
viable cells
total number of cells
· 100 (7.2)
7.5.3 Ex Vivo Generation of Dendritic Cells
Peripheral blood mononuclear cells (PBMC) were obtained from buffy coat preparations from
healthy donors (kindly provided by Dr. T. Tonn, Blutspendedienst Hessen, Germany) by stand-
ard density gradient centrifugation on Ficoll separating solution. 15mL of Ficoll separating
solution were filled into Leucosep tubes and the tubes were centrifuged for 30 seconds at 1000g
and room temperature (RT). Subsequently, 15 to 20mL of of buffy coat were poured directly
from the blood sampling bag carefully into the Leucosep tubes and centrifuged for 15min at
1000g and RT. The brakes of the centrifuge were switched off. During centrifugation, lymph-
ocytes and PBMC’s are separated from the unwanted erythrocytes and granulocytes on the
basis of their density and enriched in an interphase above the separation medium. The plasma
(supernatant) was discarded and the enriched cell fraction were harvested and transferred into
a new 50mL tube. The cells were washed twice with 50mL of PBS-EDTA (centrifugation for 10
minutes at 400g and RT) and resuspended in 50mL PBS and counted. CD14+ monocytes were
affinity-purified utilising the MACS CD14 isolation kit following the manufacturer’s instruc-
tions. Briefly, PBMC were incubated in recommended buffer with MACS CD14 MicroBeads for
15min at 4◦C, centrifuged and resuspended in PBS buffer. Subsequently, the cells were passed
through a positive selection column. This step was repeated to obtain highly purified CD14
positive cells.
The enriched cells were counted and disseminated in 30mL AIM-V medium in 75cm2 tissue
culture flasks with a cell density of 1.3 · 106cells/mL. After 1h of incubation at 37◦C 400U/mL
rhuGM-CSF and 1500U/mL IL-4 were added and the cells were cultivated for 6 days at 37◦C
and 5 % CO2. Immature dendritic cells were obtained from the CD14 positive monocytes after
6 days of cultivation. For maturation of these DCs a differentiation cytokine cocktail is added
on day 6 and the cells were cultivated for two additional days. The following four cytokines were
used in the differentiation cocktail: 1000U/mL TNF-alpha, 1000U/mL IL-1beta, 1000U/mL
IL-6 and 1μg/mL PGE2.
274 CHAPTER 7. MATERIAL AND METHODS
Table 7.24: Materials for DC generation and maturation
Ficoll separating solution Biocoll Biochrom, Berlin, Germany
Leucosep tubes 50mL Greiner, Solingen, Germany
Tubes 50mL Greiner, Solingen, Germany
Tubes 15mL Greiner, Solingen, Germany
MACS CD14 isolation kit Miltenyi, Bergisch Gladbach, Germany
MACS column small (MS) (up to 2 · 108 cells) Miltenyi, Bergisch Gladbach, Germany
MACS column big (LS) (up to 2 · 109 cells) Miltenyi, Bergisch Gladbach, Germany
Filter 3M Miltenyi, Bergisch Gladbach, Germany
Micro-beads CD14+ Miltenyi, Bergisch Gladbach, Germany
Magnet MIDI cell sorting kit Miltenyi, Bergisch Gladbach, Germany
Tissue culture flasks 75cm2 Greiner, Solingen, Germany
AIM-V Heraeus, Hanau, Germany
rhuGM-CSF 400 U
mL
R&D, Wiesbaden, Germany
rhuIL-4 2000 U
mL
R&D, Wiesbaden, Germany
TNF-α 1000 U
mL
R&D, Wiesbaden, Germany
IL-1β 1000 U
mL
R&D, Wiesbaden, Germany
IL-6 1000 U
mL
R&D, Wiesbaden, Germany
PGE2 1
μg
mL
(0.003μM) Sigma, Deisenhofen, Germany
7.5.4 Cryo Storage of Cells
For the cryopreservation of dendritic cells and PBMC, the cells were centrifuged (200g / 10min
/ 20◦C) and resuspended at a cell density of 1·107 1
mL
(PBMCs) and between 1.1·106 and 3.5·106
1
mL
(mature dendritic cells) in autologous plasma. The plasma was obtained after Ficoll-Paque
centrifugation, heat-inactivated at 56◦C for 30min, centrifuged at 1000g and 20◦C for 10min
and passed through a 2μm filter before use. 10 % DMSO were added as an anti-freezing agent
before the cells were frozen at −80◦C in a polysterene box that allowed a freezing rate of 1◦C
per minute until –70◦C is reached. Below –70◦C the tube can be immersed in liquid nitrogen,
placed in the gas phase of liquid nitrogen or in a mechanical freezer at a storage temperature
below –130◦C.
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For thawing, the cells were suspended in icecold medium as soon as all ice was melted.
Subsequently, the cells were harvested by centrifugation (200g / 10min / 20◦C) and resuspended
preheated medium at 37◦C.
Table 7.25: Materials and solutions used for the cryopreservation of primary cells
Medium AIM V Gibco, Carlsbad, CA, USA
Cryovials 1.8mL NUNC, Wiesbaden, Germany
Dimethyl sulfoxide DMSO Sigma, Deisenhofen, Germany
Tubes 50mL Greiner, Solingen, Germany
7.5.5 FACS
For analysing of cell populations by means of FACS, several directly conjugated monoclonal Abs
against surface molecules (see table 7.25 on page 275) were used to stain the cells. 2·105 cells per
specimen were suspended in 85μL of ice-cold PBS and incubated with 5μL of corresponding
mAb for 15min at 4◦C. After staining, the cells were washed once with ice-cold PBS and
fixed in 200μL of 0.5% paraformaldehyde (Sigma, Deisenhofen, Germany) in PBS. Appropriate
isotype controls were used. FACS analysis was performed using a FACSCalibur and CellQuest
3.1 software (both Becton Dickinson, Erembodegem, Belgium).
7.5.6 Apoptosis Analysis
For the analysis, if DCs or KG-1 cells undergo early programmed cell death after a short treat-
ment with a PBS solution at a pH2, an annexin V – propidiumiodide apoptosis detection kit
(Becton Dickinson, Heidelberg, Germany) was used. The analysed cells were washed once in
PBS and resuspended in the provided binding buffer. FITC-conjugated Annexin V and prop-
idiumiodide were added and incubated for 15min at room temperature in the dark. Immediate
flow cytometric analysis was performed using a FACSCalibur and CellQuest 3.1 software (both
Becton Dickinson, Erembodegem, Belgium).
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Table 7.26: Antibodies used for surface protein analysis
Antibody Clone Isotype Fluorochrome Company
reacts with
CD1a HI149 Mouse IgG1, κ CyChrome Becton Dickinson
CD3 UCHT1 Mouse IgG1, κ CyChrome Becton Dickinson
CD4 RPA-T4 Mouse IgG1, κ FITC Becton Dickinson
CD8 RPA-T8 Mouse IgG1, κ PE Becton Dickinson
CD14 M5E2 Mouse IgG2a, κ PE Becton Dickinson
CD16 3G8 Mouse IgG1, κ FITC Becton Dickinson
CD19 HIB19 Mouse IgG1, κ PE Becton Dickinson
CD25 M-A251 Mouse IgG1, κ PE Becton Dickinson
CD34 581 Mouse IgG1, κ FITC Becton Dickinson
CD45 HI30 Mouse IgG1, κ FITC Becton Dickinson
CD40 5C3 Mouse IgG1, κ FITC Becton Dickinson
CD54 (ICAM-1) HA58 Mouse IgG1, κ PE Becton Dickinson
CD71 M-A712 Mouse IgG2a, κ PE Becton Dickinson
CD80 BB1 Mouse IgM, κ FITC, PE Becton Dickinson
CD83 HB15e Mouse IgG1, κ FITC Becton Dickinson
CD86 FUN-1 Mouse IgG1, κ FITC, PE Becton Dickinson
CCR7 3D12 Rat IgG2a, κ PE Becton Dickinson
HLA-A,B,C G46-2.6 Mouse IgG1, κ FITC Becton Dickinson
HLA-DR G46-6 Mouse IgG2a, κ CyChrome Becton Dickinson
Isotype control MOPC-21 Mouse IgG1, κ all Becton Dickinson
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7.5.7 Intracellular Staining of Mammalian Cells
Vital fluorescent dyes were used for staining different compartments (membrane, cytosol or
nucleus) of the cells (see table 7.27). The cells were stained following the manufacturer’s in-
structions.
Table 7.27: Dyes used for the intracellular labelling of mammalian cells
CellTracker CMFDA green cytosolic dye Molecular Probes, Eugene, USA
CellTracker CMTMR orange cytosolic dye Molecular Probes, Eugene, USA
CellTracker CMRA orange cytosolic dye Molecular Probes, Eugene, USA
Vybrant DiO green lipophilic dye Molecular Probes, Eugene, USA
Vybrant DiI orange lipophilic dye Molecular Probes, Eugene, USA
Syto11 green nucleic dye Molecular Probes, Eugene, USA
Syto17 orange nucleic dye Molecular Probes, Eugene, USA
7.6 Microscopic Methods
Fluorescence images were obtained with an Axiovert 200 inverted microscope (Zeiss, Jena, Ger-
many) equipped with optical filters (FITC and Texas Red) and an AxioCam HR camera (Zeiss,
Jena, Germany). The images were analysed by the LSM 5 software (Zeiss, Jena, Germany).
7.6.1 Scanning Electron Microscopy (SEM)
The scanning electron microscopy characterisation of the master structures (sputtered with a
5nm gold layer) was performed using a scanning electron microscope.
Particularly, the Scanning Electron Microscopy (SEM) serves for the representation of sur-
faces. Therefore, the object of interest have to fulfil the following conditions: The object needs
to be clean, free of dust and water-free, must not be gassing out in the vacuum and the surface
needs to be electroconductive. For this reason, biological surfaces are sputtered with gold. The
specimen were overlaid with a 2.5% glutaraldehyde solution for 1 day, washed twice with PBS
and dehydrated with an increasing acetone concentration (from 20% up to 100% for 1h each).
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Finally, the objects were incubated for 1 day in 100% acetone, subjected to critical point drying
and sputtered with gold.
Table 7.28: Materials for scanning electron microscopy
scanning electron microscope LEO GEMINI 1550 Zeiss, Oberkochen, Germany
gold wire
7.7 Solutions
Phosphate Buffered Saline
Table 7.29: Formulation of phosphate buffered saline (PBS), which is an isotonic solution and
not nutritionally complete. The pH was adjusted to 7.3. The solution was autoclaved for 30min.
Distilled water 1L
NaCl 8.00 g
L
(137mM) Sigma, Deisenhofen, Germany
KCl 0.20 g
L
(27mM) Sigma, Deisenhofen, Germany
Na2HPO4 1.25
g
L
(8mM) Sigma, Deisenhofen, Germany
KH2PO4 0.20
g
L
(15mM) Sigma, Deisenhofen, Germany
EDTA Buffer
Table 7.30: Formulation of EDTA buffer. The pH was adjusted to 7.3. The solution was auto-
claved for 30min.
PBS 1L
Na2EDTA · 2H2O 0.74 gL (2mM) Sigma, Deisenhofen, Germany
Appendix A
Pump/Valve Operation Programmes
The pump and valve operation programmes, which were written for this project with LabVIEW
to operate all components from an external computer are shown in the following. LabVIEW is a
graphical programming language, which is primarily used for metrological tasks. The graphical
dataflow language and block diagram approach allows viewing and easily modification of data
or control inputs.
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